[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGXtCgQYpZR982jXOYwPM2ButXNru6GkcJ-IIkBaZTl0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"University of Minnesota",[4,6],"University of Minnesota Physicians Heart at Fairview",1179,false,234,59,1306661,60,881,[15,18,21,24,27,30,32,35],{"name":16,"count":17},"Obesity",42,{"name":19,"count":20},"Healthy",32,{"name":22,"count":23},"Cardiovascular Diseases",30,{"name":25,"count":26},"Stroke",28,{"name":28,"count":29},"Heart Diseases",22,{"name":31,"count":29},"Tobacco Use Disorder",{"name":33,"count":34},"Hypertension",21,{"name":36,"count":37},"Depression",20,[39,44,49,54,59,64,69,74,79,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06149793","SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes","2025-06-03","Empagliflozin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04881799","Phentermine\u002FTopiramate in Adolescents With Type 2 Diabetes and Obesity","2025-10-27","Phentermine\u002FTopiramate",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04783857","Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children","2026-06-02","Progesterone 200 MG Oral",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05471609","Sustained Release Oral Formulation for Treatment of Parkinson's Disease","2026-06-16","levodopa\u002Fcarbidopa oral formulation A",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04873245","Lifestyle Counseling and Medication for Adolescent Weight Management","2026-06-30","Semaglutide and Behavioral Program",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06345833","Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study","2026-07-01","1%Tranexamic acid with standard local",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05727761","Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia","2026-07-28","pioglitazone-metformin",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04098874","Bupropion for the Prevention of Postpartum Smoking Relapse","2026-07-31","Bupropion Extended Release Oral",{"nctId":80,"briefTitle":81,"date":77,"intervention":82},"NCT05416125","Vyvanse in Children Aged 6 to 12 Years","Lisdexamfetamine Dimesylate",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04910269","Outpatient Treatment With Anti-Coronavirus Immunoglobulin","2026-08-01","Hyperimmune immunoglobulin to SARS-CoV-2",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,139,178,205,223,251,277,295,313,336,364,382,403,446,477,519,569,605,623,651,669,687,705,723,741,759,777,803,852,877,902,922,947,965,986,1015,1041,1069,1087,1112,1130,1176,1201,1219,1244,1262,1287,1310,1334,1359,1380,1398,1422,1447,1470,1492,1519,1540,1565,1583,1601,1695,1738,1777,1809,1846,1884,1910,1936,1954,1980,1998,2016,2034,2059,2083,2101,2124,2142,2160,2178,2196,2222,2240,2266,2291,2318,2343,2367,2385,2410,2428,2455,2479,2505,2529,2553,2571,2598,2636,2678,2716,2750,2786,2812,2830,2854,2876,2894,2912,2930,2948,2974,2998,3022,3047,3065,3090,3114,3137,3155,3173,3197,3215,3239,3264,3282,3308,3333,3351,3369,3393,3414,3439,3457,3480,3503,3530,3611,3650,3701,3746,3790,3816,3838,3872,3906,3944,3979,4005,4038,4071,4099,4139,4161,4183,4206,4232,4250,4274,4292,4315,4340,4358,4384,4402,4426,4451,4476,4494,4512,4535,4553,4577,4595,4618,4640,4661,4684,4708,4726,4751,4775,4800,4824,4842,4868,4886,4910,4932,4955,4983,5001,5019,5037,5061,5083,5108,5138,5162,5180,5208,5226,5244,5262,5280,5304,5322,5343,5361,5379,5403,5428,5450,5478,5496,5514,5532,5550,5573,5597,5622,5647,5674,5692,5714,5738,5760,5785,5808,5831,5855,5873,5897,5919,5945,5970,5988,6011,6029,6047,6065,6083,6108,6133,6159,6186,6204,6227,6245,6268,6286,6304,6322,6345,6368,6402,6424,6449,6467,6485,6509,6527,6551,6573,6595,6619,6637,6660,6682,6704,6728,6749,6771,6793,6815,6836,6859,6882,6905,6928,6956,6981,6999,7017,7040,7063,7088,7106,7163,7212,7251,7280,7308,7338,7371,7396,7422,7466,7492,7510,7528,7546,7570,7594,7622,7648,7671,7693,7715,7733,7756,7779,7801,7824,7846,7867,7890,7908,7926,7949,7973,7996,8022,8040,8062,8084,8106,8124,8147,8173,8191,8209,8227,8245,8263,8287,8314,8332,8354,8372,8400,8418,8436,8454,8472,8490,8515,8537,8559,8585,8603,8621,8647,8665,8690,8708,8731,8752],{"intervention":97,"totalTrials":98,"cells":99},"Semaglutide",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":122,"NA":137},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT05788965","Semaglutide in CFRD","COMPLETED",[91,92],"2024-12-23","2024-12-31","2023-10-16",8,[119,120],"Cystic Fibrosis","Cystic Fibrosis-related Diabetes",[97],{"trials":123,"activeCount":136,"soonestReadout":129},[124],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT06977438","Promoting Healthy Children and Youth","NOT_YET_RECRUITING",[93],"2031-01-31","2032-01-31","2027-01-01",1020,[134],"Obesity, Childhood",[97],1,{"trials":138,"activeCount":102},[],{"intervention":140,"totalTrials":98,"cells":141},"Saline",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":176},{"trials":143,"activeCount":102},[],{"trials":145,"activeCount":102},[],{"trials":147,"activeCount":102},[],{"trials":149,"activeCount":102},[],{"trials":151,"activeCount":136,"soonestReadout":157},[152,165],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT06143306","Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement","RECRUITING",[93],"2026-10-30","2027-05-01","2024-08-14",110,[162],"Total Shoulder Arthroplasty",[164,140],"bupivacaine.",{"nctId":166,"briefTitle":167,"status":168,"phases":169,"primaryCompletion":158,"completion":158,"start":170,"enrollment":171,"conditions":172,"interventions":174},"NCT06023329","Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery","SUSPENDED",[93],"2024-05-31",36,[173],"Otolaryngologic Surgery",[175,140],"ropivacaine",{"trials":177,"activeCount":102},[],{"intervention":179,"totalTrials":136,"cells":180},"PENG block and cryoablation",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":203},{"trials":182,"activeCount":102},[],{"trials":184,"activeCount":102},[],{"trials":186,"activeCount":102},[],{"trials":188,"activeCount":102},[],{"trials":190,"activeCount":136,"soonestReadout":195},[191],{"nctId":192,"briefTitle":193,"status":155,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT06278987","Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture",[93],"2026-10-01","2027-10-01","2024-10-01",150,[200],"Hip Fractures",[179,202],"fascia iliaca compartment block",{"trials":204,"activeCount":102},[],{"intervention":202,"totalTrials":136,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":221},{"trials":208,"activeCount":102},[],{"trials":210,"activeCount":102},[],{"trials":212,"activeCount":102},[],{"trials":214,"activeCount":102},[],{"trials":216,"activeCount":136,"soonestReadout":195},[217],{"nctId":192,"briefTitle":193,"status":155,"phases":218,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":219,"interventions":220},[93],[200],[179,202],{"trials":222,"activeCount":102},[],{"intervention":224,"totalTrials":136,"cells":225},"0.5% bupivacaine",{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":249},{"trials":227,"activeCount":102},[],{"trials":229,"activeCount":102},[],{"trials":231,"activeCount":102},[],{"trials":233,"activeCount":102},[],{"trials":235,"activeCount":136,"soonestReadout":240},[236],{"nctId":237,"briefTitle":238,"status":155,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":248},"NCT06271707","Stellate Ganglion Block",[93],"2027-04-15","2027-07-15","2025-05-19",48,[245,246,247],"Esophagectomy","Pneumonectomy","Lobectomy",[224],{"trials":250,"activeCount":102},[],{"intervention":252,"totalTrials":136,"cells":253},"Cryoablation",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":275},{"trials":255,"activeCount":102},[],{"trials":257,"activeCount":102},[],{"trials":259,"activeCount":102},[],{"trials":261,"activeCount":102},[],{"trials":263,"activeCount":136,"soonestReadout":268},[264],{"nctId":265,"briefTitle":266,"status":155,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":243,"conditions":271,"interventions":273},"NCT06347874","Cryo Rib Fracture Study",[93],"2027-02-13","2027-03-13","2025-01-10",[272],"Rib Fractures",[252,274],"ESP Catheter",{"trials":276,"activeCount":102},[],{"intervention":274,"totalTrials":136,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":293},{"trials":280,"activeCount":102},[],{"trials":282,"activeCount":102},[],{"trials":284,"activeCount":102},[],{"trials":286,"activeCount":102},[],{"trials":288,"activeCount":136,"soonestReadout":268},[289],{"nctId":265,"briefTitle":266,"status":155,"phases":290,"primaryCompletion":268,"completion":269,"start":270,"enrollment":243,"conditions":291,"interventions":292},[93],[272],[252,274],{"trials":294,"activeCount":102},[],{"intervention":164,"totalTrials":136,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":311},{"trials":298,"activeCount":102},[],{"trials":300,"activeCount":102},[],{"trials":302,"activeCount":102},[],{"trials":304,"activeCount":102},[],{"trials":306,"activeCount":136,"soonestReadout":157},[307],{"nctId":153,"briefTitle":154,"status":155,"phases":308,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":309,"interventions":310},[93],[162],[164,140],{"trials":312,"activeCount":102},[],{"intervention":53,"totalTrials":136,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":334},{"trials":316,"activeCount":102},[],{"trials":318,"activeCount":102},[],{"trials":320,"activeCount":102},[],{"trials":322,"activeCount":102},[],{"trials":324,"activeCount":136,"soonestReadout":52},[325],{"nctId":50,"briefTitle":51,"status":155,"phases":326,"primaryCompletion":52,"completion":52,"start":327,"enrollment":328,"conditions":329,"interventions":333},[93],"2022-04-14",279,[330,331,332],"Smoking","Smoking Cessation","Smoking Reduction",[53],{"trials":335,"activeCount":102},[],{"intervention":337,"totalTrials":136,"cells":338},"Empagliflozin 25 MG Oral",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":362},{"trials":340,"activeCount":102},[],{"trials":342,"activeCount":102},[],{"trials":344,"activeCount":102},[],{"trials":346,"activeCount":102},[],{"trials":348,"activeCount":136,"soonestReadout":353},[349],{"nctId":350,"briefTitle":351,"status":127,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":360},"NCT07228195","SGLT2i Therapy in Islet Transplantation (SIT)",[93],"2028-12-01","2026-07-15",40,[357,358,359],"Partial Islet Function","TPIAT","Diabetes",[337,361],"Empagliflozin 10 MG Oral Tablet [Jardiance]",{"trials":363,"activeCount":102},[],{"intervention":361,"totalTrials":136,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":380},{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":102},[],{"trials":371,"activeCount":102},[],{"trials":373,"activeCount":102},[],{"trials":375,"activeCount":136,"soonestReadout":353},[376],{"nctId":350,"briefTitle":351,"status":127,"phases":377,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":378,"interventions":379},[93],[357,358,359],[337,361],{"trials":381,"activeCount":102},[],{"intervention":78,"totalTrials":136,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":401},{"trials":385,"activeCount":102},[],{"trials":387,"activeCount":102},[],{"trials":389,"activeCount":102},[],{"trials":391,"activeCount":102},[],{"trials":393,"activeCount":136,"soonestReadout":77},[394],{"nctId":75,"briefTitle":76,"status":155,"phases":395,"primaryCompletion":77,"completion":77,"start":396,"enrollment":397,"conditions":398,"interventions":400},[93],"2020-01-01",200,[399],"Postpartum Smoking Relapse",[78],{"trials":402,"activeCount":102},[],{"intervention":404,"totalTrials":98,"cells":405},"Modafinil",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":442,"NA":444},{"trials":407,"activeCount":102},[],{"trials":409,"activeCount":102},[],{"trials":411,"activeCount":102},[],{"trials":413,"activeCount":98,"soonestReadout":418},[414,433],{"nctId":415,"briefTitle":416,"status":127,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":431},"NCT07263022","Cognitive Strategies in Early Psychosis 2",[92],"2030-04-30","2026-07-07",24,[422,423,424,425,426,427,428,429,430],"Psychosis","Schizophrenia Disorder","Schizoaffective Disorder","Major Depressive Disorder With Psychotic Features","Bipolar Disorder With Psychotic Features","Psychosis NOS","Schizophreniform Disorder","Psychotic Disorder","Cognition",[404,432],"D-serine solution",{"nctId":434,"briefTitle":435,"status":155,"phases":436,"primaryCompletion":418,"completion":418,"start":437,"enrollment":438,"conditions":439,"interventions":441},"NCT07231497","Cognitive Strategies in Early Psychosis 1",[92],"2025-10-31",103,[430,440],"Healthy Participants",[404],{"trials":443,"activeCount":102},[],{"trials":445,"activeCount":102},[],{"intervention":447,"totalTrials":98,"cells":448},"empagliflozin",{"EARLY_PHASE1":449,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":473,"NA":475},{"trials":450,"activeCount":136,"soonestReadout":455},[451],{"nctId":452,"briefTitle":453,"status":155,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT06507657","Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure",[89],"2029-01-15","2024-12-12",80,[33,22],[447],{"trials":461,"activeCount":102},[],{"trials":463,"activeCount":102},[],{"trials":465,"activeCount":136,"soonestReadout":42},[466],{"nctId":40,"briefTitle":41,"status":467,"phases":468,"primaryCompletion":42,"completion":469,"start":470,"enrollment":117,"conditions":471,"interventions":472},"ACTIVE_NOT_RECRUITING",[91,92],"2026-12-31","2024-01-08",[120,119],[43],{"trials":474,"activeCount":102},[],{"trials":476,"activeCount":102},[],{"intervention":478,"totalTrials":98,"cells":479},"Standard of care",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":503,"NA":517},{"trials":481,"activeCount":102},[],{"trials":483,"activeCount":102},[],{"trials":485,"activeCount":102},[],{"trials":487,"activeCount":136,"soonestReadout":492},[488],{"nctId":489,"briefTitle":490,"status":155,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":498},"NCT06666322","Platform Trial For Cryptococcal Meningitis",[91,92],"2032-04-21","2025-05-28",2000,[496,497],"Hiv","Cryptococcal Meningitis",[478,499,500,501,502],"Oteseconazole - antifungal therapy 1","Sfu-AM2-19 Injection - antifungal therapy 2","Antifungal therapy 3","Antifungal therapy 4",{"trials":504,"activeCount":102},[505],{"nctId":506,"briefTitle":507,"status":112,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":160,"conditions":511,"interventions":514},"NCT02182115","S. Aureus Screening and Decolonization",[93],"2016-08","2014-07",[512,513],"Wound Infection Due to Staphylococcus Aureus","MRSA Infection of Postoperative Wound",[515,516],"antiseptic bundle","standard of care",{"trials":518,"activeCount":102},[],{"intervention":520,"totalTrials":521,"cells":522},"Choline bitartrate",3,{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":551,"PHASE4":565,"NA":567},{"trials":524,"activeCount":102},[],{"trials":526,"activeCount":102},[],{"trials":528,"activeCount":102},[529,539],{"nctId":530,"briefTitle":531,"status":112,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT02735473","Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders",[91],"2021-09-10","2016-06",46,[537],"Fetal Alcohol Spectrum Disorders",[520],{"nctId":540,"briefTitle":541,"status":112,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":12,"conditions":545,"interventions":550},"NCT01149538","Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure",[90,91],"2014-09","2010-07",[537,546,547,548,549],"Fetal Alcohol Syndrome","Partial Fetal Alcohol Syndrome","Alcohol Related Neurodevelopmental Disorder","Prenatal Alcohol Exposure",[520],{"trials":552,"activeCount":136,"soonestReadout":557},[553],{"nctId":554,"briefTitle":555,"status":155,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":563},"NCT06527391","Choline and Iron Deficiency",[91,92],"2027-09-21","2025-08-11",300,[561,562],"Pediatric Iron Deficiency","Anemia",[564],"choline bitartrate",{"trials":566,"activeCount":102},[],{"trials":568,"activeCount":102},[],{"intervention":87,"totalTrials":98,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":601,"NA":603},{"trials":572,"activeCount":102},[],{"trials":574,"activeCount":102},[],{"trials":576,"activeCount":102},[],{"trials":578,"activeCount":136,"soonestReadout":86},[579,588],{"nctId":84,"briefTitle":85,"status":155,"phases":580,"primaryCompletion":86,"completion":86,"start":581,"enrollment":582,"conditions":583,"interventions":587},[92],"2021-08-06",820,[584,585,586],"COVID","SARS-CoV2 Infection","Covid19",[87],{"nctId":589,"briefTitle":590,"status":112,"phases":591,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":599},"NCT04546581","Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)",[92],"2021-05-21","2020-10-08",593,[584,596,597,598],"COVID-19","SARS-CoV-2","SARS (Severe Acute Respiratory Syndrome)",[87,600],"Remdesivir",{"trials":602,"activeCount":102},[],{"trials":604,"activeCount":102},[],{"intervention":432,"totalTrials":136,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":619,"NA":621},{"trials":608,"activeCount":102},[],{"trials":610,"activeCount":102},[],{"trials":612,"activeCount":102},[],{"trials":614,"activeCount":136,"soonestReadout":418},[615],{"nctId":415,"briefTitle":416,"status":127,"phases":616,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":617,"interventions":618},[92],[422,423,424,425,426,427,428,429,430],[404,432],{"trials":620,"activeCount":102},[],{"trials":622,"activeCount":102},[],{"intervention":624,"totalTrials":136,"cells":625},"LAmB B",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":647,"NA":649},{"trials":627,"activeCount":102},[],{"trials":629,"activeCount":102},[],{"trials":631,"activeCount":102},[],{"trials":633,"activeCount":136,"soonestReadout":638},[634],{"nctId":635,"briefTitle":636,"status":127,"phases":637,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":643},"NCT07261150","Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)",[92],"2030-12-31","2026-09-15",664,[642],"Histoplasmosis",[624,644,645,646],"Posaconazole","World Health Organization (WHO)-recommended SOC","WHO-recommended SOC Itraconazole",{"trials":648,"activeCount":102},[],{"trials":650,"activeCount":102},[],{"intervention":644,"totalTrials":136,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":665,"NA":667},{"trials":654,"activeCount":102},[],{"trials":656,"activeCount":102},[],{"trials":658,"activeCount":102},[],{"trials":660,"activeCount":136,"soonestReadout":638},[661],{"nctId":635,"briefTitle":636,"status":127,"phases":662,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":663,"interventions":664},[92],[642],[624,644,645,646],{"trials":666,"activeCount":102},[],{"trials":668,"activeCount":102},[],{"intervention":645,"totalTrials":136,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":683,"NA":685},{"trials":672,"activeCount":102},[],{"trials":674,"activeCount":102},[],{"trials":676,"activeCount":102},[],{"trials":678,"activeCount":136,"soonestReadout":638},[679],{"nctId":635,"briefTitle":636,"status":127,"phases":680,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":681,"interventions":682},[92],[642],[624,644,645,646],{"trials":684,"activeCount":102},[],{"trials":686,"activeCount":102},[],{"intervention":646,"totalTrials":136,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":701,"NA":703},{"trials":690,"activeCount":102},[],{"trials":692,"activeCount":102},[],{"trials":694,"activeCount":102},[],{"trials":696,"activeCount":136,"soonestReadout":638},[697],{"nctId":635,"briefTitle":636,"status":127,"phases":698,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":699,"interventions":700},[92],[642],[624,644,645,646],{"trials":702,"activeCount":102},[],{"trials":704,"activeCount":102},[],{"intervention":499,"totalTrials":136,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":721},{"trials":708,"activeCount":102},[],{"trials":710,"activeCount":102},[],{"trials":712,"activeCount":102},[],{"trials":714,"activeCount":136,"soonestReadout":492},[715],{"nctId":489,"briefTitle":490,"status":155,"phases":716,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":717,"interventions":718},[91,92],[496,497],[478,499,500,501,502],{"trials":720,"activeCount":102},[],{"trials":722,"activeCount":102},[],{"intervention":500,"totalTrials":136,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":737,"NA":739},{"trials":726,"activeCount":102},[],{"trials":728,"activeCount":102},[],{"trials":730,"activeCount":102},[],{"trials":732,"activeCount":136,"soonestReadout":492},[733],{"nctId":489,"briefTitle":490,"status":155,"phases":734,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":735,"interventions":736},[91,92],[496,497],[478,499,500,501,502],{"trials":738,"activeCount":102},[],{"trials":740,"activeCount":102},[],{"intervention":501,"totalTrials":136,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":755,"NA":757},{"trials":744,"activeCount":102},[],{"trials":746,"activeCount":102},[],{"trials":748,"activeCount":102},[],{"trials":750,"activeCount":136,"soonestReadout":492},[751],{"nctId":489,"briefTitle":490,"status":155,"phases":752,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":753,"interventions":754},[91,92],[496,497],[478,499,500,501,502],{"trials":756,"activeCount":102},[],{"trials":758,"activeCount":102},[],{"intervention":502,"totalTrials":136,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":773,"NA":775},{"trials":762,"activeCount":102},[],{"trials":764,"activeCount":102},[],{"trials":766,"activeCount":102},[],{"trials":768,"activeCount":136,"soonestReadout":492},[769],{"nctId":489,"briefTitle":490,"status":155,"phases":770,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":771,"interventions":772},[91,92],[496,497],[478,499,500,501,502],{"trials":774,"activeCount":102},[],{"trials":776,"activeCount":102},[],{"intervention":778,"totalTrials":136,"cells":779},"Qsymia 7.5 miligrams (mg)-46 mg Extended Release",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":799,"NA":801},{"trials":781,"activeCount":102},[],{"trials":783,"activeCount":102},[],{"trials":785,"activeCount":102},[],{"trials":787,"activeCount":136,"soonestReadout":792},[788],{"nctId":789,"briefTitle":790,"status":127,"phases":791,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":798},"NCT06905626","Weight Gain Prevention in Adolescents and Young Adults",[92],"2030-03-31","2031-03-31","2026-06-01",140,[797],"Healthy Volunteers",[778],{"trials":800,"activeCount":102},[],{"trials":802,"activeCount":102},[],{"intervention":804,"totalTrials":521,"cells":805},"Metformin",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":822,"PHASE4":836,"NA":850},{"trials":807,"activeCount":102},[],{"trials":809,"activeCount":102},[],{"trials":811,"activeCount":136,"soonestReadout":816},[812],{"nctId":813,"briefTitle":814,"status":127,"phases":815,"primaryCompletion":816,"completion":816,"start":67,"enrollment":817,"conditions":818,"interventions":819},"NCT07007221","Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV",[91],"2030-12-01",600,[36,496],[804,804,804,804,820,821],"Fluoxetine","Metformin+Fluoxetine",{"trials":823,"activeCount":102},[824],{"nctId":825,"briefTitle":826,"status":112,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":833},"NCT04510194","COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)",[92],"2022-12-14","2021-01-01",1323,[586,832],"SARS-CoV Infection",[804,834,835],"Fluvoxamine","Ivermectin",{"trials":837,"activeCount":102},[838],{"nctId":839,"briefTitle":840,"status":841,"phases":842,"primaryCompletion":843,"completion":844,"start":845,"enrollment":102,"conditions":846,"interventions":848},"NCT00775164","Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study","WITHDRAWN",[93],"2010-12","2011-02","2009-01",[16,847],"Insulin Resistance",[849,804],"pioglitazone",{"trials":851,"activeCount":102},[],{"intervention":853,"totalTrials":136,"cells":854},"BPaLMZ Regimen",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":856,"activeCount":102},[],{"trials":858,"activeCount":102},[],{"trials":860,"activeCount":136,"soonestReadout":865},[861],{"nctId":862,"briefTitle":863,"status":127,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":870},"NCT07227779","B-PaLMZ for TB Meningitis",[91],"2030-08-31","2026-06-15",240,[869],"Tuberculous Meningitis",[853],{"trials":872,"activeCount":102},[],{"trials":874,"activeCount":102},[],{"trials":876,"activeCount":102},[],{"intervention":878,"totalTrials":136,"cells":879},"efgartigimod",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":881,"activeCount":102},[],{"trials":883,"activeCount":102},[],{"trials":885,"activeCount":136,"soonestReadout":890},[886],{"nctId":887,"briefTitle":888,"status":155,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":895},"NCT06831058","A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)",[91],"2028-05-01","2025-05-01",15,[894],"Immune-mediated Thrombotic Thrombocytopenic Purpura",[878],{"trials":897,"activeCount":102},[],{"trials":899,"activeCount":102},[],{"trials":901,"activeCount":102},[],{"intervention":73,"totalTrials":136,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":905,"activeCount":102},[],{"trials":907,"activeCount":102},[],{"trials":909,"activeCount":136,"soonestReadout":72},[910],{"nctId":70,"briefTitle":71,"status":155,"phases":911,"primaryCompletion":72,"completion":72,"start":912,"enrollment":171,"conditions":913,"interventions":915},[91],"2025-01-01",[914],"Oral Leukoplakia",[73],{"trials":917,"activeCount":102},[],{"trials":919,"activeCount":102},[],{"trials":921,"activeCount":102},[],{"intervention":923,"totalTrials":136,"cells":924},"Cytogam",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":926,"activeCount":102},[],{"trials":928,"activeCount":102},[],{"trials":930,"activeCount":136,"soonestReadout":935},[931],{"nctId":932,"briefTitle":933,"status":155,"phases":934,"primaryCompletion":935,"completion":935,"start":936,"enrollment":23,"conditions":937,"interventions":940},"NCT07096453","CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients",[90,91],"2027-08","2025-10-02",[938,939],"Kidney Transplant; Complications","CMV",[923],{"trials":942,"activeCount":102},[],{"trials":944,"activeCount":102},[],{"trials":946,"activeCount":102},[],{"intervention":821,"totalTrials":136,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":950,"activeCount":102},[],{"trials":952,"activeCount":102},[],{"trials":954,"activeCount":136,"soonestReadout":816},[955],{"nctId":813,"briefTitle":814,"status":127,"phases":956,"primaryCompletion":816,"completion":816,"start":67,"enrollment":817,"conditions":957,"interventions":958},[91],[36,496],[804,804,804,804,820,821],{"trials":960,"activeCount":102},[],{"trials":962,"activeCount":102},[],{"trials":964,"activeCount":102},[],{"intervention":63,"totalTrials":136,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":968,"activeCount":102},[],{"trials":970,"activeCount":102},[],{"trials":972,"activeCount":136,"soonestReadout":62},[973],{"nctId":60,"briefTitle":61,"status":467,"phases":974,"primaryCompletion":62,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":979},[91],"2027-06-30","2022-03-15",120,[134],[63],{"trials":981,"activeCount":102},[],{"trials":983,"activeCount":102},[],{"trials":985,"activeCount":102},[],{"intervention":987,"totalTrials":136,"cells":988},"Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":990,"activeCount":102},[],{"trials":992,"activeCount":102},[],{"trials":994,"activeCount":136,"soonestReadout":999},[995],{"nctId":996,"briefTitle":997,"status":467,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1008},"NCT04115514","Treatment of ARDS With Instilled T3",[91],"2026-10-31","2020-03-30",68,[1003,1004,1005,1006,1007],"ARDS, Human","Lung, Wet","Thyroid","Pulmonary Edema","Lung Inflammation",[987],{"trials":1010,"activeCount":102},[],{"trials":1012,"activeCount":102},[],{"trials":1014,"activeCount":102},[],{"intervention":1016,"totalTrials":136,"cells":1017},"Vancomycin, Neomycin and MTT",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1019,"activeCount":102},[],{"trials":1021,"activeCount":102},[],{"trials":1023,"activeCount":136,"soonestReadout":1028},[1024],{"nctId":1025,"briefTitle":1026,"status":155,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":355,"conditions":1030,"interventions":1034},"NCT06747611","Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata",[91],"2028-03-15","2025-08-21",[1031,1032,1033],"Alopecia Areata","Alopecia Totalis","Alopecia Universalis",[1016],{"trials":1036,"activeCount":102},[],{"trials":1038,"activeCount":102},[],{"trials":1040,"activeCount":102},[],{"intervention":1042,"totalTrials":136,"cells":1043},"Fisetin-dose 1",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1045,"activeCount":102},[],{"trials":1047,"activeCount":102},[],{"trials":1049,"activeCount":136,"soonestReadout":1054},[1050],{"nctId":1051,"briefTitle":1052,"status":155,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1061},"NCT05758246","Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial",[91],"2026-08-23","2023-08-23",220,[1058,1059,1060],"Sepsis","Acute Infection","Organ Failure",[1042,1062],"Fisetin-dose 2",{"trials":1064,"activeCount":102},[],{"trials":1066,"activeCount":102},[],{"trials":1068,"activeCount":102},[],{"intervention":1062,"totalTrials":136,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1072,"activeCount":102},[],{"trials":1074,"activeCount":102},[],{"trials":1076,"activeCount":136,"soonestReadout":1054},[1077],{"nctId":1051,"briefTitle":1052,"status":155,"phases":1078,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1079,"interventions":1080},[91],[1058,1059,1060],[1042,1062],{"trials":1082,"activeCount":102},[],{"trials":1084,"activeCount":102},[],{"trials":1086,"activeCount":102},[],{"intervention":1088,"totalTrials":136,"cells":1089},"MTP-101C",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1091,"activeCount":102},[],{"trials":1093,"activeCount":102},[],{"trials":1095,"activeCount":136,"soonestReadout":1100},[1096],{"nctId":1097,"briefTitle":1098,"status":155,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":977,"conditions":1102,"interventions":1104},"NCT06631586","Standardized Microbiota Transplant Therapy in Crohn's Disease",[91],"2029-06-15","2025-01-15",[1103],"Crohn Disease",[1088,1105],"MTP-101S",{"trials":1107,"activeCount":102},[],{"trials":1109,"activeCount":102},[],{"trials":1111,"activeCount":102},[],{"intervention":1105,"totalTrials":136,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1115,"activeCount":102},[],{"trials":1117,"activeCount":102},[],{"trials":1119,"activeCount":136,"soonestReadout":1100},[1120],{"nctId":1097,"briefTitle":1098,"status":155,"phases":1121,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":977,"conditions":1122,"interventions":1123},[91],[1103],[1088,1105],{"trials":1125,"activeCount":102},[],{"trials":1127,"activeCount":102},[],{"trials":1129,"activeCount":102},[],{"intervention":820,"totalTrials":1131,"cells":1132},4,{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1134,"activeCount":102},[],{"trials":1136,"activeCount":102},[],{"trials":1138,"activeCount":136,"soonestReadout":816},[1139,1143,1151],{"nctId":813,"briefTitle":814,"status":127,"phases":1140,"primaryCompletion":816,"completion":816,"start":67,"enrollment":817,"conditions":1141,"interventions":1142},[91],[36,496],[804,804,804,804,820,821],{"nctId":1144,"briefTitle":1145,"status":112,"phases":1146,"primaryCompletion":534,"completion":534,"start":1147,"enrollment":355,"conditions":1148,"interventions":1150},"NCT01802437","An Adaptive Treatment Strategy for Adolescent Depression",[90,91],"2010-11",[1149],"Adolescent Depression",[820],{"nctId":1152,"briefTitle":1153,"status":112,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":892,"conditions":1157,"interventions":1158},"NCT02017535","An Adaptive Treatment Strategy for Adolescent Depression-Continuation",[90,91],"2018-10-01","2012-06",[1149],[820],{"trials":1160,"activeCount":102},[],{"trials":1162,"activeCount":102},[],{"trials":1164,"activeCount":102},[1165],{"nctId":1166,"briefTitle":1167,"status":112,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT00733525","Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa",[94],"2005-04","2005-08","2000-09",293,[1174],"Eating Disorders",[820],{"intervention":1177,"totalTrials":136,"cells":1178},"H1ssF vaccine",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1180,"activeCount":102},[],{"trials":1182,"activeCount":136,"soonestReadout":1187},[1183],{"nctId":1184,"briefTitle":1185,"status":127,"phases":1186,"primaryCompletion":1187,"completion":1187,"start":86,"enrollment":1188,"conditions":1189,"interventions":1191},"NCT07340047","H1ssF Flu Vaccine Clinical Trial",[90],"2028-03-01",112,[1190],"Influenza",[1177,1192],"Flucelvax seasonal vaccine",{"trials":1194,"activeCount":102},[],{"trials":1196,"activeCount":102},[],{"trials":1198,"activeCount":102},[],{"trials":1200,"activeCount":102},[],{"intervention":1192,"totalTrials":136,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":102},[],{"trials":1206,"activeCount":136,"soonestReadout":1187},[1207],{"nctId":1184,"briefTitle":1185,"status":127,"phases":1208,"primaryCompletion":1187,"completion":1187,"start":86,"enrollment":1188,"conditions":1209,"interventions":1210},[90],[1190],[1177,1192],{"trials":1212,"activeCount":102},[],{"trials":1214,"activeCount":102},[],{"trials":1216,"activeCount":102},[],{"trials":1218,"activeCount":102},[],{"intervention":1220,"totalTrials":136,"cells":1221},"MTT with antibiotic preconditioning + fiber supplementation",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1223,"activeCount":102},[],{"trials":1225,"activeCount":136,"soonestReadout":999},[1226],{"nctId":1227,"briefTitle":1228,"status":155,"phases":1229,"primaryCompletion":999,"completion":1230,"start":1231,"enrollment":420,"conditions":1232,"interventions":1234},"NCT06481852","A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension",[90],"2027-04-30","2024-10-28",[1233],"Pulmonary Arterial Hypertension",[1220,1235],"MTT with antibiotic preconditioning + placebo supplementation",{"trials":1237,"activeCount":102},[],{"trials":1239,"activeCount":102},[],{"trials":1241,"activeCount":102},[],{"trials":1243,"activeCount":102},[],{"intervention":1235,"totalTrials":136,"cells":1245},{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1247,"activeCount":102},[],{"trials":1249,"activeCount":136,"soonestReadout":999},[1250],{"nctId":1227,"briefTitle":1228,"status":155,"phases":1251,"primaryCompletion":999,"completion":1230,"start":1231,"enrollment":420,"conditions":1252,"interventions":1253},[90],[1233],[1220,1235],{"trials":1255,"activeCount":102},[],{"trials":1257,"activeCount":102},[],{"trials":1259,"activeCount":102},[],{"trials":1261,"activeCount":102},[],{"intervention":1263,"totalTrials":136,"cells":1264},"Orally administered preparation of fecal microbiota",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1285},{"trials":1266,"activeCount":102},[],{"trials":1268,"activeCount":136,"soonestReadout":1273},[1269],{"nctId":1270,"briefTitle":1271,"status":155,"phases":1272,"primaryCompletion":1273,"completion":1273,"start":1274,"enrollment":355,"conditions":1275,"interventions":1278},"NCT06692179","An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection",[90],"2027-02-18","2025-02-18",[1276,1277],"Recurrent Clostridioides Difficile Infection","Colonic Surgery",[1263],{"trials":1280,"activeCount":102},[],{"trials":1282,"activeCount":102},[],{"trials":1284,"activeCount":102},[],{"trials":1286,"activeCount":102},[],{"intervention":1288,"totalTrials":136,"cells":1289},"IMT",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1291,"activeCount":102},[],{"trials":1293,"activeCount":136,"soonestReadout":1298},[1294],{"nctId":1295,"briefTitle":1296,"status":155,"phases":1297,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":355,"conditions":1300,"interventions":1301},"NCT06370884","Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection",[90],"2026-09-01","2024-02-01",[1276,1277],[1288],{"trials":1303,"activeCount":102},[],{"trials":1305,"activeCount":102},[],{"trials":1307,"activeCount":102},[],{"trials":1309,"activeCount":102},[],{"intervention":1311,"totalTrials":136,"cells":1312},"External non-invasive stimulation",{"EARLY_PHASE1":1313,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1314,"activeCount":136,"soonestReadout":1319},[1315],{"nctId":1316,"briefTitle":1317,"status":155,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":23,"conditions":1321,"interventions":1323},"NCT05327829","Stimulating After Recovery From Traumatic Brain Injury",[89],"2028-01-15","2025-03-31",[1322],"TBI (Traumatic Brain Injury)",[1311],{"trials":1325,"activeCount":102},[],{"trials":1327,"activeCount":102},[],{"trials":1329,"activeCount":102},[],{"trials":1331,"activeCount":102},[],{"trials":1333,"activeCount":102},[],{"intervention":1335,"totalTrials":136,"cells":1336},"alcohol condition",{"EARLY_PHASE1":1337,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1338,"activeCount":136,"soonestReadout":1343},[1339],{"nctId":1340,"briefTitle":1341,"status":155,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1348},"NCT06659991","JIT: Effect of Pain on DT in TMD",[89],"2029-09-07","2025-05-14",160,[1347],"Temporomandibular Disorder (TMD)",[1335],{"trials":1350,"activeCount":102},[],{"trials":1352,"activeCount":102},[],{"trials":1354,"activeCount":102},[],{"trials":1356,"activeCount":102},[],{"trials":1358,"activeCount":102},[],{"intervention":58,"totalTrials":136,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1362,"activeCount":136,"soonestReadout":57},[1363],{"nctId":55,"briefTitle":56,"status":155,"phases":1364,"primaryCompletion":57,"completion":57,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1368},[89],"2025-06-12",6,[797],[58,1369],"levodopa\u002Fcarbidopa oral formulation B",{"trials":1371,"activeCount":102},[],{"trials":1373,"activeCount":102},[],{"trials":1375,"activeCount":102},[],{"trials":1377,"activeCount":102},[],{"trials":1379,"activeCount":102},[],{"intervention":1369,"totalTrials":136,"cells":1381},{"EARLY_PHASE1":1382,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1383,"activeCount":136,"soonestReadout":57},[1384],{"nctId":55,"briefTitle":56,"status":155,"phases":1385,"primaryCompletion":57,"completion":57,"start":1365,"enrollment":1366,"conditions":1386,"interventions":1387},[89],[797],[58,1369],{"trials":1389,"activeCount":102},[],{"trials":1391,"activeCount":102},[],{"trials":1393,"activeCount":102},[],{"trials":1395,"activeCount":102},[],{"trials":1397,"activeCount":102},[],{"intervention":1399,"totalTrials":136,"cells":1400},"Fecal Microbiota - lyophilized",{"EARLY_PHASE1":1401,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1402,"activeCount":136,"soonestReadout":1298},[1403],{"nctId":1404,"briefTitle":1405,"status":155,"phases":1406,"primaryCompletion":1298,"completion":1298,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1411},"NCT06058520","Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa",[89],"2023-10-01",16,[1410],"Hidradenitis Suppurativa",[1399],{"trials":1413,"activeCount":102},[],{"trials":1415,"activeCount":102},[],{"trials":1417,"activeCount":102},[],{"trials":1419,"activeCount":102},[],{"trials":1421,"activeCount":102},[],{"intervention":1423,"totalTrials":136,"cells":1424},"oral vancomycin and oral amoxicillin",{"EARLY_PHASE1":1425,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1443,"NA":1445},{"trials":1426,"activeCount":136,"soonestReadout":1431},[1427],{"nctId":1428,"briefTitle":1429,"status":155,"phases":1430,"primaryCompletion":1431,"completion":1432,"start":1433,"enrollment":26,"conditions":1434,"interventions":1436},"NCT06197308","Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC",[89],"2027-03-31","2027-09-01","2024-03-01",[1435],"Primary Sclerosing Cholangitis",[1423],{"trials":1438,"activeCount":102},[],{"trials":1440,"activeCount":102},[],{"trials":1442,"activeCount":102},[],{"trials":1444,"activeCount":102},[],{"trials":1446,"activeCount":102},[],{"intervention":1448,"totalTrials":136,"cells":1449},"mirdametinib and vorinostat",{"EARLY_PHASE1":1450,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1468},{"trials":1451,"activeCount":136,"soonestReadout":131},[1452],{"nctId":1453,"briefTitle":1454,"status":155,"phases":1455,"primaryCompletion":131,"completion":131,"start":1456,"enrollment":117,"conditions":1457,"interventions":1459},"NCT06693284","A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",[89],"2025-11-20",[1458],"Primary Malignant Peripheral Nerve Sheath Tumors",[1448],{"trials":1461,"activeCount":102},[],{"trials":1463,"activeCount":102},[],{"trials":1465,"activeCount":102},[],{"trials":1467,"activeCount":102},[],{"trials":1469,"activeCount":102},[],{"intervention":48,"totalTrials":136,"cells":1471},{"EARLY_PHASE1":1472,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1473,"activeCount":136,"soonestReadout":47},[1474],{"nctId":45,"briefTitle":46,"status":467,"phases":1475,"primaryCompletion":47,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1481},[89],"2026-10-27","2022-07-07",13,[1480],"Pediatric Obesity",[48],{"trials":1483,"activeCount":102},[],{"trials":1485,"activeCount":102},[],{"trials":1487,"activeCount":102},[],{"trials":1489,"activeCount":102},[],{"trials":1491,"activeCount":102},[],{"intervention":1493,"totalTrials":136,"cells":1494},"Prophylactic antibiotics postoperatively.",{"EARLY_PHASE1":1495,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1496,"activeCount":136,"soonestReadout":1501},[1497],{"nctId":1498,"briefTitle":1499,"status":155,"phases":1500,"primaryCompletion":1501,"completion":1501,"start":1502,"enrollment":977,"conditions":1503,"interventions":1508},"NCT06190197","Prophylactic Antibiotics in Cystectomy With Diversion",[89],"2027-10-15","2024-05-13",[1504,1505,1506,1507],"Muscle-Invasive Bladder Carcinoma","Radical Cystectomy","Ileal Conduit","Neobladder Diversion",[1493],{"trials":1510,"activeCount":102},[],{"trials":1512,"activeCount":102},[],{"trials":1514,"activeCount":102},[],{"trials":1516,"activeCount":102},[],{"trials":1518,"activeCount":102},[],{"intervention":82,"totalTrials":136,"cells":1520},{"EARLY_PHASE1":1521,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1522,"activeCount":136,"soonestReadout":77},[1523],{"nctId":80,"briefTitle":81,"status":467,"phases":1524,"primaryCompletion":77,"completion":1525,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1529},[89],"2027-07-31","2023-12-20",44,[134],[82],{"trials":1531,"activeCount":102},[],{"trials":1533,"activeCount":102},[],{"trials":1535,"activeCount":102},[],{"trials":1537,"activeCount":102},[],{"trials":1539,"activeCount":102},[],{"intervention":68,"totalTrials":136,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1543,"activeCount":136,"soonestReadout":67},[1544],{"nctId":65,"briefTitle":66,"status":155,"phases":1545,"primaryCompletion":67,"completion":67,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1552},[89],"2024-07-01",50,[1549,1550,1551],"Hemophilia","Hemorrhage","Facelift Surgery",[68,1553,1554],"3% TXA","1% TXA with local plus 3% TXA-soaked pledgets",{"trials":1556,"activeCount":102},[],{"trials":1558,"activeCount":102},[],{"trials":1560,"activeCount":102},[],{"trials":1562,"activeCount":102},[],{"trials":1564,"activeCount":102},[],{"intervention":1553,"totalTrials":136,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":136,"soonestReadout":67},[1569],{"nctId":65,"briefTitle":66,"status":155,"phases":1570,"primaryCompletion":67,"completion":67,"start":1546,"enrollment":1547,"conditions":1571,"interventions":1572},[89],[1549,1550,1551],[68,1553,1554],{"trials":1574,"activeCount":102},[],{"trials":1576,"activeCount":102},[],{"trials":1578,"activeCount":102},[],{"trials":1580,"activeCount":102},[],{"trials":1582,"activeCount":102},[],{"intervention":1554,"totalTrials":136,"cells":1584},{"EARLY_PHASE1":1585,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1586,"activeCount":136,"soonestReadout":67},[1587],{"nctId":65,"briefTitle":66,"status":155,"phases":1588,"primaryCompletion":67,"completion":67,"start":1546,"enrollment":1547,"conditions":1589,"interventions":1590},[89],[1549,1550,1551],[68,1553,1554],{"trials":1592,"activeCount":102},[],{"trials":1594,"activeCount":102},[],{"trials":1596,"activeCount":102},[],{"trials":1598,"activeCount":102},[],{"trials":1600,"activeCount":102},[],{"intervention":1602,"totalTrials":117,"cells":1603},"Bupivacaine",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1622,"PHASE4":1624,"NA":1693},{"trials":1605,"activeCount":102},[],{"trials":1607,"activeCount":102},[],{"trials":1609,"activeCount":102},[1610],{"nctId":1611,"briefTitle":1612,"status":112,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT03587636","Liposome Bupivacaine Interscalene Total Shoulder",[91],"2021-03-15","2021-03-17","2018-09-17",77,[1619],"Acute Pain",[1621,1602],"liposome bupivacaine",{"trials":1623,"activeCount":102},[],{"trials":1625,"activeCount":102},[1626,1641,1653,1661,1668,1677,1684],{"nctId":1627,"briefTitle":1628,"status":112,"phases":1629,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1635},"NCT02519023","TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy",[93],"2017-05","2017-06","2016-07",87,[1619],[1636,1602,1637,1638,1639,1640],"Liposomal Bupivacaine","Epinephrine","acetaminophen","ibuprofen","Oxycodone",{"nctId":1642,"briefTitle":1643,"status":112,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":1647,"conditions":1648,"interventions":1650},"NCT03636542","Evaluation of Diaphragm Movement After an Interscalene Block",[93],"2020-06-03","2018-08-01",26,[1649],"Phrenic Nerve Paralysis",[1651,1652],"liposomal bupivacaine","bupivacaine",{"nctId":1654,"briefTitle":1655,"status":112,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":12,"conditions":1659,"interventions":1660},"NCT02289079","TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Robotic Hysterectomy",[93],"2014-10","2013-06",[1619],[1602,1651],{"nctId":1662,"briefTitle":1663,"status":112,"phases":1664,"primaryCompletion":1546,"completion":1546,"start":1665,"enrollment":1188,"conditions":1666,"interventions":1667},"NCT03599635","Pec Infiltration With Liposomal Bupivacaine for Breast Surgery",[93],"2018-07-01",[1619],[1651,1602],{"nctId":1669,"briefTitle":1670,"status":841,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":102,"conditions":1674,"interventions":1676},"NCT03020563","Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?",[93],"2018-01-01","2017-08-23",[1675],"Clavicle Fracture",[1636,1602],{"nctId":1678,"briefTitle":1679,"status":112,"phases":1680,"primaryCompletion":510,"completion":1657,"start":1681,"enrollment":12,"conditions":1682,"interventions":1683},"NCT02287623","Subcostal TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Donor Nephrectomy Patients: A Prospective Study",[93],"2013-05",[1619],[1651,1652],{"nctId":1685,"briefTitle":1686,"status":112,"phases":1687,"primaryCompletion":1688,"completion":1689,"start":1690,"enrollment":457,"conditions":1691,"interventions":1692},"NCT03587584","Liposomal Bupivacaine Interscalene Blocks for Rotator Cuff Repair",[93],"2021-05-25","2021-06-08","2018-07-25",[1619],[1651,1602],{"trials":1694,"activeCount":102},[],{"intervention":1651,"totalTrials":1696,"cells":1697},7,{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1736},{"trials":1699,"activeCount":102},[],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":102},[],{"trials":1705,"activeCount":102},[],{"trials":1707,"activeCount":102},[1708,1712,1716,1720,1724,1728,1732],{"nctId":1627,"briefTitle":1628,"status":112,"phases":1709,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":1710,"interventions":1711},[93],[1619],[1636,1602,1637,1638,1639,1640],{"nctId":1642,"briefTitle":1643,"status":112,"phases":1713,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":1647,"conditions":1714,"interventions":1715},[93],[1649],[1651,1652],{"nctId":1654,"briefTitle":1655,"status":112,"phases":1717,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":12,"conditions":1718,"interventions":1719},[93],[1619],[1602,1651],{"nctId":1662,"briefTitle":1663,"status":112,"phases":1721,"primaryCompletion":1546,"completion":1546,"start":1665,"enrollment":1188,"conditions":1722,"interventions":1723},[93],[1619],[1651,1602],{"nctId":1669,"briefTitle":1670,"status":841,"phases":1725,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":102,"conditions":1726,"interventions":1727},[93],[1675],[1636,1602],{"nctId":1678,"briefTitle":1679,"status":112,"phases":1729,"primaryCompletion":510,"completion":1657,"start":1681,"enrollment":12,"conditions":1730,"interventions":1731},[93],[1619],[1651,1652],{"nctId":1685,"briefTitle":1686,"status":112,"phases":1733,"primaryCompletion":1688,"completion":1689,"start":1690,"enrollment":457,"conditions":1734,"interventions":1735},[93],[1619],[1651,1602],{"trials":1737,"activeCount":102},[],{"intervention":1739,"totalTrials":98,"cells":1740},"Efavirenz",{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1749,"NA":1775},{"trials":1742,"activeCount":102},[],{"trials":1744,"activeCount":102},[],{"trials":1746,"activeCount":102},[],{"trials":1748,"activeCount":102},[],{"trials":1750,"activeCount":102},[1751,1763],{"nctId":1752,"briefTitle":1753,"status":112,"phases":1754,"primaryCompletion":1755,"completion":1756,"start":1757,"enrollment":1408,"conditions":1758,"interventions":1761},"NCT01087814","Sustiva Levels With Use of a Gel Capsule",[93],"2010-09","2011-09","2010-02",[1759,1760],"HIV","HIV Infections",[1739,1762],"Over-encapsulated efavirenz",{"nctId":1764,"briefTitle":1765,"status":112,"phases":1766,"primaryCompletion":1767,"completion":1768,"start":1147,"enrollment":1769,"conditions":1770,"interventions":1772},"NCT01075152","Cryptococcal Optimal ART Timing Trial",[93],"2012-10","2013-03",177,[497,1760,1771],"AIDS",[1773,1774],"efavirenz","nucleoside",{"trials":1776,"activeCount":102},[],{"intervention":1637,"totalTrials":98,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1801,"NA":1807},{"trials":1780,"activeCount":102},[],{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[],{"trials":1786,"activeCount":102},[1787],{"nctId":1788,"briefTitle":1789,"status":841,"phases":1790,"primaryCompletion":1791,"completion":1792,"start":1793,"enrollment":102,"conditions":1794,"interventions":1798},"NCT03513445","Peri-Incisional Drug Injection in Lumbar Spine Surgery",[92],"2022-03","2022-09","2018-06-01",[1795,1796,1797],"Lumbar Disc Herniation","Degenerative Disc Disease","Spondylolisthesis",[1799,1637,1800],"Morphine","naropin",{"trials":1802,"activeCount":102},[1803],{"nctId":1627,"briefTitle":1628,"status":112,"phases":1804,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":1805,"interventions":1806},[93],[1619],[1636,1602,1637,1638,1639,1640],{"trials":1808,"activeCount":102},[],{"intervention":1810,"totalTrials":98,"cells":1811},"Sublingual Sufentanil",{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1844},{"trials":1813,"activeCount":102},[],{"trials":1815,"activeCount":102},[],{"trials":1817,"activeCount":102},[],{"trials":1819,"activeCount":102},[],{"trials":1821,"activeCount":102},[1822,1835],{"nctId":1823,"briefTitle":1824,"status":112,"phases":1825,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1833},"NCT04177862","Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center",[93],"2020-01-31","2019-12-11",75,[1830,1831,1832],"Pain","Pain, Acute","Anesthesia",[1810,1834],"IV Fentanyl",{"nctId":1836,"briefTitle":1837,"status":112,"phases":1838,"primaryCompletion":1839,"completion":1839,"start":1840,"enrollment":1841,"conditions":1842,"interventions":1843},"NCT04387136","Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center",[93],"2021-02-04","2020-10-14",53,[1830,1831,1832],[1810],{"trials":1845,"activeCount":102},[],{"intervention":1847,"totalTrials":98,"cells":1848},"Fluconazole",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1870,"NA":1882},{"trials":1850,"activeCount":102},[],{"trials":1852,"activeCount":102},[],{"trials":1854,"activeCount":102},[],{"trials":1856,"activeCount":102},[1857],{"nctId":1858,"briefTitle":1859,"status":1860,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":29,"conditions":1864,"interventions":1868},"NCT03002012","Cryptococcal Antigen Screening Plus Sertraline","TERMINATED",[92],"2018-03-13","2017-11-15",[1865,1866,1867],"Cryptococcosis","Cryptococcal Infections","AIDS-Related Opportunistic Infections",[1869,1847],"Sertraline",{"trials":1871,"activeCount":102},[1872],{"nctId":1873,"briefTitle":1874,"status":112,"phases":1875,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1881},"NCT01535469","Operational Research for Cryptococcal Antigen Screening",[93],"2015-06","2012-07-01",3049,[497,1880,1865],"Cryptococcus Neoformans",[1847],{"trials":1883,"activeCount":102},[],{"intervention":1885,"totalTrials":98,"cells":1886},"Ropivacaine",{"EARLY_PHASE1":1887,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1902,"NA":1908},{"trials":1888,"activeCount":102},[1889],{"nctId":1890,"briefTitle":1891,"status":112,"phases":1892,"primaryCompletion":1657,"completion":1657,"start":1893,"enrollment":1547,"conditions":1894,"interventions":1895},"NCT02361775","Paravertebral Catheters for VATS Procedures",[89],"2012-07",[1619],[1885],{"trials":1897,"activeCount":102},[],{"trials":1899,"activeCount":102},[],{"trials":1901,"activeCount":102},[],{"trials":1903,"activeCount":102},[1904],{"nctId":166,"briefTitle":167,"status":168,"phases":1905,"primaryCompletion":158,"completion":158,"start":170,"enrollment":171,"conditions":1906,"interventions":1907},[93],[173],[175,140],{"trials":1909,"activeCount":102},[],{"intervention":1911,"totalTrials":136,"cells":1912},"Tacrolimus",{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1921,"NA":1934},{"trials":1914,"activeCount":102},[],{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":102},[],{"trials":1920,"activeCount":102},[],{"trials":1922,"activeCount":102},[1923],{"nctId":1924,"briefTitle":1925,"status":1860,"phases":1926,"completion":1927,"start":1928,"enrollment":1929,"conditions":1930,"interventions":1932},"NCT00177138","Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation",[93],"2006-11","2004-07",9,[1931],"Diabetes Mellitus",[1911,1933],"Alemtuzumab",{"trials":1935,"activeCount":102},[],{"intervention":1933,"totalTrials":136,"cells":1937},{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1944,"PHASE4":1946,"NA":1952},{"trials":1939,"activeCount":102},[],{"trials":1941,"activeCount":102},[],{"trials":1943,"activeCount":102},[],{"trials":1945,"activeCount":102},[],{"trials":1947,"activeCount":102},[1948],{"nctId":1924,"briefTitle":1925,"status":1860,"phases":1949,"completion":1927,"start":1928,"enrollment":1929,"conditions":1950,"interventions":1951},[93],[1931],[1911,1933],{"trials":1953,"activeCount":102},[],{"intervention":1955,"totalTrials":136,"cells":1956},"Lorazepam",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1965,"NA":1978},{"trials":1958,"activeCount":102},[],{"trials":1960,"activeCount":102},[],{"trials":1962,"activeCount":102},[],{"trials":1964,"activeCount":102},[],{"trials":1966,"activeCount":102},[1967],{"nctId":1968,"briefTitle":1969,"status":112,"phases":1970,"primaryCompletion":509,"completion":509,"start":1971,"enrollment":12,"conditions":1972,"interventions":1974},"NCT01889602","Characterizing and Predicting Drug Effects on Cognition",[93],"2013-07",[1973],"Cognitive Deficits",[1955,1975,1976,1977],"Topiramate 100mg","Topiramate 150mg","Topiramate 200mg",{"trials":1979,"activeCount":102},[],{"intervention":1975,"totalTrials":136,"cells":1981},{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1990,"NA":1996},{"trials":1983,"activeCount":102},[],{"trials":1985,"activeCount":102},[],{"trials":1987,"activeCount":102},[],{"trials":1989,"activeCount":102},[],{"trials":1991,"activeCount":102},[1992],{"nctId":1968,"briefTitle":1969,"status":112,"phases":1993,"primaryCompletion":509,"completion":509,"start":1971,"enrollment":12,"conditions":1994,"interventions":1995},[93],[1973],[1955,1975,1976,1977],{"trials":1997,"activeCount":102},[],{"intervention":1976,"totalTrials":136,"cells":1999},{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2014},{"trials":2001,"activeCount":102},[],{"trials":2003,"activeCount":102},[],{"trials":2005,"activeCount":102},[],{"trials":2007,"activeCount":102},[],{"trials":2009,"activeCount":102},[2010],{"nctId":1968,"briefTitle":1969,"status":112,"phases":2011,"primaryCompletion":509,"completion":509,"start":1971,"enrollment":12,"conditions":2012,"interventions":2013},[93],[1973],[1955,1975,1976,1977],{"trials":2015,"activeCount":102},[],{"intervention":1977,"totalTrials":136,"cells":2017},{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2032},{"trials":2019,"activeCount":102},[],{"trials":2021,"activeCount":102},[],{"trials":2023,"activeCount":102},[],{"trials":2025,"activeCount":102},[],{"trials":2027,"activeCount":102},[2028],{"nctId":1968,"briefTitle":1969,"status":112,"phases":2029,"primaryCompletion":509,"completion":509,"start":1971,"enrollment":12,"conditions":2030,"interventions":2031},[93],[1973],[1955,1975,1976,1977],{"trials":2033,"activeCount":102},[],{"intervention":2035,"totalTrials":136,"cells":2036},"Exparel",{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2057},{"trials":2038,"activeCount":102},[],{"trials":2040,"activeCount":102},[],{"trials":2042,"activeCount":102},[],{"trials":2044,"activeCount":102},[],{"trials":2046,"activeCount":102},[2047],{"nctId":2048,"briefTitle":2049,"status":841,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":102,"conditions":2054,"interventions":2056},"NCT03377595","Post C-Section Pain Control Using EXPAREL",[93],"2019-08-30","2019-09-01","2019-07-02",[2055],"Pain, Postoperative",[2035,2035],{"trials":2058,"activeCount":102},[],{"intervention":2060,"totalTrials":136,"cells":2061},"celecoxib",{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2070,"NA":2081},{"trials":2063,"activeCount":102},[],{"trials":2065,"activeCount":102},[],{"trials":2067,"activeCount":102},[],{"trials":2069,"activeCount":102},[],{"trials":2071,"activeCount":102},[2072],{"nctId":2073,"briefTitle":2074,"status":841,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":102,"conditions":2078,"interventions":2080},"NCT00304317","Celecoxib (Celebrex) in the Management of Acute Renal Colic",[93],"2008-08","2006-03",[2079],"Ureteral Calculi",[2060],{"trials":2082,"activeCount":102},[],{"intervention":1762,"totalTrials":136,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2099},{"trials":2086,"activeCount":102},[],{"trials":2088,"activeCount":102},[],{"trials":2090,"activeCount":102},[],{"trials":2092,"activeCount":102},[],{"trials":2094,"activeCount":102},[2095],{"nctId":1752,"briefTitle":1753,"status":112,"phases":2096,"primaryCompletion":1755,"completion":1756,"start":1757,"enrollment":1408,"conditions":2097,"interventions":2098},[93],[1759,1760],[1739,1762],{"trials":2100,"activeCount":102},[],{"intervention":2102,"totalTrials":136,"cells":2103},"Capsaicin",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2122},{"trials":2105,"activeCount":102},[],{"trials":2107,"activeCount":102},[],{"trials":2109,"activeCount":102},[],{"trials":2111,"activeCount":102},[],{"trials":2113,"activeCount":102},[2114],{"nctId":2115,"briefTitle":2116,"status":112,"phases":2117,"completion":2118,"start":2119,"enrollment":420,"conditions":2120,"interventions":2121},"NCT00176969","Response of Topical Capsaicin in Alopecia Areata",[93],"2000-06","1997-08",[1031],[2102],{"trials":2123,"activeCount":102},[],{"intervention":1638,"totalTrials":136,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2140},{"trials":2127,"activeCount":102},[],{"trials":2129,"activeCount":102},[],{"trials":2131,"activeCount":102},[],{"trials":2133,"activeCount":102},[],{"trials":2135,"activeCount":102},[2136],{"nctId":1627,"briefTitle":1628,"status":112,"phases":2137,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":2138,"interventions":2139},[93],[1619],[1636,1602,1637,1638,1639,1640],{"trials":2141,"activeCount":102},[],{"intervention":1639,"totalTrials":136,"cells":2143},{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2150,"PHASE4":2152,"NA":2158},{"trials":2145,"activeCount":102},[],{"trials":2147,"activeCount":102},[],{"trials":2149,"activeCount":102},[],{"trials":2151,"activeCount":102},[],{"trials":2153,"activeCount":102},[2154],{"nctId":1627,"briefTitle":1628,"status":112,"phases":2155,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":2156,"interventions":2157},[93],[1619],[1636,1602,1637,1638,1639,1640],{"trials":2159,"activeCount":102},[],{"intervention":1640,"totalTrials":136,"cells":2161},{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2168,"PHASE4":2170,"NA":2176},{"trials":2163,"activeCount":102},[],{"trials":2165,"activeCount":102},[],{"trials":2167,"activeCount":102},[],{"trials":2169,"activeCount":102},[],{"trials":2171,"activeCount":102},[2172],{"nctId":1627,"briefTitle":1628,"status":112,"phases":2173,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":2174,"interventions":2175},[93],[1619],[1636,1602,1637,1638,1639,1640],{"trials":2177,"activeCount":102},[],{"intervention":1834,"totalTrials":136,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2194},{"trials":2181,"activeCount":102},[],{"trials":2183,"activeCount":102},[],{"trials":2185,"activeCount":102},[],{"trials":2187,"activeCount":102},[],{"trials":2189,"activeCount":102},[2190],{"nctId":1823,"briefTitle":1824,"status":112,"phases":2191,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":1828,"conditions":2192,"interventions":2193},[93],[1830,1831,1832],[1810,1834],{"trials":2195,"activeCount":102},[],{"intervention":2197,"totalTrials":136,"cells":2198},"etanercept",{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2220},{"trials":2200,"activeCount":102},[],{"trials":2202,"activeCount":102},[],{"trials":2204,"activeCount":102},[],{"trials":2206,"activeCount":102},[],{"trials":2208,"activeCount":102},[2209],{"nctId":2210,"briefTitle":2211,"status":112,"phases":2212,"primaryCompletion":2213,"completion":891,"start":2214,"enrollment":2215,"conditions":2216,"interventions":2218},"NCT02713997","Anti-inflammatory Therapy to Improve Outcomes After TPIAT",[93],"2023-07-01","2016-12",43,[2217],"Pancreatitis, Chronic; Diabetes; Transplant",[2197,2219],"Alpha 1-Antitrypsin",{"trials":2221,"activeCount":102},[],{"intervention":2219,"totalTrials":136,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2232,"NA":2238},{"trials":2225,"activeCount":102},[],{"trials":2227,"activeCount":102},[],{"trials":2229,"activeCount":102},[],{"trials":2231,"activeCount":102},[],{"trials":2233,"activeCount":102},[2234],{"nctId":2210,"briefTitle":2211,"status":112,"phases":2235,"primaryCompletion":2213,"completion":891,"start":2214,"enrollment":2215,"conditions":2236,"interventions":2237},[93],[2217],[2197,2219],{"trials":2239,"activeCount":102},[],{"intervention":2241,"totalTrials":136,"cells":2242},"Losartan 100mg",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2264},{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":102},[],{"trials":2248,"activeCount":102},[],{"trials":2250,"activeCount":102},[],{"trials":2252,"activeCount":102},[2253],{"nctId":2254,"briefTitle":2255,"status":112,"phases":2256,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":2259,"conditions":2260,"interventions":2263},"NCT00067990","Angiotensin II Blockade for Chronic Allograft Nephropathy",[93],"2011-06","2002-12",153,[2261,2262],"Kidney Disease","Proteinuria",[2241],{"trials":2265,"activeCount":102},[],{"intervention":2267,"totalTrials":136,"cells":2268},"Sitagliptin",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2289},{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[],{"trials":2276,"activeCount":102},[],{"trials":2278,"activeCount":102},[2279],{"nctId":2280,"briefTitle":2281,"status":112,"phases":2282,"primaryCompletion":2283,"completion":534,"start":2284,"enrollment":2285,"conditions":2286,"interventions":2288},"NCT01186562","Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant",[93],"2015-07","2010-08",83,[2287,359],"Pancreatitis",[2267],{"trials":2290,"activeCount":102},[],{"intervention":2292,"totalTrials":136,"cells":2293},"nicotine patch plus nicotine gum\u002Flozenge",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2302,"NA":2316},{"trials":2295,"activeCount":102},[],{"trials":2297,"activeCount":102},[],{"trials":2299,"activeCount":102},[],{"trials":2301,"activeCount":102},[],{"trials":2303,"activeCount":102},[2304],{"nctId":2305,"briefTitle":2306,"status":112,"phases":2307,"primaryCompletion":2308,"completion":2308,"start":2309,"enrollment":2310,"conditions":2311,"interventions":2315},"NCT01932996","Enhancing Smoking Cessation in the Homeless Population",[93],"2018-10-31","2015-01",352,[2312,2313,2314],"Cigarette Smoking","Tobacco Smoking","Smoking, Tobacco",[2292],{"trials":2317,"activeCount":102},[],{"intervention":2319,"totalTrials":136,"cells":2320},"Cyclosporins\u002FTacrolimus",{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2341},{"trials":2322,"activeCount":102},[],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[],{"trials":2330,"activeCount":102},[2331],{"nctId":2332,"briefTitle":2333,"status":841,"phases":2334,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":102,"conditions":2337,"interventions":2339},"NCT01492894","Kidney Allograft Dysfunction Without Reversible Causes",[93],"2011-10","2008-01",[2338],"Kidney Graft Dysfunction",[2319,2340],"Sirolimus",{"trials":2342,"activeCount":102},[],{"intervention":2344,"totalTrials":136,"cells":2345},"Fondaparinux",{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2365},{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":102},[],{"trials":2353,"activeCount":102},[],{"trials":2355,"activeCount":102},[2356],{"nctId":2357,"briefTitle":2358,"status":841,"phases":2359,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":102,"conditions":2362,"interventions":2364},"NCT00377091","Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy",[93],"2007-11","2007-06",[2363],"Pulmonary Embolism",[2344],{"trials":2366,"activeCount":102},[],{"intervention":849,"totalTrials":136,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2377,"NA":2383},{"trials":2370,"activeCount":102},[],{"trials":2372,"activeCount":102},[],{"trials":2374,"activeCount":102},[],{"trials":2376,"activeCount":102},[],{"trials":2378,"activeCount":102},[2379],{"nctId":839,"briefTitle":840,"status":841,"phases":2380,"primaryCompletion":843,"completion":844,"start":845,"enrollment":102,"conditions":2381,"interventions":2382},[93],[16,847],[849,804],{"trials":2384,"activeCount":102},[],{"intervention":2386,"totalTrials":136,"cells":2387},"All licensed antiretroviral medications",{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2408},{"trials":2389,"activeCount":102},[],{"trials":2391,"activeCount":102},[],{"trials":2393,"activeCount":102},[],{"trials":2395,"activeCount":102},[],{"trials":2397,"activeCount":102},[2398],{"nctId":2399,"briefTitle":2400,"status":112,"phases":2401,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":2404,"conditions":2405,"interventions":2407},"NCT00867048","Strategic Timing of Antiretroviral Treatment",[93],"2022-07-27","2009-04-15",4688,[2406],"HIV Infection",[2386],{"trials":2409,"activeCount":102},[],{"intervention":515,"totalTrials":136,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2426},{"trials":2413,"activeCount":102},[],{"trials":2415,"activeCount":102},[],{"trials":2417,"activeCount":102},[],{"trials":2419,"activeCount":102},[],{"trials":2421,"activeCount":102},[2422],{"nctId":506,"briefTitle":507,"status":112,"phases":2423,"primaryCompletion":509,"completion":509,"start":510,"enrollment":160,"conditions":2424,"interventions":2425},[93],[512,513],[515,516],{"trials":2427,"activeCount":102},[],{"intervention":2429,"totalTrials":136,"cells":2430},"miglustat",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2439,"NA":2453},{"trials":2432,"activeCount":102},[],{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":102},[],{"trials":2438,"activeCount":102},[],{"trials":2440,"activeCount":102},[2441],{"nctId":2442,"briefTitle":2443,"status":1860,"phases":2444,"primaryCompletion":2445,"completion":2445,"start":2446,"enrollment":1408,"conditions":2447,"interventions":2452},"NCT02030015","Synergistic Enteral Regimen for Treatment of the Gangliosidoses",[93],"2019-07-31","2015-12-22",[2448,2449,2450,2451],"GM1 Gangliosidoses","GM2 Gangliosidoses","Tay-Sachs Disease","Sandhoff Disease",[2429],{"trials":2454,"activeCount":102},[],{"intervention":2456,"totalTrials":136,"cells":2457},"insulin pre-treatment",{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2477},{"trials":2459,"activeCount":102},[],{"trials":2461,"activeCount":102},[],{"trials":2463,"activeCount":102},[],{"trials":2465,"activeCount":102},[],{"trials":2467,"activeCount":102},[2468],{"nctId":2469,"briefTitle":2470,"status":841,"phases":2471,"primaryCompletion":2472,"completion":2472,"start":2473,"enrollment":102,"conditions":2474,"interventions":2476},"NCT01875107","Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients",[93],"2014-08","2013-08",[2475],"Hyperglycemia in Pregnant Diabetic Patients",[2456],{"trials":2478,"activeCount":102},[],{"intervention":2480,"totalTrials":136,"cells":2481},"Ropivacaine 0.2% Injectable Solution",{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2486,"PHASE3":2488,"PHASE4":2490,"NA":2503},{"trials":2483,"activeCount":102},[],{"trials":2485,"activeCount":102},[],{"trials":2487,"activeCount":102},[],{"trials":2489,"activeCount":102},[],{"trials":2491,"activeCount":102},[2492],{"nctId":2493,"briefTitle":2494,"status":112,"phases":2495,"primaryCompletion":2496,"completion":2496,"start":2497,"enrollment":20,"conditions":2498,"interventions":2502},"NCT04472299","Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery",[93],"2025-07-08","2021-04-09",[2499,2500,2501],"New Onset Atrial Fibrillation","Anesthesia, Local","Cardiac Disease",[2480],{"trials":2504,"activeCount":102},[],{"intervention":2506,"totalTrials":136,"cells":2507},"abatacept",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2527},{"trials":2509,"activeCount":102},[],{"trials":2511,"activeCount":102},[],{"trials":2513,"activeCount":102},[],{"trials":2515,"activeCount":102},[],{"trials":2517,"activeCount":102},[2518],{"nctId":2519,"briefTitle":2520,"status":112,"phases":2521,"primaryCompletion":2522,"completion":558,"start":2523,"enrollment":2524,"conditions":2525,"interventions":2526},"NCT05822583","Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial",[93],"2025-06-21","2023-07-06",285,[596],[2506],{"trials":2528,"activeCount":102},[],{"intervention":2530,"totalTrials":136,"cells":2531},"Escitalopram",{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2538,"PHASE4":2540,"NA":2551},{"trials":2533,"activeCount":102},[],{"trials":2535,"activeCount":102},[],{"trials":2537,"activeCount":102},[],{"trials":2539,"activeCount":102},[],{"trials":2541,"activeCount":102},[2542],{"nctId":2543,"briefTitle":2544,"status":112,"phases":2545,"primaryCompletion":2546,"completion":2547,"start":2548,"enrollment":892,"conditions":2549,"interventions":2550},"NCT00872027","Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit",[93],"2011-04","2011-07","2009-04",[36],[2530],{"trials":2552,"activeCount":102},[],{"intervention":1774,"totalTrials":136,"cells":2554},{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2561,"PHASE4":2563,"NA":2569},{"trials":2556,"activeCount":102},[],{"trials":2558,"activeCount":102},[],{"trials":2560,"activeCount":102},[],{"trials":2562,"activeCount":102},[],{"trials":2564,"activeCount":102},[2565],{"nctId":1764,"briefTitle":1765,"status":112,"phases":2566,"primaryCompletion":1767,"completion":1768,"start":1147,"enrollment":1769,"conditions":2567,"interventions":2568},[93],[497,1760,1771],[1773,1774],{"trials":2570,"activeCount":102},[],{"intervention":2572,"totalTrials":136,"cells":2573},"minocycline HCl microspheres",{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2596},{"trials":2575,"activeCount":102},[],{"trials":2577,"activeCount":102},[],{"trials":2579,"activeCount":102},[],{"trials":2581,"activeCount":102},[],{"trials":2583,"activeCount":102},[2584],{"nctId":2585,"briefTitle":2586,"status":112,"phases":2587,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":2590,"conditions":2591,"interventions":2595},"NCT03762915","Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg",[93],"2022-04-01","2019-05-20",70,[2592,2593,2594],"SRP","Minocycline HCl Microspheres","Biomarkers",[2572],{"trials":2597,"activeCount":102},[],{"intervention":1869,"totalTrials":521,"cells":2599},{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2615,"PHASE4":2632,"NA":2634},{"trials":2601,"activeCount":102},[],{"trials":2603,"activeCount":102},[],{"trials":2605,"activeCount":102},[2606],{"nctId":2607,"briefTitle":2608,"status":112,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2473,"enrollment":2611,"conditions":2612,"interventions":2614},"NCT02797808","Effects of Sertraline on Brain Connectivity in Adolescents With OCD",[90,91],"2017-01-31",41,[2613],"OCD",[1869],{"trials":2616,"activeCount":102},[2617,2621],{"nctId":1858,"briefTitle":1859,"status":1860,"phases":2618,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":29,"conditions":2619,"interventions":2620},[92],[1865,1866,1867],[1869,1847],{"nctId":2622,"briefTitle":2623,"status":112,"phases":2624,"primaryCompletion":2625,"completion":2626,"start":2627,"enrollment":2628,"conditions":2629,"interventions":2631},"NCT01802385","Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis",[92],"2017-09","2017-09-27","2015-03-09",460,[497,2630],"Fungal Meningitis",[1869],{"trials":2633,"activeCount":102},[],{"trials":2635,"activeCount":102},[],{"intervention":2637,"totalTrials":98,"cells":2638},"Atorvastatin",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2659,"PHASE4":2674,"NA":2676},{"trials":2640,"activeCount":102},[],{"trials":2642,"activeCount":102},[],{"trials":2644,"activeCount":102},[2645],{"nctId":2646,"briefTitle":2647,"status":112,"phases":2648,"primaryCompletion":2649,"completion":2650,"start":2651,"enrollment":2652,"conditions":2653,"interventions":2657},"NCT01733953","Statin Therapy in Young Adult Survivors of Childhood Cancer",[91],"2015-11","2016-03","2012-11",27,[2654,2655,2656],"Cardiovascular Disease","Childhood ALL","Childhood NHL",[2637,2658],"Sugar Pill",{"trials":2660,"activeCount":102},[2661],{"nctId":2662,"briefTitle":2663,"status":841,"phases":2664,"primaryCompletion":2650,"completion":534,"start":2665,"enrollment":102,"conditions":2666,"interventions":2671},"NCT01442428","Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial",[91,92],"2014-01",[2667,2668,2669,2670],"Immune Reconstitution Inflammatory Syndrome","Immune Reconstitution Syndrome","Tuberculosis","HIV-infection\u002FAids",[2672,2637,2673],"Dexamethasone","Naproxen",{"trials":2675,"activeCount":102},[],{"trials":2677,"activeCount":102},[],{"intervention":2679,"totalTrials":98,"cells":2680},"Hydroxychloroquine",{"EARLY_PHASE1":2681,"PHASE1":2683,"PHASE2":2685,"PHASE3":2687,"PHASE4":2712,"NA":2714},{"trials":2682,"activeCount":102},[],{"trials":2684,"activeCount":102},[],{"trials":2686,"activeCount":102},[],{"trials":2688,"activeCount":102},[2689,2701],{"nctId":2690,"briefTitle":2691,"status":112,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":2695,"conditions":2696,"interventions":2700},"NCT04328467","Pre-exposure Prophylaxis for SARS-Coronavirus-2",[92],"2020-07-13","2020-04-06",1483,[596,2697,2698,2699],"Corona Virus Infection","ARDS","Acute Respiratory Distress Syndrome",[2679],{"nctId":2702,"briefTitle":2703,"status":112,"phases":2704,"primaryCompletion":2705,"completion":2705,"start":2706,"enrollment":2707,"conditions":2708,"interventions":2711},"NCT04308668","Post-exposure Prophylaxis \u002F Preemptive Therapy for SARS-Coronavirus-2",[92],"2020-05-20","2020-03-17",1312,[2697,2699,832,2709,2710],"Coronavirus","Coronavirus Infections",[2679],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"intervention":2717,"totalTrials":98,"cells":2718},"Bupropion",{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2723,"PHASE3":2725,"PHASE4":2746,"NA":2748},{"trials":2720,"activeCount":102},[],{"trials":2722,"activeCount":102},[],{"trials":2724,"activeCount":102},[],{"trials":2726,"activeCount":102},[2727,2735],{"nctId":2728,"briefTitle":2729,"status":2730,"phases":2731,"primaryCompletion":1757,"completion":544,"start":1927,"enrollment":977,"conditions":2732,"interventions":2733},"NCT00419731","Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation","UNKNOWN",[91,92],[31],[2717,2734],"Bupropion + Naltrexone",{"nctId":2736,"briefTitle":2737,"status":112,"phases":2738,"primaryCompletion":1755,"completion":1755,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2744},"NCT00749658","Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence",[91,92],"2008-11",121,[2742,2743],"Nicotine Dependence","Nicotine Withdrawal",[2717,2745],"Varenicline",{"trials":2747,"activeCount":102},[],{"trials":2749,"activeCount":102},[],{"intervention":2751,"totalTrials":98,"cells":2752},"brivaracetam",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2770,"PHASE4":2782,"NA":2784},{"trials":2754,"activeCount":102},[],{"trials":2756,"activeCount":102},[],{"trials":2758,"activeCount":102},[2759],{"nctId":2760,"briefTitle":2761,"status":112,"phases":2762,"primaryCompletion":2763,"completion":2764,"start":2765,"enrollment":420,"conditions":2766,"interventions":2768},"NCT04379011","Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury",[90,91],"2024-03-31","2024-09-01","2021-02-01",[2767],"Spinal Cord Injuries",[2769],"Brivaracetam",{"trials":2771,"activeCount":102},[2772],{"nctId":2773,"briefTitle":2774,"status":112,"phases":2775,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":1527,"conditions":2779,"interventions":2781},"NCT05639946","Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial",[92],"2024-10-07","2024-10-16","2023-01-01",[2767,2780],"Neuropathic Pain",[2751],{"trials":2783,"activeCount":102},[],{"trials":2785,"activeCount":102},[],{"intervention":2787,"totalTrials":136,"cells":2788},"antihypertensive agents",{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2793,"PHASE3":2795,"PHASE4":2808,"NA":2810},{"trials":2790,"activeCount":102},[],{"trials":2792,"activeCount":102},[],{"trials":2794,"activeCount":102},[],{"trials":2796,"activeCount":102},[2797],{"nctId":2798,"briefTitle":2799,"status":112,"phases":2800,"completion":2801,"start":2802,"conditions":2803,"interventions":2806},"NCT00000487","Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)",[92],"1998-07","1972-06",[22,2804,28,2805],"Coronary Disease","Myocardial Ischemia",[2787,2807],"diuretics",{"trials":2809,"activeCount":102},[],{"trials":2811,"activeCount":102},[],{"intervention":2807,"totalTrials":136,"cells":2813},{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2820,"PHASE4":2826,"NA":2828},{"trials":2815,"activeCount":102},[],{"trials":2817,"activeCount":102},[],{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":102},[2822],{"nctId":2798,"briefTitle":2799,"status":112,"phases":2823,"completion":2801,"start":2802,"conditions":2824,"interventions":2825},[92],[22,2804,28,2805],[2787,2807],{"trials":2827,"activeCount":102},[],{"trials":2829,"activeCount":102},[],{"intervention":2831,"totalTrials":136,"cells":2832},"Proleukin",{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2839,"PHASE4":2850,"NA":2852},{"trials":2834,"activeCount":102},[],{"trials":2836,"activeCount":102},[],{"trials":2838,"activeCount":102},[],{"trials":2840,"activeCount":102},[2841],{"nctId":2842,"briefTitle":2843,"status":112,"phases":2844,"primaryCompletion":2845,"completion":2845,"start":2846,"enrollment":2847,"conditions":2848,"interventions":2849},"NCT00013611","Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)",[92],"2007-01","2001-03",1695,[2406],[2831],{"trials":2851,"activeCount":102},[],{"trials":2853,"activeCount":102},[],{"intervention":2855,"totalTrials":136,"cells":2856},"Diphenylcyclopropenone (DPCP) Ointment",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2872,"NA":2874},{"trials":2858,"activeCount":102},[],{"trials":2860,"activeCount":102},[],{"trials":2862,"activeCount":102},[],{"trials":2864,"activeCount":102},[2865],{"nctId":2866,"briefTitle":2867,"status":1860,"phases":2868,"primaryCompletion":2764,"completion":2764,"start":2869,"enrollment":1131,"conditions":2870,"interventions":2871},"NCT03651752","DPCP for the Treatment of Alopecia Areata",[92],"2024-04-01",[1031],[2855],{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":102},[],{"intervention":2672,"totalTrials":136,"cells":2877},{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2884,"PHASE4":2890,"NA":2892},{"trials":2879,"activeCount":102},[],{"trials":2881,"activeCount":102},[],{"trials":2883,"activeCount":102},[],{"trials":2885,"activeCount":102},[2886],{"nctId":2662,"briefTitle":2663,"status":841,"phases":2887,"primaryCompletion":2650,"completion":534,"start":2665,"enrollment":102,"conditions":2888,"interventions":2889},[91,92],[2667,2668,2669,2670],[2672,2637,2673],{"trials":2891,"activeCount":102},[],{"trials":2893,"activeCount":102},[],{"intervention":2673,"totalTrials":136,"cells":2895},{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2900,"PHASE3":2902,"PHASE4":2908,"NA":2910},{"trials":2897,"activeCount":102},[],{"trials":2899,"activeCount":102},[],{"trials":2901,"activeCount":102},[],{"trials":2903,"activeCount":102},[2904],{"nctId":2662,"briefTitle":2663,"status":841,"phases":2905,"primaryCompletion":2650,"completion":534,"start":2665,"enrollment":102,"conditions":2906,"interventions":2907},[91,92],[2667,2668,2669,2670],[2672,2637,2673],{"trials":2909,"activeCount":102},[],{"trials":2911,"activeCount":102},[],{"intervention":1799,"totalTrials":136,"cells":2913},{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2920,"PHASE4":2926,"NA":2928},{"trials":2915,"activeCount":102},[],{"trials":2917,"activeCount":102},[],{"trials":2919,"activeCount":102},[],{"trials":2921,"activeCount":102},[2922],{"nctId":1788,"briefTitle":1789,"status":841,"phases":2923,"primaryCompletion":1791,"completion":1792,"start":1793,"enrollment":102,"conditions":2924,"interventions":2925},[92],[1795,1796,1797],[1799,1637,1800],{"trials":2927,"activeCount":102},[],{"trials":2929,"activeCount":102},[],{"intervention":1800,"totalTrials":136,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2944,"NA":2946},{"trials":2933,"activeCount":102},[],{"trials":2935,"activeCount":102},[],{"trials":2937,"activeCount":102},[],{"trials":2939,"activeCount":102},[2940],{"nctId":1788,"briefTitle":1789,"status":841,"phases":2941,"primaryCompletion":1791,"completion":1792,"start":1793,"enrollment":102,"conditions":2942,"interventions":2943},[92],[1795,1796,1797],[1799,1637,1800],{"trials":2945,"activeCount":102},[],{"trials":2947,"activeCount":102},[],{"intervention":2949,"totalTrials":136,"cells":2950},"Vitamin C",{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2957,"PHASE4":2970,"NA":2972},{"trials":2952,"activeCount":102},[],{"trials":2954,"activeCount":102},[],{"trials":2956,"activeCount":102},[],{"trials":2958,"activeCount":102},[2959],{"nctId":2960,"briefTitle":2961,"status":112,"phases":2962,"primaryCompletion":2963,"completion":2964,"start":2965,"enrollment":2966,"conditions":2967,"interventions":2969},"NCT03338569","Vitamin C and Septic Shock",[91,92],"2020-06-30","2020-08-10","2017-12-20",125,[2968,1058],"Septic Shock",[2949],{"trials":2971,"activeCount":102},[],{"trials":2973,"activeCount":102},[],{"intervention":2975,"totalTrials":136,"cells":2976},"Shionogi Protease Inhibitor",{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2981,"PHASE3":2983,"PHASE4":2994,"NA":2996},{"trials":2978,"activeCount":102},[],{"trials":2980,"activeCount":102},[],{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[2985],{"nctId":2986,"briefTitle":2987,"status":1860,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":2990,"enrollment":2991,"conditions":2992,"interventions":2993},"NCT05605093","Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)",[92],"2025-10-28","2022-12-23",602,[596],[2975],{"trials":2995,"activeCount":102},[],{"trials":2997,"activeCount":102},[],{"intervention":2999,"totalTrials":136,"cells":3000},"quetiapine extended-release",{"EARLY_PHASE1":3001,"PHASE1":3003,"PHASE2":3005,"PHASE3":3007,"PHASE4":3018,"NA":3020},{"trials":3002,"activeCount":102},[],{"trials":3004,"activeCount":102},[],{"trials":3006,"activeCount":102},[],{"trials":3008,"activeCount":102},[3009],{"nctId":3010,"briefTitle":3011,"status":112,"phases":3012,"primaryCompletion":1768,"completion":1768,"start":3013,"enrollment":3014,"conditions":3015,"interventions":3017},"NCT00880919","Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)",[92],"2008-06",95,[3016],"Borderline Personality Disorder",[2999],{"trials":3019,"activeCount":102},[],{"trials":3021,"activeCount":102},[],{"intervention":3023,"totalTrials":136,"cells":3024},"novolog insulin",{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3029,"PHASE3":3031,"PHASE4":3043,"NA":3045},{"trials":3026,"activeCount":102},[],{"trials":3028,"activeCount":102},[],{"trials":3030,"activeCount":102},[],{"trials":3032,"activeCount":102},[3033],{"nctId":3034,"briefTitle":3035,"status":1860,"phases":3036,"primaryCompletion":3037,"completion":3037,"start":3038,"enrollment":3039,"conditions":3040,"interventions":3041},"NCT02496780","The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients",[91,92],"2022-07","2015-08",65,[119],[3023,3042],"levemir insulin",{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"intervention":3042,"totalTrials":136,"cells":3048},{"EARLY_PHASE1":3049,"PHASE1":3051,"PHASE2":3053,"PHASE3":3055,"PHASE4":3061,"NA":3063},{"trials":3050,"activeCount":102},[],{"trials":3052,"activeCount":102},[],{"trials":3054,"activeCount":102},[],{"trials":3056,"activeCount":102},[3057],{"nctId":3034,"briefTitle":3035,"status":1860,"phases":3058,"primaryCompletion":3037,"completion":3037,"start":3038,"enrollment":3039,"conditions":3059,"interventions":3060},[91,92],[119],[3023,3042],{"trials":3062,"activeCount":102},[],{"trials":3064,"activeCount":102},[],{"intervention":3066,"totalTrials":136,"cells":3067},"Zileuton",{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3074,"PHASE4":3086,"NA":3088},{"trials":3069,"activeCount":102},[],{"trials":3071,"activeCount":102},[],{"trials":3073,"activeCount":102},[],{"trials":3075,"activeCount":102},[3076],{"nctId":3077,"briefTitle":3078,"status":1860,"phases":3079,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":3083,"interventions":3085},"NCT00493974","Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)",[92],"2008-12","2007-03",119,[3084],"Pulmonary Disease, Chronic Obstructive",[3066],{"trials":3087,"activeCount":102},[],{"trials":3089,"activeCount":102},[],{"intervention":3091,"totalTrials":136,"cells":3092},"Metoprolol succinate",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3110,"NA":3112},{"trials":3094,"activeCount":102},[],{"trials":3096,"activeCount":102},[],{"trials":3098,"activeCount":102},[],{"trials":3100,"activeCount":102},[3101],{"nctId":3102,"briefTitle":3103,"status":1860,"phases":3104,"primaryCompletion":2052,"completion":3105,"start":3106,"enrollment":3107,"conditions":3108,"interventions":3109},"NCT02587351","Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease",[92],"2019-12-01","2016-05-01",532,[3084],[3091],{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[],{"intervention":3115,"totalTrials":136,"cells":3116},"Standard care using current drugs",{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3133,"NA":3135},{"trials":3118,"activeCount":102},[],{"trials":3120,"activeCount":102},[],{"trials":3122,"activeCount":102},[],{"trials":3124,"activeCount":102},[3125],{"nctId":3126,"briefTitle":3127,"status":841,"phases":3128,"primaryCompletion":2283,"completion":2283,"start":3129,"enrollment":102,"conditions":3130,"interventions":3132},"NCT01347684","Assessing the Effectiveness of Two Treatment Strategies for Tension-type Headache",[92],"2012-04",[3131],"Tension-type Headache",[3115],{"trials":3134,"activeCount":102},[],{"trials":3136,"activeCount":102},[],{"intervention":834,"totalTrials":136,"cells":3138},{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3151,"NA":3153},{"trials":3140,"activeCount":102},[],{"trials":3142,"activeCount":102},[],{"trials":3144,"activeCount":102},[],{"trials":3146,"activeCount":102},[3147],{"nctId":825,"briefTitle":826,"status":112,"phases":3148,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":3149,"interventions":3150},[92],[586,832],[804,834,835],{"trials":3152,"activeCount":102},[],{"trials":3154,"activeCount":102},[],{"intervention":835,"totalTrials":136,"cells":3156},{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3169,"NA":3171},{"trials":3158,"activeCount":102},[],{"trials":3160,"activeCount":102},[],{"trials":3162,"activeCount":102},[],{"trials":3164,"activeCount":102},[3165],{"nctId":825,"briefTitle":826,"status":112,"phases":3166,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":3167,"interventions":3168},[92],[586,832],[804,834,835],{"trials":3170,"activeCount":102},[],{"trials":3172,"activeCount":102},[],{"intervention":3174,"totalTrials":136,"cells":3175},"Pneumovax",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3182,"PHASE4":3193,"NA":3195},{"trials":3177,"activeCount":102},[],{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[3184],{"nctId":3185,"briefTitle":3186,"status":112,"phases":3187,"primaryCompletion":3188,"completion":3188,"start":3081,"enrollment":3189,"conditions":3190,"interventions":3191},"NCT00457977","Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease",[92],"2011-05",181,[3084],[3174,3192],"Prevnar",{"trials":3194,"activeCount":102},[],{"trials":3196,"activeCount":102},[],{"intervention":3192,"totalTrials":136,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3205,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":102},[],{"trials":3202,"activeCount":102},[],{"trials":3204,"activeCount":102},[],{"trials":3206,"activeCount":102},[3207],{"nctId":3185,"briefTitle":3186,"status":112,"phases":3208,"primaryCompletion":3188,"completion":3188,"start":3081,"enrollment":3189,"conditions":3209,"interventions":3210},[92],[3084],[3174,3192],{"trials":3212,"activeCount":102},[],{"trials":3214,"activeCount":102},[],{"intervention":3216,"totalTrials":136,"cells":3217},"Alfuzosin Hydrochloride",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3224,"PHASE4":3235,"NA":3237},{"trials":3219,"activeCount":102},[],{"trials":3221,"activeCount":102},[],{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[3226],{"nctId":3227,"briefTitle":3228,"status":112,"phases":3229,"primaryCompletion":3230,"completion":3230,"start":3231,"enrollment":12,"conditions":3232,"interventions":3234},"NCT00467467","Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort",[92],"2007-10","2006-06",[3233],"Ureteral Stent Discomfort",[3216],{"trials":3236,"activeCount":102},[],{"trials":3238,"activeCount":102},[],{"intervention":3240,"totalTrials":136,"cells":3241},"eszopiclone",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3248,"PHASE4":3260,"NA":3262},{"trials":3243,"activeCount":102},[],{"trials":3245,"activeCount":102},[],{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":102},[3250],{"nctId":3251,"briefTitle":3252,"status":112,"phases":3253,"primaryCompletion":3254,"completion":3254,"start":3255,"enrollment":23,"conditions":3256,"interventions":3259},"NCT00515177","Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study",[91,92],"2009-06","2007-08",[3257,3258],"Chronic Insomnia","Primary Insomnia",[3240],{"trials":3261,"activeCount":102},[],{"trials":3263,"activeCount":102},[],{"intervention":2734,"totalTrials":136,"cells":3265},{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3278,"NA":3280},{"trials":3267,"activeCount":102},[],{"trials":3269,"activeCount":102},[],{"trials":3271,"activeCount":102},[],{"trials":3273,"activeCount":102},[3274],{"nctId":2728,"briefTitle":2729,"status":2730,"phases":3275,"primaryCompletion":1757,"completion":544,"start":1927,"enrollment":977,"conditions":3276,"interventions":3277},[91,92],[31],[2717,2734],{"trials":3279,"activeCount":102},[],{"trials":3281,"activeCount":102},[],{"intervention":3283,"totalTrials":136,"cells":3284},"Intravenous nicardipine hydrochloride",{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3291,"PHASE4":3304,"NA":3306},{"trials":3286,"activeCount":102},[],{"trials":3288,"activeCount":102},[],{"trials":3290,"activeCount":102},[],{"trials":3292,"activeCount":102},[3293],{"nctId":3294,"briefTitle":3295,"status":1860,"phases":3296,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":3300,"conditions":3301,"interventions":3303},"NCT01176565","Antihypertensive Treatment of Acute Cerebral Hemorrhage-II",[92],"2015-12-21","2016-03-08","2011-05-15",1000,[3302],"Intracerebral Hemorrhage",[3283],{"trials":3305,"activeCount":102},[],{"trials":3307,"activeCount":102},[],{"intervention":3309,"totalTrials":136,"cells":3310},"SMT + SSM",{"EARLY_PHASE1":3311,"PHASE1":3313,"PHASE2":3315,"PHASE3":3317,"PHASE4":3329,"NA":3331},{"trials":3312,"activeCount":102},[],{"trials":3314,"activeCount":102},[],{"trials":3316,"activeCount":102},[],{"trials":3318,"activeCount":102},[3319],{"nctId":3320,"briefTitle":3321,"status":112,"phases":3322,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":3300,"conditions":3325,"interventions":3327},"NCT03581123","Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain",[92],"2024-06-12","2018-11-01",[1619,3326],"Low Back Pain, Mechanical",[3309,3328],"Standard Medical Care",{"trials":3330,"activeCount":102},[],{"trials":3332,"activeCount":102},[],{"intervention":3328,"totalTrials":136,"cells":3334},{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3347,"NA":3349},{"trials":3336,"activeCount":102},[],{"trials":3338,"activeCount":102},[],{"trials":3340,"activeCount":102},[],{"trials":3342,"activeCount":102},[3343],{"nctId":3320,"briefTitle":3321,"status":112,"phases":3344,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":3300,"conditions":3345,"interventions":3346},[92],[1619,3326],[3309,3328],{"trials":3348,"activeCount":102},[],{"trials":3350,"activeCount":102},[],{"intervention":600,"totalTrials":136,"cells":3352},{"EARLY_PHASE1":3353,"PHASE1":3355,"PHASE2":3357,"PHASE3":3359,"PHASE4":3365,"NA":3367},{"trials":3354,"activeCount":102},[],{"trials":3356,"activeCount":102},[],{"trials":3358,"activeCount":102},[],{"trials":3360,"activeCount":102},[3361],{"nctId":589,"briefTitle":590,"status":112,"phases":3362,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":3363,"interventions":3364},[92],[584,596,597,598],[87,600],{"trials":3366,"activeCount":102},[],{"trials":3368,"activeCount":102},[],{"intervention":3370,"totalTrials":136,"cells":3371},"Lifestyle Management",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3378,"PHASE4":3389,"NA":3391},{"trials":3373,"activeCount":102},[],{"trials":3375,"activeCount":102},[],{"trials":3377,"activeCount":102},[],{"trials":3379,"activeCount":102},[3380],{"nctId":3381,"briefTitle":3382,"status":841,"phases":3383,"primaryCompletion":3384,"completion":3385,"start":3386,"enrollment":102,"conditions":3387,"interventions":3388},"NCT04678323","Pharmacotherapy for Pediatric Obesity: A Phentermine Clinical Trial",[92],"2027-12","2028-06","2022-01",[134],[3370],{"trials":3390,"activeCount":102},[],{"trials":3392,"activeCount":102},[],{"intervention":3394,"totalTrials":136,"cells":3395},"chloroquine phosphate",{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3410,"NA":3412},{"trials":3397,"activeCount":102},[],{"trials":3399,"activeCount":102},[],{"trials":3401,"activeCount":102},[],{"trials":3403,"activeCount":102},[3404],{"nctId":3405,"briefTitle":3406,"status":1860,"phases":3407,"primaryCompletion":3080,"completion":3254,"start":2077,"enrollment":1478,"conditions":3408,"interventions":3409},"NCT00308620","Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine",[91,92],[1760],[3394],{"trials":3411,"activeCount":102},[],{"trials":3413,"activeCount":102},[],{"intervention":3415,"totalTrials":136,"cells":3416},"Very Low Nicotine Content Cigarettes",{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3423,"PHASE4":3435,"NA":3437},{"trials":3418,"activeCount":102},[],{"trials":3420,"activeCount":102},[],{"trials":3422,"activeCount":102},[],{"trials":3424,"activeCount":102},[3425],{"nctId":3426,"briefTitle":3427,"status":112,"phases":3428,"primaryCompletion":3429,"completion":3430,"start":1793,"enrollment":3431,"conditions":3432,"interventions":3433},"NCT03272685","Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace",[92],"2022-09-30","2023-01-10",799,[2313,2742],[3415,3434],"Normal Nicotine Content Cigarettes",{"trials":3436,"activeCount":102},[],{"trials":3438,"activeCount":102},[],{"intervention":3434,"totalTrials":136,"cells":3440},{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3445,"PHASE3":3447,"PHASE4":3453,"NA":3455},{"trials":3442,"activeCount":102},[],{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":102},[3449],{"nctId":3426,"briefTitle":3427,"status":112,"phases":3450,"primaryCompletion":3429,"completion":3430,"start":1793,"enrollment":3431,"conditions":3451,"interventions":3452},[92],[2313,2742],[3415,3434],{"trials":3454,"activeCount":102},[],{"trials":3456,"activeCount":102},[],{"intervention":3458,"totalTrials":136,"cells":3459},"Glargine insulin",{"EARLY_PHASE1":3460,"PHASE1":3462,"PHASE2":3464,"PHASE3":3466,"PHASE4":3476,"NA":3478},{"trials":3461,"activeCount":102},[],{"trials":3463,"activeCount":102},[],{"trials":3465,"activeCount":102},[],{"trials":3467,"activeCount":102},[3468],{"nctId":3469,"briefTitle":3470,"status":112,"phases":3471,"completion":1170,"start":3472,"enrollment":37,"conditions":3473,"interventions":3475},"NCT00222521","Insulin Glargine Vs Standard Insulin Therapy",[92],"2003-04",[3474],"Cystic Fibrosis Related Diabetes",[3458],{"trials":3477,"activeCount":102},[],{"trials":3479,"activeCount":102},[],{"intervention":3481,"totalTrials":136,"cells":3482},"simvastatin",{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3489,"PHASE4":3499,"NA":3501},{"trials":3484,"activeCount":102},[],{"trials":3486,"activeCount":102},[],{"trials":3488,"activeCount":102},[],{"trials":3490,"activeCount":102},[3491],{"nctId":3492,"briefTitle":3493,"status":1860,"phases":3494,"primaryCompletion":2665,"completion":2665,"start":3495,"enrollment":3496,"conditions":3497,"interventions":3498},"NCT01061671","Simvastatin Therapy for Moderate and Severe COPD",[92],"2010-03",885,[3084],[3481],{"trials":3500,"activeCount":102},[],{"trials":3502,"activeCount":102},[],{"intervention":3504,"totalTrials":136,"cells":3505},"triamcinolone",{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3510,"PHASE3":3512,"PHASE4":3526,"NA":3528},{"trials":3507,"activeCount":102},[],{"trials":3509,"activeCount":102},[],{"trials":3511,"activeCount":102},[],{"trials":3513,"activeCount":102},[3514],{"nctId":3515,"briefTitle":3516,"status":112,"phases":3517,"primaryCompletion":3518,"completion":3518,"start":3519,"enrollment":3520,"conditions":3521,"interventions":3525},"NCT00000569","Lung Health Study II",[92],"1999-05","1993-09",1116,[3522,3523,3524],"Lung Diseases","Lung Diseases, Obstructive","Chronic Obstructive Pulmonary Disease",[3504],{"trials":3527,"activeCount":102},[],{"trials":3529,"activeCount":102},[],{"intervention":3531,"totalTrials":1696,"cells":3532},"Naltrexone",{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3545,"PHASE3":3605,"PHASE4":3607,"NA":3609},{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[3537],{"nctId":3538,"briefTitle":3539,"status":112,"phases":3540,"primaryCompletion":1792,"completion":1792,"start":2283,"enrollment":117,"conditions":3541,"interventions":3543},"NCT02268448","Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function",[90],[3542],"Cutaneous Nerves CNS Itch",[3544,3531],"Clonidine",{"trials":3546,"activeCount":102},[3547,3557,3565,3575,3586,3596],{"nctId":3548,"briefTitle":3549,"status":841,"phases":3550,"primaryCompletion":2763,"completion":2763,"start":3551,"enrollment":102,"conditions":3552,"interventions":3556},"NCT04154033","Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone",[91],"2020-10-01",[3553,3554,3555],"Atopic Dermatitis","Pruritus","Dermatitis",[3531],{"nctId":3558,"briefTitle":3559,"status":841,"phases":3560,"primaryCompletion":3561,"completion":3561,"start":2361,"enrollment":102,"conditions":3562,"interventions":3564},"NCT00467454","Naltrexone in the Treatment of Pyromania",[91],"2010-04",[3563],"Pyromania",[3531],{"nctId":3566,"briefTitle":3567,"status":112,"phases":3568,"primaryCompletion":3569,"completion":3569,"start":3570,"enrollment":3571,"conditions":3572,"interventions":3574},"NCT00332579","Double-Blind Naltrexone in Kleptomania",[91],"2008-09-01","2006-05-01",25,[3573],"Kleptomania",[3531],{"nctId":3576,"briefTitle":3577,"status":112,"phases":3578,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":3581,"conditions":3582,"interventions":3585},"NCT01053078","Naltrexone and Hypoglycemia in Type 1 Diabetes",[90,91],"2014-06","2009-10",29,[3583,3584],"Type 1 Diabetes","Hypoglycemia Unawareness",[3531],{"nctId":3587,"briefTitle":3588,"status":112,"phases":3589,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":1696,"conditions":3592,"interventions":3594},"NCT00467558","Double-Blind Naltrexone in Compulsive Sexual Behavior",[91],"2010-06","2007-05",[3593],"Compulsive Sexual Behavior",[3531,3595],"Sugar pill",{"nctId":3597,"briefTitle":3598,"status":841,"phases":3599,"primaryCompletion":3600,"completion":3600,"start":3601,"enrollment":102,"conditions":3602,"interventions":3604},"NCT04325802","Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone",[91],"2024-06","2022-12-31",[3553,3554,3603,3555],"Pruritus Chronic",[3531],{"trials":3606,"activeCount":102},[],{"trials":3608,"activeCount":102},[],{"trials":3610,"activeCount":102},[],{"intervention":3612,"totalTrials":521,"cells":3613},"Losartan",{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3618,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3615,"activeCount":102},[],{"trials":3617,"activeCount":102},[],{"trials":3619,"activeCount":102},[3620,3628,3636],{"nctId":3621,"briefTitle":3622,"status":112,"phases":3623,"primaryCompletion":2765,"completion":2765,"start":3624,"enrollment":3625,"conditions":3626,"interventions":3627},"NCT04312009","Losartan for Patients With COVID-19 Requiring Hospitalization",[91],"2020-04-13",205,[2697,2699,832],[3612],{"nctId":3629,"briefTitle":3630,"status":112,"phases":3631,"primaryCompletion":2765,"completion":2765,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3635},"NCT04311177","Losartan for Patients With COVID-19 Not Requiring Hospitalization",[91],"2020-04-09",117,[2697,2699,832],[3612],{"nctId":3637,"briefTitle":3638,"status":112,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":543,"enrollment":3641,"conditions":3642,"interventions":3643},"NCT01852942","Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV",[91],"2019-07-16",52,[2406,1760],[3612],{"trials":3645,"activeCount":102},[],{"trials":3647,"activeCount":102},[],{"trials":3649,"activeCount":102},[],{"intervention":3651,"totalTrials":521,"cells":3652},"anti-thymocyte globulin",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3654,"activeCount":102},[],{"trials":3656,"activeCount":102},[],{"trials":3658,"activeCount":102},[3659,3671,3684],{"nctId":3660,"briefTitle":3661,"status":1860,"phases":3662,"primaryCompletion":843,"completion":3663,"start":2360,"enrollment":3664,"conditions":3665,"interventions":3668},"NCT00672204","Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes",[90,91],"2012-08",23,[3666,3667],"Type 1 Diabetes Mellitus","Hypoglycemia",[3669,3670,2340,3651],"Allogeneic islets of Langerhans transplant","Raptiva",{"nctId":3672,"briefTitle":3673,"status":112,"phases":3674,"start":3675,"enrollment":23,"conditions":3676,"interventions":3678},"NCT00005898","Phase I\u002FII Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia",[90,91],"2000-02",[3677],"Fanconi's Anemia",[3651,3679,3680,3681,3682,3683],"cyclophosphamide","cyclosporine","filgrastim","fludarabine","methylprednisolone",{"nctId":3685,"briefTitle":3686,"status":112,"phases":3687,"primaryCompletion":3688,"completion":3688,"start":3689,"enrollment":1366,"conditions":3690,"interventions":3691},"NCT00286624","Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation",[90,91],"2006-08","2003-03",[3666,3667],[3692,3693,3651,3694],"Allogeneic Islets of Langerhans","Everolimus","Cyclosporine",{"trials":3696,"activeCount":102},[],{"trials":3698,"activeCount":102},[],{"trials":3700,"activeCount":102},[],{"intervention":3702,"totalTrials":521,"cells":3703},"Exenatide",{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3721,"PHASE3":3740,"PHASE4":3742,"NA":3744},{"trials":3705,"activeCount":102},[],{"trials":3707,"activeCount":102},[3708],{"nctId":3709,"briefTitle":3710,"status":112,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":3714,"conditions":3715,"interventions":3717},"NCT02685852","Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia",[90],"2019-07-22","2016-02",11,[3716],"Hyperinsulinemic Hypoglycemia",[3702,3718,3719,3720],"Acarbose","Exenatide Placebo","Acarbose Placebo",{"trials":3722,"activeCount":102},[3723,3732],{"nctId":3724,"briefTitle":3725,"status":112,"phases":3726,"primaryCompletion":844,"completion":844,"start":3727,"enrollment":3728,"conditions":3729,"interventions":3731},"NCT00886626","GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children",[91],"2009-05",12,[3730],"Obesity, Morbid",[3702],{"nctId":3733,"briefTitle":3734,"status":112,"phases":3735,"primaryCompletion":3736,"completion":1767,"start":3737,"enrollment":1647,"conditions":3738,"interventions":3739},"NCT01237197","Exenatide in Extreme Pediatric Obesity",[91],"2012-05","2010-10",[16],[3702],{"trials":3741,"activeCount":102},[],{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"intervention":3747,"totalTrials":521,"cells":3748},"N-acetyl cysteine",{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3763,"PHASE3":3784,"PHASE4":3786,"NA":3788},{"trials":3750,"activeCount":102},[],{"trials":3752,"activeCount":102},[3753],{"nctId":3754,"briefTitle":3755,"status":112,"phases":3756,"completion":3757,"start":3758,"enrollment":171,"conditions":3759,"interventions":3761},"NCT00273702","An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling",[90],"2006-09","2006-01",[3760],"Pathological Gambling",[3762],"N-Acetyl Cysteine",{"trials":3764,"activeCount":102},[3765,3776],{"nctId":3766,"briefTitle":3767,"status":112,"phases":3768,"primaryCompletion":3769,"completion":3770,"start":3771,"enrollment":1527,"conditions":3772,"interventions":3775},"NCT04005053","Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents",[91],"2022-05-08","2022-10-01","2019-08-01",[3773,36,3774],"Self-Harm","Suicide",[3747],{"nctId":3777,"briefTitle":3778,"status":112,"phases":3779,"primaryCompletion":3780,"completion":3780,"start":3781,"enrollment":29,"conditions":3782,"interventions":3783},"NCT02206152","A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes",[90,91],"2017-12","2015-02",[3583,3584],[3747],{"trials":3785,"activeCount":102},[],{"trials":3787,"activeCount":102},[],{"trials":3789,"activeCount":102},[],{"intervention":3669,"totalTrials":98,"cells":3791},{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3793,"activeCount":102},[],{"trials":3795,"activeCount":102},[],{"trials":3797,"activeCount":102},[3798,3802],{"nctId":3660,"briefTitle":3661,"status":1860,"phases":3799,"primaryCompletion":843,"completion":3663,"start":2360,"enrollment":3664,"conditions":3800,"interventions":3801},[90,91],[3666,3667],[3669,3670,2340,3651],{"nctId":3803,"briefTitle":3804,"status":112,"phases":3805,"primaryCompletion":3806,"completion":3807,"start":1171,"enrollment":117,"conditions":3808,"interventions":3809},"NCT00285233","Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes",[90,91],"2004-09","2005-03",[3583,3667],[3669],{"trials":3811,"activeCount":102},[],{"trials":3813,"activeCount":102},[],{"trials":3815,"activeCount":102},[],{"intervention":2658,"totalTrials":98,"cells":3817},{"EARLY_PHASE1":3818,"PHASE1":3820,"PHASE2":3822,"PHASE3":3832,"PHASE4":3834,"NA":3836},{"trials":3819,"activeCount":102},[],{"trials":3821,"activeCount":102},[],{"trials":3823,"activeCount":102},[3824,3828],{"nctId":2646,"briefTitle":2647,"status":112,"phases":3825,"primaryCompletion":2649,"completion":2650,"start":2651,"enrollment":2652,"conditions":3826,"interventions":3827},[91],[2654,2655,2656],[2637,2658],{"nctId":3587,"briefTitle":3588,"status":112,"phases":3829,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":1696,"conditions":3830,"interventions":3831},[91],[3593],[3531,3595],{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":102},[],{"trials":3837,"activeCount":102},[],{"intervention":3839,"totalTrials":98,"cells":3840},"Topiramate",{"EARLY_PHASE1":3841,"PHASE1":3852,"PHASE2":3854,"PHASE3":3866,"PHASE4":3868,"NA":3870},{"trials":3842,"activeCount":102},[3843],{"nctId":3844,"briefTitle":3845,"status":112,"phases":3846,"primaryCompletion":3847,"completion":3847,"start":3848,"enrollment":3849,"conditions":3850,"interventions":3851},"NCT04986631","Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP",[89],"2024-09-26","2022-04-04",62,[134],[3839],{"trials":3853,"activeCount":102},[],{"trials":3855,"activeCount":102},[3856],{"nctId":3857,"briefTitle":3858,"status":112,"phases":3859,"primaryCompletion":3860,"completion":3861,"start":1658,"enrollment":3862,"conditions":3863,"interventions":3865},"NCT01859013","Topiramate in Adolescents With Severe Obesity",[91],"2015-12","2017-04",34,[3730,16,3864],"Weight Loss",[3839],{"trials":3867,"activeCount":102},[],{"trials":3869,"activeCount":102},[],{"trials":3871,"activeCount":102},[],{"intervention":3873,"totalTrials":98,"cells":3874},"Vancomycin",{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3888,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3876,"activeCount":102},[],{"trials":3878,"activeCount":102},[3879],{"nctId":3880,"briefTitle":3881,"status":112,"phases":3882,"primaryCompletion":3883,"completion":3884,"start":2283,"enrollment":117,"conditions":3885,"interventions":3887},"NCT02464020","A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis",[90],"2017-05-01","2018-12-01",[1435,3886],"Inflammatory Bowel Disease",[3873],{"trials":3889,"activeCount":102},[3890],{"nctId":3891,"briefTitle":3892,"status":1860,"phases":3893,"primaryCompletion":3894,"completion":3894,"start":534,"enrollment":3728,"conditions":3895,"interventions":3897},"NCT02730962","Interventional Bioremediation of Microbiota in Metabolic Syndrome",[91],"2018-01",[3896],"Pre-Diabetes",[3873,3898,3899],"Neomycin","Clindamycin",{"trials":3901,"activeCount":102},[],{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[],{"intervention":3907,"totalTrials":98,"cells":3908},"valacyclovir",{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3910,"activeCount":102},[],{"trials":3912,"activeCount":102},[],{"trials":3914,"activeCount":102},[3915,3924],{"nctId":3916,"briefTitle":3917,"status":112,"phases":3918,"primaryCompletion":3919,"completion":3919,"start":3920,"enrollment":37,"conditions":3921,"interventions":3923},"NCT00274404","Controlled Trial of Valacyclovir in Infectious Mononucleosis",[90,91],"2005-09","2004-02",[3922],"Infectious Mononucleosis",[3907],{"nctId":3925,"briefTitle":3926,"status":112,"phases":3927,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":3930,"conditions":3931,"interventions":3935},"NCT01972035","ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation",[91],"2021-02-28","2014-08-01",137,[3932,3933,3934],"Transplantation Infection","Epstein-Barr Virus Infections","Cytomegalovirus Infections",[3936,3937],"Valacyclovir","Valganciclovir",{"trials":3939,"activeCount":102},[],{"trials":3941,"activeCount":102},[],{"trials":3943,"activeCount":102},[],{"intervention":3945,"totalTrials":98,"cells":3946},"Ketamine",{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3963,"PHASE3":3973,"PHASE4":3975,"NA":3977},{"trials":3948,"activeCount":102},[],{"trials":3950,"activeCount":102},[3951],{"nctId":3952,"briefTitle":3953,"status":112,"phases":3954,"primaryCompletion":3955,"completion":3956,"start":3957,"enrollment":3958,"conditions":3959,"interventions":3962},"NCT04032301","Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans",[90],"2024-09-16","2024-11-10","2019-09-30",67,[3960,3961],"Post-Traumatic Stress Disorders","Major Depressive Disorder",[3945],{"trials":3964,"activeCount":102},[3965],{"nctId":3966,"briefTitle":3967,"status":112,"phases":3968,"primaryCompletion":3969,"completion":3969,"start":543,"enrollment":3970,"conditions":3971,"interventions":3972},"NCT02078817","Ketamine in Adolescents With Treatment-Resistant Depression",[91],"2018-03",14,[3961],[3945],{"trials":3974,"activeCount":102},[],{"trials":3976,"activeCount":102},[],{"trials":3978,"activeCount":102},[],{"intervention":3681,"totalTrials":98,"cells":3980},{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3993,"PHASE3":3999,"PHASE4":4001,"NA":4003},{"trials":3982,"activeCount":102},[],{"trials":3984,"activeCount":102},[3985],{"nctId":3986,"briefTitle":3987,"status":2730,"phases":3988,"start":3989,"enrollment":1366,"conditions":3990,"interventions":3991},"NCT00005896","Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia",[90],"2000-03",[3677],[3681,3992],"Autologous stem cells transduced with FACC retroviral vector",{"trials":3994,"activeCount":102},[3995],{"nctId":3672,"briefTitle":3673,"status":112,"phases":3996,"start":3675,"enrollment":23,"conditions":3997,"interventions":3998},[90,91],[3677],[3651,3679,3680,3681,3682,3683],{"trials":4000,"activeCount":102},[],{"trials":4002,"activeCount":102},[],{"trials":4004,"activeCount":102},[],{"intervention":4006,"totalTrials":98,"cells":4007},"Carvedilol",{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4022,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4009,"activeCount":102},[],{"trials":4011,"activeCount":102},[4012],{"nctId":4013,"briefTitle":4014,"status":1860,"phases":4015,"primaryCompletion":1876,"completion":534,"start":4016,"enrollment":4017,"conditions":4018,"interventions":4021},"NCT02120339","Carvedilol PAH A Pilot Study of Efficacy and Safety",[90],"2014-05",5,[4019,4020],"Pulmonary Hypertension","Cardiac MRI \u003C40",[4006],{"trials":4023,"activeCount":102},[4024],{"nctId":4025,"briefTitle":4026,"status":1860,"phases":4027,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":98,"conditions":4030,"interventions":4031},"NCT02507011","Beta-blockers in Pulmonary Arterial Hypertension",[91],"2019-07-01","2016-01-31",[1233],[4006],{"trials":4033,"activeCount":102},[],{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[],{"intervention":4039,"totalTrials":98,"cells":4040},"Intranasal Oxytocin",{"EARLY_PHASE1":4041,"PHASE1":4053,"PHASE2":4055,"PHASE3":4065,"PHASE4":4067,"NA":4069},{"trials":4042,"activeCount":102},[4043],{"nctId":4044,"briefTitle":4045,"status":112,"phases":4046,"primaryCompletion":4047,"completion":4047,"start":4048,"enrollment":1408,"conditions":4049,"interventions":4051},"NCT03414112","The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa",[89],"2021-04-30","2018-09-25",[4050],"Anorexia Nervosa",[4052],"Intranasal oxytocin",{"trials":4054,"activeCount":102},[],{"trials":4056,"activeCount":102},[4057],{"nctId":4058,"briefTitle":4059,"status":112,"phases":4060,"primaryCompletion":4061,"completion":4061,"start":4016,"enrollment":2652,"conditions":4062,"interventions":4064},"NCT02493426","Single Dose Intranasal Oxytocin and Cognitive Effects in Autism",[91],"2021-03-31",[4063],"Autism Spectrum Disorders",[4039],{"trials":4066,"activeCount":102},[],{"trials":4068,"activeCount":102},[],{"trials":4070,"activeCount":102},[],{"intervention":3937,"totalTrials":98,"cells":4072},{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4093,"PHASE4":4095,"NA":4097},{"trials":4074,"activeCount":102},[],{"trials":4076,"activeCount":102},[],{"trials":4078,"activeCount":102},[4079,4083],{"nctId":3925,"briefTitle":3926,"status":112,"phases":4080,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":3930,"conditions":4081,"interventions":4082},[91],[3932,3933,3934],[3936,3937],{"nctId":4084,"briefTitle":4085,"status":112,"phases":4086,"primaryCompletion":4087,"completion":4087,"start":2257,"enrollment":4088,"conditions":4089,"interventions":4092},"NCT01329185","Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients",[91],"2014-04",17,[4090,4091],"EBV Viremia","CMV Viremia",[3937],{"trials":4094,"activeCount":102},[],{"trials":4096,"activeCount":102},[],{"trials":4098,"activeCount":102},[],{"intervention":4100,"totalTrials":98,"cells":4101},"Nicotine Patch",{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4133,"PHASE4":4135,"NA":4137},{"trials":4103,"activeCount":102},[],{"trials":4105,"activeCount":102},[],{"trials":4107,"activeCount":102},[4108,4117],{"nctId":4109,"briefTitle":4110,"status":112,"phases":4111,"primaryCompletion":4112,"completion":1156,"start":4113,"enrollment":4114,"conditions":4115,"interventions":4116},"NCT01050569","Innovative Interventions for Smoking Cessation",[91],"2011-12","2008-10",235,[31],[4100],{"nctId":4118,"briefTitle":4119,"status":112,"phases":4120,"primaryCompletion":4121,"completion":4121,"start":4122,"enrollment":4123,"conditions":4124,"interventions":4130},"NCT03822416","Treating Smokers With Mental Illness",[91],"2020-05-04","2019-03-01",38,[331,2312,4125,4126,3961,4127,4128,4129],"Schizophrenia","Psychotic Disorders","Bipolar Disorder I","Bipolar II Disorder","Mental Illness",[4131,4132],"Nicotine patch","Nicotine lozenge",{"trials":4134,"activeCount":102},[],{"trials":4136,"activeCount":102},[],{"trials":4138,"activeCount":102},[],{"intervention":3680,"totalTrials":98,"cells":4140},{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4155,"PHASE4":4157,"NA":4159},{"trials":4142,"activeCount":102},[],{"trials":4144,"activeCount":102},[],{"trials":4146,"activeCount":102},[4147,4151],{"nctId":3672,"briefTitle":3673,"status":112,"phases":4148,"start":3675,"enrollment":23,"conditions":4149,"interventions":4150},[90,91],[3677],[3651,3679,3680,3681,3682,3683],{"nctId":3685,"briefTitle":3686,"status":112,"phases":4152,"primaryCompletion":3688,"completion":3688,"start":3689,"enrollment":1366,"conditions":4153,"interventions":4154},[90,91],[3666,3667],[3692,3693,3651,3694],{"trials":4156,"activeCount":102},[],{"trials":4158,"activeCount":102},[],{"trials":4160,"activeCount":102},[],{"intervention":4162,"totalTrials":136,"cells":4163},"Cidofovir",{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4177,"PHASE4":4179,"NA":4181},{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[4170],{"nctId":4171,"briefTitle":4172,"status":841,"phases":4173,"primaryCompletion":534,"completion":534,"start":534,"enrollment":102,"conditions":4174,"interventions":4176},"NCT02567149","Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.",[91],[4175],"Warts",[4162],{"trials":4178,"activeCount":102},[],{"trials":4180,"activeCount":102},[],{"trials":4182,"activeCount":102},[],{"intervention":4184,"totalTrials":136,"cells":4185},"Entresto",{"EARLY_PHASE1":4186,"PHASE1":4188,"PHASE2":4190,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4187,"activeCount":102},[],{"trials":4189,"activeCount":102},[],{"trials":4191,"activeCount":102},[4192],{"nctId":4193,"briefTitle":4194,"status":1860,"phases":4195,"primaryCompletion":3324,"completion":3324,"start":4196,"enrollment":1366,"conditions":4197,"interventions":4199},"NCT02636283","Use of Entresto Sacubitril\u002FValsartan for the Treatment of Peripheral Arterial Disease",[91],"2017-12-31",[4198],"Peripheral Arterial Disease",[4184],{"trials":4201,"activeCount":102},[],{"trials":4203,"activeCount":102},[],{"trials":4205,"activeCount":102},[],{"intervention":4207,"totalTrials":136,"cells":4208},"liposomal bupivacaine Periarticular",{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4226,"PHASE4":4228,"NA":4230},{"trials":4210,"activeCount":102},[],{"trials":4212,"activeCount":102},[],{"trials":4214,"activeCount":102},[4215],{"nctId":4216,"briefTitle":4217,"status":841,"phases":4218,"primaryCompletion":2214,"completion":4219,"start":3860,"enrollment":102,"conditions":4220,"interventions":4224},"NCT02616367","Comparison of Comparison of Ropivacaine and Liposomal Bupivacaine for Total Knee Arthroplasty",[91],"2017-03",[4221,4222,4223],"Arthroplasty","Replacement","Knee",[4207,4225],"Ropivacaine Periarticular",{"trials":4227,"activeCount":102},[],{"trials":4229,"activeCount":102},[],{"trials":4231,"activeCount":102},[],{"intervention":4225,"totalTrials":136,"cells":4233},{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4238,"PHASE3":4244,"PHASE4":4246,"NA":4248},{"trials":4235,"activeCount":102},[],{"trials":4237,"activeCount":102},[],{"trials":4239,"activeCount":102},[4240],{"nctId":4216,"briefTitle":4217,"status":841,"phases":4241,"primaryCompletion":2214,"completion":4219,"start":3860,"enrollment":102,"conditions":4242,"interventions":4243},[91],[4221,4222,4223],[4207,4225],{"trials":4245,"activeCount":102},[],{"trials":4247,"activeCount":102},[],{"trials":4249,"activeCount":102},[],{"intervention":4251,"totalTrials":136,"cells":4252},"Green tea extract supplement",{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4257,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4254,"activeCount":102},[],{"trials":4256,"activeCount":102},[],{"trials":4258,"activeCount":102},[4259],{"nctId":4260,"briefTitle":4261,"status":112,"phases":4262,"primaryCompletion":3579,"completion":3579,"start":4263,"enrollment":4264,"conditions":4265,"interventions":4267},"NCT00917735","Green Tea and Reduction of Breast Cancer Risk",[91],"2009-07",1075,[4266],"Breast Cancer",[4251],{"trials":4269,"activeCount":102},[],{"trials":4271,"activeCount":102},[],{"trials":4273,"activeCount":102},[],{"intervention":3670,"totalTrials":136,"cells":4275},{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4280,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4277,"activeCount":102},[],{"trials":4279,"activeCount":102},[],{"trials":4281,"activeCount":102},[4282],{"nctId":3660,"briefTitle":3661,"status":1860,"phases":4283,"primaryCompletion":843,"completion":3663,"start":2360,"enrollment":3664,"conditions":4284,"interventions":4285},[90,91],[3666,3667],[3669,3670,2340,3651],{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":102},[],{"trials":4291,"activeCount":102},[],{"intervention":4293,"totalTrials":136,"cells":4294},"hOKT3γ1",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4296,"activeCount":102},[],{"trials":4298,"activeCount":102},[],{"trials":4300,"activeCount":102},[4301],{"nctId":4302,"briefTitle":4303,"status":112,"phases":4304,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":1366,"conditions":4307,"interventions":4308},"NCT00285194","hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients",[90,91],"2004-01","2000-04",[3583,3667],[3692,4293],{"trials":4310,"activeCount":102},[],{"trials":4312,"activeCount":102},[],{"trials":4314,"activeCount":102},[],{"intervention":4316,"totalTrials":136,"cells":4317},"Nebivolol",{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4322,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4319,"activeCount":102},[],{"trials":4321,"activeCount":102},[],{"trials":4323,"activeCount":102},[4324],{"nctId":4325,"briefTitle":4326,"status":112,"phases":4327,"primaryCompletion":4328,"completion":4328,"start":4329,"enrollment":4330,"conditions":4331,"interventions":4332},"NCT01522950","A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function",[91],"2016-10","2010-05",76,[33],[4316,4333],"atenolol",{"trials":4335,"activeCount":102},[],{"trials":4337,"activeCount":102},[],{"trials":4339,"activeCount":102},[],{"intervention":4333,"totalTrials":136,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4352,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":102},[],{"trials":4345,"activeCount":102},[],{"trials":4347,"activeCount":102},[4348],{"nctId":4325,"briefTitle":4326,"status":112,"phases":4349,"primaryCompletion":4328,"completion":4328,"start":4329,"enrollment":4330,"conditions":4350,"interventions":4351},[91],[33],[4316,4333],{"trials":4353,"activeCount":102},[],{"trials":4355,"activeCount":102},[],{"trials":4357,"activeCount":102},[],{"intervention":4359,"totalTrials":136,"cells":4360},"immediate-release tacrolimus",{"EARLY_PHASE1":4361,"PHASE1":4363,"PHASE2":4365,"PHASE3":4378,"PHASE4":4380,"NA":4382},{"trials":4362,"activeCount":102},[],{"trials":4364,"activeCount":102},[],{"trials":4366,"activeCount":102},[4367],{"nctId":4368,"briefTitle":4369,"status":112,"phases":4370,"primaryCompletion":4371,"completion":4371,"start":4372,"enrollment":4373,"conditions":4374,"interventions":4376},"NCT03437577","Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients",[90,91],"2020-03-31","2018-05-08",18,[4375],"Kidney Transplant Failure and Rejection",[4359,4377],"extended release tacrolimus",{"trials":4379,"activeCount":102},[],{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[],{"intervention":4377,"totalTrials":136,"cells":4385},{"EARLY_PHASE1":4386,"PHASE1":4388,"PHASE2":4390,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4387,"activeCount":102},[],{"trials":4389,"activeCount":102},[],{"trials":4391,"activeCount":102},[4392],{"nctId":4368,"briefTitle":4369,"status":112,"phases":4393,"primaryCompletion":4371,"completion":4371,"start":4372,"enrollment":4373,"conditions":4394,"interventions":4395},[90,91],[4375],[4359,4377],{"trials":4397,"activeCount":102},[],{"trials":4399,"activeCount":102},[],{"trials":4401,"activeCount":102},[],{"intervention":4403,"totalTrials":136,"cells":4404},"Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4420,"PHASE4":4422,"NA":4424},{"trials":4406,"activeCount":102},[],{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":102},[4411],{"nctId":4412,"briefTitle":4413,"status":112,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":3571,"conditions":4417,"interventions":4419},"NCT00869024","Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement",[90,91],"2016-03-29","2011-11-10",[4418],"Heart Failure",[4403],{"trials":4421,"activeCount":102},[],{"trials":4423,"activeCount":102},[],{"trials":4425,"activeCount":102},[],{"intervention":4427,"totalTrials":136,"cells":4428},"Naloxone then placebo",{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4445,"PHASE4":4447,"NA":4449},{"trials":4430,"activeCount":102},[],{"trials":4432,"activeCount":102},[],{"trials":4434,"activeCount":102},[4435],{"nctId":4436,"briefTitle":4437,"status":112,"phases":4438,"primaryCompletion":4439,"completion":4440,"start":4441,"enrollment":23,"conditions":4442,"interventions":4444},"NCT03149770","Naloxone, Hypoglycemia and Exercise",[91],"2022-05-01","2023-04-01","2017-09-18",[4443],"Diabetes Mellitus, Type 1",[4427],{"trials":4446,"activeCount":102},[],{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[],{"intervention":4452,"totalTrials":136,"cells":4453},"carvedilol phosphate",{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4470,"PHASE4":4472,"NA":4474},{"trials":4455,"activeCount":102},[],{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[4460],{"nctId":4461,"briefTitle":4462,"status":112,"phases":4463,"primaryCompletion":1755,"completion":843,"start":2360,"enrollment":4464,"conditions":4465,"interventions":4467},"NCT00553969","Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease",[90,91],101,[4466],"Pre-hypertension",[4452,4468,4469],"lisinopril","carvedilol phosphate and lisinopril",{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[],{"intervention":4468,"totalTrials":136,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4488,"PHASE4":4490,"NA":4492},{"trials":4479,"activeCount":102},[],{"trials":4481,"activeCount":102},[],{"trials":4483,"activeCount":102},[4484],{"nctId":4461,"briefTitle":4462,"status":112,"phases":4485,"primaryCompletion":1755,"completion":843,"start":2360,"enrollment":4464,"conditions":4486,"interventions":4487},[90,91],[4466],[4452,4468,4469],{"trials":4489,"activeCount":102},[],{"trials":4491,"activeCount":102},[],{"trials":4493,"activeCount":102},[],{"intervention":4469,"totalTrials":136,"cells":4495},{"EARLY_PHASE1":4496,"PHASE1":4498,"PHASE2":4500,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4497,"activeCount":102},[],{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[4502],{"nctId":4461,"briefTitle":4462,"status":112,"phases":4503,"primaryCompletion":1755,"completion":843,"start":2360,"enrollment":4464,"conditions":4504,"interventions":4505},[90,91],[4466],[4452,4468,4469],{"trials":4507,"activeCount":102},[],{"trials":4509,"activeCount":102},[],{"trials":4511,"activeCount":102},[],{"intervention":4513,"totalTrials":136,"cells":4514},"intra-nasal naloxone",{"EARLY_PHASE1":4515,"PHASE1":4517,"PHASE2":4519,"PHASE3":4529,"PHASE4":4531,"NA":4533},{"trials":4516,"activeCount":102},[],{"trials":4518,"activeCount":102},[],{"trials":4520,"activeCount":102},[4521],{"nctId":4522,"briefTitle":4523,"status":1860,"phases":4524,"primaryCompletion":4525,"completion":4525,"start":534,"enrollment":3714,"conditions":4526,"interventions":4527},"NCT02700048","Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia",[90,91],"2021-07",[3584,3583],[4513,4528],"Intra-nasal saline",{"trials":4530,"activeCount":102},[],{"trials":4532,"activeCount":102},[],{"trials":4534,"activeCount":102},[],{"intervention":4528,"totalTrials":136,"cells":4536},{"EARLY_PHASE1":4537,"PHASE1":4539,"PHASE2":4541,"PHASE3":4547,"PHASE4":4549,"NA":4551},{"trials":4538,"activeCount":102},[],{"trials":4540,"activeCount":102},[],{"trials":4542,"activeCount":102},[4543],{"nctId":4522,"briefTitle":4523,"status":1860,"phases":4544,"primaryCompletion":4525,"completion":4525,"start":534,"enrollment":3714,"conditions":4545,"interventions":4546},[90,91],[3584,3583],[4513,4528],{"trials":4548,"activeCount":102},[],{"trials":4550,"activeCount":102},[],{"trials":4552,"activeCount":102},[],{"intervention":4554,"totalTrials":136,"cells":4555},"levetiracetam",{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4560,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4557,"activeCount":102},[],{"trials":4559,"activeCount":102},[],{"trials":4561,"activeCount":102},[4562],{"nctId":4563,"briefTitle":4564,"status":112,"phases":4565,"primaryCompletion":4566,"completion":4566,"start":4567,"enrollment":3862,"conditions":4568,"interventions":4570},"NCT02002819","Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability",[91],"2020-07-21","2014-10-16",[4569],"Alzheimer's Disease",[4554],{"trials":4572,"activeCount":102},[],{"trials":4574,"activeCount":102},[],{"trials":4576,"activeCount":102},[],{"intervention":1621,"totalTrials":136,"cells":4578},{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4580,"activeCount":102},[],{"trials":4582,"activeCount":102},[],{"trials":4584,"activeCount":102},[4585],{"nctId":1611,"briefTitle":1612,"status":112,"phases":4586,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":4587,"interventions":4588},[91],[1619],[1621,1602],{"trials":4590,"activeCount":102},[],{"trials":4592,"activeCount":102},[],{"trials":4594,"activeCount":102},[],{"intervention":4596,"totalTrials":136,"cells":4597},"Chlorhexidine",{"EARLY_PHASE1":4598,"PHASE1":4600,"PHASE2":4602,"PHASE3":4612,"PHASE4":4614,"NA":4616},{"trials":4599,"activeCount":102},[],{"trials":4601,"activeCount":102},[],{"trials":4603,"activeCount":102},[4604],{"nctId":4605,"briefTitle":4606,"status":112,"phases":4607,"primaryCompletion":4608,"completion":396,"start":4609,"enrollment":1527,"conditions":4610,"interventions":4611},"NCT02252588","The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease",[91],"2019-12-15","2014-09-01",[3524],[4596],{"trials":4613,"activeCount":102},[],{"trials":4615,"activeCount":102},[],{"trials":4617,"activeCount":102},[],{"intervention":4619,"totalTrials":136,"cells":4620},"Nicotine Gum",{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"trials":4626,"activeCount":102},[4627],{"nctId":4628,"briefTitle":4629,"status":112,"phases":4630,"primaryCompletion":1681,"completion":4016,"start":3561,"enrollment":4631,"conditions":4632,"interventions":4633},"NCT00710034","Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine",[91],391,[31],[4619],{"trials":4635,"activeCount":102},[],{"trials":4637,"activeCount":102},[],{"trials":4639,"activeCount":102},[],{"intervention":4641,"totalTrials":136,"cells":4642},"Valomaciclovir",{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4655,"PHASE4":4657,"NA":4659},{"trials":4644,"activeCount":102},[],{"trials":4646,"activeCount":102},[],{"trials":4648,"activeCount":102},[4649],{"nctId":4650,"briefTitle":4651,"status":112,"phases":4652,"primaryCompletion":4263,"completion":1757,"start":2360,"enrollment":3664,"conditions":4653,"interventions":4654},"NCT00575185","Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection",[90,91],[3922],[4641],{"trials":4656,"activeCount":102},[],{"trials":4658,"activeCount":102},[],{"trials":4660,"activeCount":102},[],{"intervention":4662,"totalTrials":136,"cells":4663},"Intralesional Triamcinolone Acetonide 10 mg\u002FmL",{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4678,"PHASE4":4680,"NA":4682},{"trials":4665,"activeCount":102},[],{"trials":4667,"activeCount":102},[],{"trials":4669,"activeCount":102},[4670],{"nctId":4671,"briefTitle":4672,"status":112,"phases":4673,"primaryCompletion":4674,"completion":3860,"start":4675,"enrollment":3970,"conditions":4676,"interventions":4677},"NCT01797432","Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata",[91],"2014-11","2009-03",[1031],[4662],{"trials":4679,"activeCount":102},[],{"trials":4681,"activeCount":102},[],{"trials":4683,"activeCount":102},[],{"intervention":4685,"totalTrials":136,"cells":4686},"Botulinum toxin",{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4702,"PHASE4":4704,"NA":4706},{"trials":4688,"activeCount":102},[],{"trials":4690,"activeCount":102},[],{"trials":4692,"activeCount":102},[4693],{"nctId":4694,"briefTitle":4695,"status":841,"phases":4696,"primaryCompletion":4697,"completion":4697,"start":1156,"enrollment":102,"conditions":4698,"interventions":4700},"NCT00701233","Botulinum Toxin for Carpal Tunnel Syndrome",[91],"2018-10",[4699],"Carpal Tunnel Syndrome",[4685,4701],"Corticosteroid injection into Carpal Tunnel",{"trials":4703,"activeCount":102},[],{"trials":4705,"activeCount":102},[],{"trials":4707,"activeCount":102},[],{"intervention":4701,"totalTrials":136,"cells":4709},{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4714,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4711,"activeCount":102},[],{"trials":4713,"activeCount":102},[],{"trials":4715,"activeCount":102},[4716],{"nctId":4694,"briefTitle":4695,"status":841,"phases":4717,"primaryCompletion":4697,"completion":4697,"start":1156,"enrollment":102,"conditions":4718,"interventions":4719},[91],[4699],[4685,4701],{"trials":4721,"activeCount":102},[],{"trials":4723,"activeCount":102},[],{"trials":4725,"activeCount":102},[],{"intervention":4727,"totalTrials":136,"cells":4728},"phenethyl isothiocyanate",{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4745,"PHASE4":4747,"NA":4749},{"trials":4730,"activeCount":102},[],{"trials":4732,"activeCount":102},[],{"trials":4734,"activeCount":102},[4735],{"nctId":4736,"briefTitle":4737,"status":112,"phases":4738,"primaryCompletion":4739,"completion":4739,"start":4740,"enrollment":4741,"conditions":4742,"interventions":4744},"NCT00691132","Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers",[91],"2013-01","2009-02",107,[4743,31],"Lung Cancer",[4727],{"trials":4746,"activeCount":102},[],{"trials":4748,"activeCount":102},[],{"trials":4750,"activeCount":102},[],{"intervention":4752,"totalTrials":136,"cells":4753},"Levodopa",{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4769,"PHASE4":4771,"NA":4773},{"trials":4755,"activeCount":102},[],{"trials":4757,"activeCount":102},[],{"trials":4759,"activeCount":102},[4760],{"nctId":4761,"briefTitle":4762,"status":112,"phases":4763,"primaryCompletion":4764,"completion":4764,"start":1755,"enrollment":4765,"conditions":4766,"interventions":4768},"NCT01176435","Trial of L-DOPA as a Treatment to Improve Vision in Albinism",[91],"2014-12",45,[4767],"Albinism",[4752,4752],{"trials":4770,"activeCount":102},[],{"trials":4772,"activeCount":102},[],{"trials":4774,"activeCount":102},[],{"intervention":4776,"totalTrials":136,"cells":4777},"RMT",{"EARLY_PHASE1":4778,"PHASE1":4780,"PHASE2":4782,"PHASE3":4794,"PHASE4":4796,"NA":4798},{"trials":4779,"activeCount":102},[],{"trials":4781,"activeCount":102},[],{"trials":4783,"activeCount":102},[4784],{"nctId":4785,"briefTitle":4786,"status":841,"phases":4787,"primaryCompletion":4788,"completion":4788,"start":4789,"enrollment":102,"conditions":4790,"interventions":4793},"NCT05726396","A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis",[91],"2026-02-01","2025-09-23",[4791,4792],"Immune-related Colitis","Colitis",[4776],{"trials":4795,"activeCount":102},[],{"trials":4797,"activeCount":102},[],{"trials":4799,"activeCount":102},[],{"intervention":4801,"totalTrials":136,"cells":4802},"U-500 insulin, 100 syringe units",{"EARLY_PHASE1":4803,"PHASE1":4805,"PHASE2":4807,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4804,"activeCount":102},[],{"trials":4806,"activeCount":102},[],{"trials":4808,"activeCount":102},[4809],{"nctId":4810,"briefTitle":4811,"status":112,"phases":4812,"primaryCompletion":3780,"completion":3780,"start":2283,"enrollment":4088,"conditions":4813,"interventions":4816},"NCT02148250","PK\u002FPD Study of U-500 Regular Insulin",[91],[4814,847,4815],"Type 2 Diabetes","High Insulin Requirements",[4801,4817],"U-500 insulin, 200 syringe units",{"trials":4819,"activeCount":102},[],{"trials":4821,"activeCount":102},[],{"trials":4823,"activeCount":102},[],{"intervention":4817,"totalTrials":136,"cells":4825},{"EARLY_PHASE1":4826,"PHASE1":4828,"PHASE2":4830,"PHASE3":4836,"PHASE4":4838,"NA":4840},{"trials":4827,"activeCount":102},[],{"trials":4829,"activeCount":102},[],{"trials":4831,"activeCount":102},[4832],{"nctId":4810,"briefTitle":4811,"status":112,"phases":4833,"primaryCompletion":3780,"completion":3780,"start":2283,"enrollment":4088,"conditions":4834,"interventions":4835},[91],[4814,847,4815],[4801,4817],{"trials":4837,"activeCount":102},[],{"trials":4839,"activeCount":102},[],{"trials":4841,"activeCount":102},[],{"intervention":4843,"totalTrials":136,"cells":4844},"N-803 and bNAbs",{"EARLY_PHASE1":4845,"PHASE1":4847,"PHASE2":4849,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4846,"activeCount":102},[],{"trials":4848,"activeCount":102},[],{"trials":4850,"activeCount":102},[4851],{"nctId":4852,"briefTitle":4853,"status":841,"phases":4854,"primaryCompletion":4855,"completion":4855,"start":396,"enrollment":102,"conditions":4856,"interventions":4860},"NCT04144335","N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV",[90,91],"2020-12-31",[496,4857,1760,1771,4858,4859],"HIV\u002FAIDS","AIDS and Infections","Aids\u002FHiv Problem",[4843,4861],"haNK™ Cells",{"trials":4863,"activeCount":102},[],{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":102},[],{"intervention":4861,"totalTrials":136,"cells":4869},{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4874,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4871,"activeCount":102},[],{"trials":4873,"activeCount":102},[],{"trials":4875,"activeCount":102},[4876],{"nctId":4852,"briefTitle":4853,"status":841,"phases":4877,"primaryCompletion":4855,"completion":4855,"start":396,"enrollment":102,"conditions":4878,"interventions":4879},[90,91],[496,4857,1760,1771,4858,4859],[4843,4861],{"trials":4881,"activeCount":102},[],{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"intervention":4887,"totalTrials":136,"cells":4888},"Yellow Fever Vaccine",{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4904,"PHASE4":4906,"NA":4908},{"trials":4890,"activeCount":102},[],{"trials":4892,"activeCount":102},[],{"trials":4894,"activeCount":102},[4895],{"nctId":4896,"briefTitle":4897,"status":112,"phases":4898,"primaryCompletion":4899,"completion":4899,"start":4900,"enrollment":2215,"conditions":4901,"interventions":4903},"NCT04269265","The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination",[90,91],"2023-10-23","2020-07-01",[4902],"Yellow Fever",[4887],{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[],{"intervention":4911,"totalTrials":136,"cells":4912},"Usual Care Group",{"EARLY_PHASE1":4913,"PHASE1":4915,"PHASE2":4917,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4914,"activeCount":102},[],{"trials":4916,"activeCount":102},[],{"trials":4918,"activeCount":102},[4919],{"nctId":4920,"briefTitle":4921,"status":112,"phases":4922,"primaryCompletion":845,"completion":845,"start":1927,"enrollment":4923,"conditions":4924,"interventions":4925},"NCT00218296","Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use",[91],332,[31],[4911],{"trials":4927,"activeCount":102},[],{"trials":4929,"activeCount":102},[],{"trials":4931,"activeCount":102},[],{"intervention":4933,"totalTrials":136,"cells":4934},"Lamictal",{"EARLY_PHASE1":4935,"PHASE1":4937,"PHASE2":4939,"PHASE3":4949,"PHASE4":4951,"NA":4953},{"trials":4936,"activeCount":102},[],{"trials":4938,"activeCount":102},[],{"trials":4940,"activeCount":102},[4941],{"nctId":4942,"briefTitle":4943,"status":112,"phases":4944,"completion":3757,"start":3758,"enrollment":3571,"conditions":4945,"interventions":4948},"NCT00269594","An Open-Label Study Of Lamictal In Neurotic Excoriation",[91],[4946,4947],"Neurotic Disorders","Obsessive-Compulsive Disorder",[4933],{"trials":4950,"activeCount":102},[],{"trials":4952,"activeCount":102},[],{"trials":4954,"activeCount":102},[],{"intervention":4956,"totalTrials":136,"cells":4957},"Cyclosporine & Cellcept",{"EARLY_PHASE1":4958,"PHASE1":4960,"PHASE2":4962,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4959,"activeCount":102},[],{"trials":4961,"activeCount":102},[],{"trials":4963,"activeCount":102},[4964],{"nctId":4965,"briefTitle":4966,"status":112,"phases":4967,"primaryCompletion":4968,"completion":4968,"start":4969,"enrollment":4970,"conditions":4971,"interventions":4973},"NCT01062555","Calcineurin Inhibitor Sparing After Kidney Transplantation",[90,91],"2014-04-03","2006-10-01",527,[4972],"CNI Side Effects",[4956,4974,4975,4976],"Prograf & Cellcept","Low Dose CNI (Cyclosporine or FK) and Cellcept","Rapamune and Cellcept",{"trials":4978,"activeCount":102},[],{"trials":4980,"activeCount":102},[],{"trials":4982,"activeCount":102},[],{"intervention":4974,"totalTrials":136,"cells":4984},{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4989,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":102},[],{"trials":4990,"activeCount":102},[4991],{"nctId":4965,"briefTitle":4966,"status":112,"phases":4992,"primaryCompletion":4968,"completion":4968,"start":4969,"enrollment":4970,"conditions":4993,"interventions":4994},[90,91],[4972],[4956,4974,4975,4976],{"trials":4996,"activeCount":102},[],{"trials":4998,"activeCount":102},[],{"trials":5000,"activeCount":102},[],{"intervention":4975,"totalTrials":136,"cells":5002},{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5007,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":5004,"activeCount":102},[],{"trials":5006,"activeCount":102},[],{"trials":5008,"activeCount":102},[5009],{"nctId":4965,"briefTitle":4966,"status":112,"phases":5010,"primaryCompletion":4968,"completion":4968,"start":4969,"enrollment":4970,"conditions":5011,"interventions":5012},[90,91],[4972],[4956,4974,4975,4976],{"trials":5014,"activeCount":102},[],{"trials":5016,"activeCount":102},[],{"trials":5018,"activeCount":102},[],{"intervention":4976,"totalTrials":136,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5025,"PHASE3":5031,"PHASE4":5033,"NA":5035},{"trials":5022,"activeCount":102},[],{"trials":5024,"activeCount":102},[],{"trials":5026,"activeCount":102},[5027],{"nctId":4965,"briefTitle":4966,"status":112,"phases":5028,"primaryCompletion":4968,"completion":4968,"start":4969,"enrollment":4970,"conditions":5029,"interventions":5030},[90,91],[4972],[4956,4974,4975,4976],{"trials":5032,"activeCount":102},[],{"trials":5034,"activeCount":102},[],{"trials":5036,"activeCount":102},[],{"intervention":5038,"totalTrials":136,"cells":5039},"Phentermine-Topiramate",{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5044,"PHASE3":5055,"PHASE4":5057,"NA":5059},{"trials":5041,"activeCount":102},[],{"trials":5043,"activeCount":102},[],{"trials":5045,"activeCount":102},[5046],{"nctId":5047,"briefTitle":5048,"status":112,"phases":5049,"primaryCompletion":5050,"completion":5050,"start":5051,"enrollment":5052,"conditions":5053,"interventions":5054},"NCT04298203","Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity",[91],"2026-05-22","2021-08-04",100,[16],[5038],{"trials":5056,"activeCount":102},[],{"trials":5058,"activeCount":102},[],{"trials":5060,"activeCount":102},[],{"intervention":5062,"totalTrials":136,"cells":5063},"Gabapentin",{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5068,"PHASE3":5077,"PHASE4":5079,"NA":5081},{"trials":5065,"activeCount":102},[],{"trials":5067,"activeCount":102},[],{"trials":5069,"activeCount":102},[5070],{"nctId":5071,"briefTitle":5072,"status":841,"phases":5073,"primaryCompletion":3579,"completion":3579,"start":3129,"enrollment":102,"conditions":5074,"interventions":5076},"NCT01588314","Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease",[91],[5075,2780],"Fabry Disease",[5062],{"trials":5078,"activeCount":102},[],{"trials":5080,"activeCount":102},[],{"trials":5082,"activeCount":102},[],{"intervention":5084,"totalTrials":136,"cells":5085},"ACTH",{"EARLY_PHASE1":5086,"PHASE1":5088,"PHASE2":5090,"PHASE3":5102,"PHASE4":5104,"NA":5106},{"trials":5087,"activeCount":102},[],{"trials":5089,"activeCount":102},[],{"trials":5091,"activeCount":102},[5092],{"nctId":5093,"briefTitle":5094,"status":1860,"phases":5095,"primaryCompletion":3601,"completion":3601,"start":5096,"enrollment":10,"conditions":5097,"interventions":5101},"NCT01950234","ACTH in Progressive Forms of MS",[91],"2014-04-17",[5098,5099,5100],"Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis","Progressive Relapsing Multiple Sclerosis",[5084],{"trials":5103,"activeCount":102},[],{"trials":5105,"activeCount":102},[],{"trials":5107,"activeCount":102},[],{"intervention":5109,"totalTrials":136,"cells":5110},"zoledronic acid",{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5115,"PHASE3":5132,"PHASE4":5134,"NA":5136},{"trials":5112,"activeCount":102},[],{"trials":5114,"activeCount":102},[],{"trials":5116,"activeCount":102},[5117],{"nctId":5118,"briefTitle":5119,"status":112,"phases":5120,"primaryCompletion":5121,"completion":5122,"start":5123,"enrollment":5124,"conditions":5125,"interventions":5131},"NCT00321932","Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant",[91],"2011-03","2012-03","2005-07",61,[5126,5127,5128,5129,5130],"Leukemia","Lymphoma","Myelodysplastic Syndromes","Osteoporosis","Ovarian Cancer",[5109],{"trials":5133,"activeCount":102},[],{"trials":5135,"activeCount":102},[],{"trials":5137,"activeCount":102},[],{"intervention":5139,"totalTrials":136,"cells":5140},"Low-dose Progesterone",{"EARLY_PHASE1":5141,"PHASE1":5143,"PHASE2":5145,"PHASE3":5156,"PHASE4":5158,"NA":5160},{"trials":5142,"activeCount":102},[],{"trials":5144,"activeCount":102},[],{"trials":5146,"activeCount":102},[5147],{"nctId":5148,"briefTitle":5149,"status":112,"phases":5150,"primaryCompletion":1631,"completion":1631,"start":5151,"enrollment":3014,"conditions":5152,"interventions":5154},"NCT01811225","Smoking, Sex Hormones, and Pregnancy",[91],"2012-12",[2742,5153],"Contraception",[5139,5155],"High-dose Progesterone",{"trials":5157,"activeCount":102},[],{"trials":5159,"activeCount":102},[],{"trials":5161,"activeCount":102},[],{"intervention":5155,"totalTrials":136,"cells":5163},{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5168,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5165,"activeCount":102},[],{"trials":5167,"activeCount":102},[],{"trials":5169,"activeCount":102},[5170],{"nctId":5148,"briefTitle":5149,"status":112,"phases":5171,"primaryCompletion":1631,"completion":1631,"start":5151,"enrollment":3014,"conditions":5172,"interventions":5173},[91],[2742,5153],[5139,5155],{"trials":5175,"activeCount":102},[],{"trials":5177,"activeCount":102},[],{"trials":5179,"activeCount":102},[],{"intervention":5181,"totalTrials":136,"cells":5182},"chlorthalidone",{"EARLY_PHASE1":5183,"PHASE1":5185,"PHASE2":5187,"PHASE3":5202,"PHASE4":5204,"NA":5206},{"trials":5184,"activeCount":102},[],{"trials":5186,"activeCount":102},[],{"trials":5188,"activeCount":102},[5189],{"nctId":5190,"briefTitle":5191,"status":112,"phases":5192,"completion":5193,"start":5194,"conditions":5195,"interventions":5197},"NCT00000522","Treatment of Mild Hypertension Study (TOMHS)",[91],"1994-05","1985-08",[22,28,33,5196],"Vascular Diseases",[5181,5198,5199,5200,5201],"acebutolol","doxazosin","amlodipine","enalapril",{"trials":5203,"activeCount":102},[],{"trials":5205,"activeCount":102},[],{"trials":5207,"activeCount":102},[],{"intervention":5198,"totalTrials":136,"cells":5209},{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5220,"PHASE4":5222,"NA":5224},{"trials":5211,"activeCount":102},[],{"trials":5213,"activeCount":102},[],{"trials":5215,"activeCount":102},[5216],{"nctId":5190,"briefTitle":5191,"status":112,"phases":5217,"completion":5193,"start":5194,"conditions":5218,"interventions":5219},[91],[22,28,33,5196],[5181,5198,5199,5200,5201],{"trials":5221,"activeCount":102},[],{"trials":5223,"activeCount":102},[],{"trials":5225,"activeCount":102},[],{"intervention":5199,"totalTrials":136,"cells":5227},{"EARLY_PHASE1":5228,"PHASE1":5230,"PHASE2":5232,"PHASE3":5238,"PHASE4":5240,"NA":5242},{"trials":5229,"activeCount":102},[],{"trials":5231,"activeCount":102},[],{"trials":5233,"activeCount":102},[5234],{"nctId":5190,"briefTitle":5191,"status":112,"phases":5235,"completion":5193,"start":5194,"conditions":5236,"interventions":5237},[91],[22,28,33,5196],[5181,5198,5199,5200,5201],{"trials":5239,"activeCount":102},[],{"trials":5241,"activeCount":102},[],{"trials":5243,"activeCount":102},[],{"intervention":5200,"totalTrials":136,"cells":5245},{"EARLY_PHASE1":5246,"PHASE1":5248,"PHASE2":5250,"PHASE3":5256,"PHASE4":5258,"NA":5260},{"trials":5247,"activeCount":102},[],{"trials":5249,"activeCount":102},[],{"trials":5251,"activeCount":102},[5252],{"nctId":5190,"briefTitle":5191,"status":112,"phases":5253,"completion":5193,"start":5194,"conditions":5254,"interventions":5255},[91],[22,28,33,5196],[5181,5198,5199,5200,5201],{"trials":5257,"activeCount":102},[],{"trials":5259,"activeCount":102},[],{"trials":5261,"activeCount":102},[],{"intervention":5201,"totalTrials":136,"cells":5263},{"EARLY_PHASE1":5264,"PHASE1":5266,"PHASE2":5268,"PHASE3":5274,"PHASE4":5276,"NA":5278},{"trials":5265,"activeCount":102},[],{"trials":5267,"activeCount":102},[],{"trials":5269,"activeCount":102},[5270],{"nctId":5190,"briefTitle":5191,"status":112,"phases":5271,"completion":5193,"start":5194,"conditions":5272,"interventions":5273},[91],[22,28,33,5196],[5181,5198,5199,5200,5201],{"trials":5275,"activeCount":102},[],{"trials":5277,"activeCount":102},[],{"trials":5279,"activeCount":102},[],{"intervention":5281,"totalTrials":136,"cells":5282},"AMBITION trial control",{"EARLY_PHASE1":5283,"PHASE1":5285,"PHASE2":5287,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5284,"activeCount":102},[],{"trials":5286,"activeCount":102},[],{"trials":5288,"activeCount":102},[5289],{"nctId":5290,"briefTitle":5291,"status":112,"phases":5292,"primaryCompletion":5293,"completion":5293,"start":5294,"enrollment":243,"conditions":5295,"interventions":5296},"NCT06414512","Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis",[91],"2024-10-02","2024-04-09",[497],[5281,5297],"Flucytosine",{"trials":5299,"activeCount":102},[],{"trials":5301,"activeCount":102},[],{"trials":5303,"activeCount":102},[],{"intervention":5297,"totalTrials":136,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5307,"activeCount":102},[],{"trials":5309,"activeCount":102},[],{"trials":5311,"activeCount":102},[5312],{"nctId":5290,"briefTitle":5291,"status":112,"phases":5313,"primaryCompletion":5293,"completion":5293,"start":5294,"enrollment":243,"conditions":5314,"interventions":5315},[91],[497],[5281,5297],{"trials":5317,"activeCount":102},[],{"trials":5319,"activeCount":102},[],{"trials":5321,"activeCount":102},[],{"intervention":5323,"totalTrials":136,"cells":5324},"Triamcinolone Acetonide 10 mg\u002FmL",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5337,"PHASE4":5339,"NA":5341},{"trials":5326,"activeCount":102},[],{"trials":5328,"activeCount":102},[],{"trials":5330,"activeCount":102},[5331],{"nctId":5332,"briefTitle":5333,"status":112,"phases":5334,"primaryCompletion":3254,"completion":5121,"start":3591,"enrollment":4373,"conditions":5335,"interventions":5336},"NCT00484679","Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg\u002FmL (Kenalog-10) in Patients With Alopecia Areata",[91],[1031],[5323],{"trials":5338,"activeCount":102},[],{"trials":5340,"activeCount":102},[],{"trials":5342,"activeCount":102},[],{"intervention":3898,"totalTrials":136,"cells":5344},{"EARLY_PHASE1":5345,"PHASE1":5347,"PHASE2":5349,"PHASE3":5355,"PHASE4":5357,"NA":5359},{"trials":5346,"activeCount":102},[],{"trials":5348,"activeCount":102},[],{"trials":5350,"activeCount":102},[5351],{"nctId":3891,"briefTitle":3892,"status":1860,"phases":5352,"primaryCompletion":3894,"completion":3894,"start":534,"enrollment":3728,"conditions":5353,"interventions":5354},[91],[3896],[3873,3898,3899],{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[],{"trials":5360,"activeCount":102},[],{"intervention":3899,"totalTrials":136,"cells":5362},{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5367,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5364,"activeCount":102},[],{"trials":5366,"activeCount":102},[],{"trials":5368,"activeCount":102},[5369],{"nctId":3891,"briefTitle":3892,"status":1860,"phases":5370,"primaryCompletion":3894,"completion":3894,"start":534,"enrollment":3728,"conditions":5371,"interventions":5372},[91],[3896],[3873,3898,3899],{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[],{"trials":5378,"activeCount":102},[],{"intervention":5380,"totalTrials":136,"cells":5381},"Oral Magnesium Supplement",{"EARLY_PHASE1":5382,"PHASE1":5384,"PHASE2":5386,"PHASE3":5397,"PHASE4":5399,"NA":5401},{"trials":5383,"activeCount":102},[],{"trials":5385,"activeCount":102},[],{"trials":5387,"activeCount":102},[5388],{"nctId":5389,"briefTitle":5390,"status":112,"phases":5391,"primaryCompletion":5392,"completion":5392,"start":5393,"enrollment":10,"conditions":5394,"interventions":5396},"NCT02837328","Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias",[91],"2017-09-15","2017-03-01",[5395],"Premature Atrial Contraction",[5380],{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[],{"trials":5402,"activeCount":102},[],{"intervention":5404,"totalTrials":136,"cells":5405},"Buprenorphine-Naloxone",{"EARLY_PHASE1":5406,"PHASE1":5408,"PHASE2":5410,"PHASE3":5422,"PHASE4":5424,"NA":5426},{"trials":5407,"activeCount":102},[],{"trials":5409,"activeCount":102},[],{"trials":5411,"activeCount":102},[5412],{"nctId":5413,"briefTitle":5414,"status":112,"phases":5415,"primaryCompletion":5416,"completion":5417,"start":5418,"enrollment":582,"conditions":5419,"interventions":5421},"NCT03026790","Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study",[91],"2022-03-17","2022-10-30","2017-10-19",[5420],"Chronic Pain",[5404],{"trials":5423,"activeCount":102},[],{"trials":5425,"activeCount":102},[],{"trials":5427,"activeCount":102},[],{"intervention":5429,"totalTrials":136,"cells":5430},"Nicotine gum and lozenge",{"EARLY_PHASE1":5431,"PHASE1":5433,"PHASE2":5435,"PHASE3":5444,"PHASE4":5446,"NA":5448},{"trials":5432,"activeCount":102},[],{"trials":5434,"activeCount":102},[],{"trials":5436,"activeCount":102},[5437],{"nctId":5438,"briefTitle":5439,"status":112,"phases":5440,"primaryCompletion":4740,"completion":4740,"start":2845,"enrollment":5441,"conditions":5442,"interventions":5443},"NCT00469079","Health Effects of SLT, Cigarette Smoking, and New Tobacco Products",[91],130,[2742],[5429],{"trials":5445,"activeCount":102},[],{"trials":5447,"activeCount":102},[],{"trials":5449,"activeCount":102},[],{"intervention":5451,"totalTrials":136,"cells":5452},"Post-Laser Minoxidil 2%",{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5457,"PHASE3":5472,"PHASE4":5474,"NA":5476},{"trials":5454,"activeCount":102},[],{"trials":5456,"activeCount":102},[],{"trials":5458,"activeCount":102},[5459],{"nctId":5460,"briefTitle":5461,"status":841,"phases":5462,"primaryCompletion":2213,"completion":2213,"start":3429,"enrollment":102,"conditions":5463,"interventions":5467},"NCT03852992","Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia",[91],[5464,5465,5466],"Male Pattern Hair Loss","Androgenetic Alopecia","Male Pattern Baldness",[5451,5468,5469,5470,5471],"At-Home Minoxidil 5%","Post-laser 5mg minoxidil","Post-laser 10mg minoxidil","Post-laser 20mg minoxidil",{"trials":5473,"activeCount":102},[],{"trials":5475,"activeCount":102},[],{"trials":5477,"activeCount":102},[],{"intervention":5468,"totalTrials":136,"cells":5479},{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5481,"activeCount":102},[],{"trials":5483,"activeCount":102},[],{"trials":5485,"activeCount":102},[5486],{"nctId":5460,"briefTitle":5461,"status":841,"phases":5487,"primaryCompletion":2213,"completion":2213,"start":3429,"enrollment":102,"conditions":5488,"interventions":5489},[91],[5464,5465,5466],[5451,5468,5469,5470,5471],{"trials":5491,"activeCount":102},[],{"trials":5493,"activeCount":102},[],{"trials":5495,"activeCount":102},[],{"intervention":5469,"totalTrials":136,"cells":5497},{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5502,"PHASE3":5508,"PHASE4":5510,"NA":5512},{"trials":5499,"activeCount":102},[],{"trials":5501,"activeCount":102},[],{"trials":5503,"activeCount":102},[5504],{"nctId":5460,"briefTitle":5461,"status":841,"phases":5505,"primaryCompletion":2213,"completion":2213,"start":3429,"enrollment":102,"conditions":5506,"interventions":5507},[91],[5464,5465,5466],[5451,5468,5469,5470,5471],{"trials":5509,"activeCount":102},[],{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[],{"intervention":5470,"totalTrials":136,"cells":5515},{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5520,"PHASE3":5526,"PHASE4":5528,"NA":5530},{"trials":5517,"activeCount":102},[],{"trials":5519,"activeCount":102},[],{"trials":5521,"activeCount":102},[5522],{"nctId":5460,"briefTitle":5461,"status":841,"phases":5523,"primaryCompletion":2213,"completion":2213,"start":3429,"enrollment":102,"conditions":5524,"interventions":5525},[91],[5464,5465,5466],[5451,5468,5469,5470,5471],{"trials":5527,"activeCount":102},[],{"trials":5529,"activeCount":102},[],{"trials":5531,"activeCount":102},[],{"intervention":5471,"totalTrials":136,"cells":5533},{"EARLY_PHASE1":5534,"PHASE1":5536,"PHASE2":5538,"PHASE3":5544,"PHASE4":5546,"NA":5548},{"trials":5535,"activeCount":102},[],{"trials":5537,"activeCount":102},[],{"trials":5539,"activeCount":102},[5540],{"nctId":5460,"briefTitle":5461,"status":841,"phases":5541,"primaryCompletion":2213,"completion":2213,"start":3429,"enrollment":102,"conditions":5542,"interventions":5543},[91],[5464,5465,5466],[5451,5468,5469,5470,5471],{"trials":5545,"activeCount":102},[],{"trials":5547,"activeCount":102},[],{"trials":5549,"activeCount":102},[],{"intervention":5551,"totalTrials":136,"cells":5552},"Sclerotherapy",{"EARLY_PHASE1":5553,"PHASE1":5555,"PHASE2":5557,"PHASE3":5567,"PHASE4":5569,"NA":5571},{"trials":5554,"activeCount":102},[],{"trials":5556,"activeCount":102},[],{"trials":5558,"activeCount":102},[5559],{"nctId":5560,"briefTitle":5561,"status":112,"phases":5562,"primaryCompletion":543,"completion":543,"start":844,"enrollment":4373,"conditions":5563,"interventions":5566},"NCT01408732","Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia",[90,91],[5564,5565],"Epistaxis","Hereditary Hemorrhagic Telangiectasia",[5551],{"trials":5568,"activeCount":102},[],{"trials":5570,"activeCount":102},[],{"trials":5572,"activeCount":102},[],{"intervention":5574,"totalTrials":136,"cells":5575},"4000 IU vitamin D3",{"EARLY_PHASE1":5576,"PHASE1":5578,"PHASE2":5580,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5577,"activeCount":102},[],{"trials":5579,"activeCount":102},[],{"trials":5581,"activeCount":102},[5582],{"nctId":5583,"briefTitle":5584,"status":841,"phases":5585,"primaryCompletion":5586,"completion":5586,"start":5587,"enrollment":102,"conditions":5588,"interventions":5590},"NCT03037593","High Dose Cholecalciferol to Reduce the Incidence of Gestational Diabetes in High Risk Pregnant Women",[90,91],"2020-06","2017-06-01",[5589],"Gestational Diabetes",[5574],{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[],{"trials":5596,"activeCount":102},[],{"intervention":5598,"totalTrials":136,"cells":5599},"Selective Serotonin Reuptake Inhibitor",{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5604,"PHASE3":5616,"PHASE4":5618,"NA":5620},{"trials":5601,"activeCount":102},[],{"trials":5603,"activeCount":102},[],{"trials":5605,"activeCount":102},[5606],{"nctId":5607,"briefTitle":5608,"status":112,"phases":5609,"primaryCompletion":5610,"completion":5610,"start":5611,"enrollment":5612,"conditions":5613,"interventions":5615},"NCT03222570","An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression",[91],"2024-04-28","2018-02-26",90,[5614],"Depressive Disorder",[5598],{"trials":5617,"activeCount":102},[],{"trials":5619,"activeCount":102},[],{"trials":5621,"activeCount":102},[],{"intervention":5623,"totalTrials":136,"cells":5624},"Memantine",{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5641,"PHASE4":5643,"NA":5645},{"trials":5626,"activeCount":102},[],{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":102},[5631],{"nctId":5632,"briefTitle":5633,"status":112,"phases":5634,"primaryCompletion":5635,"completion":5635,"start":5636,"enrollment":5637,"conditions":5638,"interventions":5640},"NCT00830375","Memantine Treatment of Compulsive Buying",[91],"2010-08-01","2008-12-01",10,[5639],"Compulsive Buying",[5623],{"trials":5642,"activeCount":102},[],{"trials":5644,"activeCount":102},[],{"trials":5646,"activeCount":102},[],{"intervention":5648,"totalTrials":136,"cells":5649},"IR-TPM",{"EARLY_PHASE1":5650,"PHASE1":5652,"PHASE2":5654,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5651,"activeCount":102},[],{"trials":5653,"activeCount":102},[],{"trials":5655,"activeCount":102},[5656],{"nctId":5657,"briefTitle":5658,"status":841,"phases":5659,"primaryCompletion":5660,"completion":5661,"start":5662,"enrollment":102,"conditions":5663,"interventions":5666},"NCT03280342","Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine",[91],"2018-08-20","2018-09-13","2017-10-30",[5664,5665],"Migraine","Headache",[5648,5667],"XR-TPM",{"trials":5669,"activeCount":102},[],{"trials":5671,"activeCount":102},[],{"trials":5673,"activeCount":102},[],{"intervention":5667,"totalTrials":136,"cells":5675},{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5686,"PHASE4":5688,"NA":5690},{"trials":5677,"activeCount":102},[],{"trials":5679,"activeCount":102},[],{"trials":5681,"activeCount":102},[5682],{"nctId":5657,"briefTitle":5658,"status":841,"phases":5683,"primaryCompletion":5660,"completion":5661,"start":5662,"enrollment":102,"conditions":5684,"interventions":5685},[91],[5664,5665],[5648,5667],{"trials":5687,"activeCount":102},[],{"trials":5689,"activeCount":102},[],{"trials":5691,"activeCount":102},[],{"intervention":5693,"totalTrials":136,"cells":5694},"Syntocinon",{"EARLY_PHASE1":5695,"PHASE1":5697,"PHASE2":5699,"PHASE3":5708,"PHASE4":5710,"NA":5712},{"trials":5696,"activeCount":102},[],{"trials":5698,"activeCount":102},[],{"trials":5700,"activeCount":102},[5701],{"nctId":5702,"briefTitle":5703,"status":841,"phases":5704,"primaryCompletion":3969,"completion":3969,"start":5705,"enrollment":102,"conditions":5706,"interventions":5707},"NCT02090829","Intranasal Oxytocin and Learning in Autism",[91],"2014-03",[4063],[5693],{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[],{"trials":5713,"activeCount":102},[],{"intervention":5715,"totalTrials":136,"cells":5716},"Instilled T3",{"EARLY_PHASE1":5717,"PHASE1":5719,"PHASE2":5721,"PHASE3":5732,"PHASE4":5734,"NA":5736},{"trials":5718,"activeCount":102},[],{"trials":5720,"activeCount":102},[],{"trials":5722,"activeCount":102},[5723],{"nctId":5724,"briefTitle":5725,"status":841,"phases":5726,"primaryCompletion":5727,"completion":5728,"start":5729,"enrollment":102,"conditions":5730,"interventions":5731},"NCT04725110","Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome",[91],"2030-10-15","2031-10-15","2026-01-15",[586,832,2698,1003],[5715],{"trials":5733,"activeCount":102},[],{"trials":5735,"activeCount":102},[],{"trials":5737,"activeCount":102},[],{"intervention":5739,"totalTrials":136,"cells":5740},"Bupropion HCl",{"EARLY_PHASE1":5741,"PHASE1":5743,"PHASE2":5745,"PHASE3":5754,"PHASE4":5756,"NA":5758},{"trials":5742,"activeCount":102},[],{"trials":5744,"activeCount":102},[],{"trials":5746,"activeCount":102},[5747],{"nctId":5748,"briefTitle":5749,"status":112,"phases":5750,"primaryCompletion":3663,"completion":3663,"start":5751,"enrollment":420,"conditions":5752,"interventions":5753},"NCT01111149","Varenicline and Smoking Cessation in Schizophrenia",[91],"2009-12",[4125,331],[2745,5739],{"trials":5755,"activeCount":102},[],{"trials":5757,"activeCount":102},[],{"trials":5759,"activeCount":102},[],{"intervention":5761,"totalTrials":136,"cells":5762},"Magnesium sulfate",{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5764,"activeCount":102},[],{"trials":5766,"activeCount":102},[],{"trials":5768,"activeCount":102},[5769],{"nctId":5770,"briefTitle":5771,"status":112,"phases":5772,"primaryCompletion":5773,"completion":5773,"start":5774,"enrollment":5775,"conditions":5776,"interventions":5778},"NCT04812028","Magnesium Sulfate for Analgesia in Pediatric Transplant",[91],"2023-08-10","2021-03-01",66,[5777],"Postoperative Pain",[5761],{"trials":5780,"activeCount":102},[],{"trials":5782,"activeCount":102},[],{"trials":5784,"activeCount":102},[],{"intervention":5786,"totalTrials":136,"cells":5787},"Oral Glutathione",{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5802,"PHASE4":5804,"NA":5806},{"trials":5789,"activeCount":102},[],{"trials":5791,"activeCount":102},[],{"trials":5793,"activeCount":102},[5794],{"nctId":5795,"briefTitle":5796,"status":112,"phases":5797,"primaryCompletion":5798,"completion":5798,"start":5799,"enrollment":12,"conditions":5800,"interventions":5801},"NCT03020719","The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis",[91],"2018-12-12","2017-06-14",[119],[5786],{"trials":5803,"activeCount":102},[],{"trials":5805,"activeCount":102},[],{"trials":5807,"activeCount":102},[],{"intervention":5809,"totalTrials":136,"cells":5810},"Dexmedetomidine",{"EARLY_PHASE1":5811,"PHASE1":5813,"PHASE2":5815,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5812,"activeCount":102},[],{"trials":5814,"activeCount":102},[],{"trials":5816,"activeCount":102},[5817],{"nctId":5818,"briefTitle":5819,"status":112,"phases":5820,"primaryCompletion":510,"completion":2283,"start":1768,"enrollment":892,"conditions":5821,"interventions":5824},"NCT01606852","Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients",[90,91],[5822,5823],"Acute Respiratory Failure","Anxiety",[5809],{"trials":5826,"activeCount":102},[],{"trials":5828,"activeCount":102},[],{"trials":5830,"activeCount":102},[],{"intervention":5832,"totalTrials":136,"cells":5833},"Weight loss with pharmacotherapy",{"EARLY_PHASE1":5834,"PHASE1":5836,"PHASE2":5838,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5835,"activeCount":102},[],{"trials":5837,"activeCount":102},[],{"trials":5839,"activeCount":102},[5840],{"nctId":5841,"briefTitle":5842,"status":112,"phases":5843,"primaryCompletion":5844,"completion":5844,"start":3860,"enrollment":5052,"conditions":5845,"interventions":5847},"NCT02496611","Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity",[91],"2020-08-14",[5846],"Severe Obesity",[5832,5848],"Weight loss without pharmacotherapy",{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":102},[],{"trials":5854,"activeCount":102},[],{"intervention":5848,"totalTrials":136,"cells":5856},{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5861,"PHASE3":5867,"PHASE4":5869,"NA":5871},{"trials":5858,"activeCount":102},[],{"trials":5860,"activeCount":102},[],{"trials":5862,"activeCount":102},[5863],{"nctId":5841,"briefTitle":5842,"status":112,"phases":5864,"primaryCompletion":5844,"completion":5844,"start":3860,"enrollment":5052,"conditions":5865,"interventions":5866},[91],[5846],[5832,5848],{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":102},[],{"trials":5872,"activeCount":102},[],{"intervention":5874,"totalTrials":136,"cells":5875},"Qsymia and lifestyle management therapy",{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5880,"PHASE3":5891,"PHASE4":5893,"NA":5895},{"trials":5877,"activeCount":102},[],{"trials":5879,"activeCount":102},[],{"trials":5881,"activeCount":102},[5882],{"nctId":5883,"briefTitle":5884,"status":841,"phases":5885,"primaryCompletion":5886,"completion":935,"start":5887,"enrollment":102,"conditions":5888,"interventions":5890},"NCT05834062","Phentermine\u002FTopiramate as Preventive Pharmacotherapy for Obesity",[91],"2026-08","2023-10-17",[5889],"Obesity, Adolescent",[5874],{"trials":5892,"activeCount":102},[],{"trials":5894,"activeCount":102},[],{"trials":5896,"activeCount":102},[],{"intervention":5898,"totalTrials":136,"cells":5899},"lisdexamfetamine\u002FBehavior Therapy",{"EARLY_PHASE1":5900,"PHASE1":5902,"PHASE2":5904,"PHASE3":5913,"PHASE4":5915,"NA":5917},{"trials":5901,"activeCount":102},[],{"trials":5903,"activeCount":102},[],{"trials":5905,"activeCount":102},[5906],{"nctId":5907,"briefTitle":5908,"status":112,"phases":5909,"primaryCompletion":4739,"completion":4739,"start":4263,"enrollment":2215,"conditions":5910,"interventions":5912},"NCT00958282","Treatment of Cocaine Dependence With Lisdexamfetamine",[91],[5911],"Cocaine Dependence",[5898],{"trials":5914,"activeCount":102},[],{"trials":5916,"activeCount":102},[],{"trials":5918,"activeCount":102},[],{"intervention":5920,"totalTrials":136,"cells":5921},"Extended Release Lamotrigine",{"EARLY_PHASE1":5922,"PHASE1":5924,"PHASE2":5926,"PHASE3":5939,"PHASE4":5941,"NA":5943},{"trials":5923,"activeCount":102},[],{"trials":5925,"activeCount":102},[],{"trials":5927,"activeCount":102},[5928],{"nctId":5929,"briefTitle":5930,"status":112,"phases":5931,"primaryCompletion":5932,"completion":5932,"start":2739,"enrollment":3728,"conditions":5933,"interventions":5938},"NCT00789113","Determination of Absorption and Elimination of Lamotrigine-XR",[90,91],"2011-01",[5934,5935,5936,5937],"Epilepsy","Seizures","Bipolar Disorder","Bipolar Depression",[5920],{"trials":5940,"activeCount":102},[],{"trials":5942,"activeCount":102},[],{"trials":5944,"activeCount":102},[],{"intervention":5946,"totalTrials":136,"cells":5947},"Phentermine Pill",{"EARLY_PHASE1":5948,"PHASE1":5950,"PHASE2":5952,"PHASE3":5964,"PHASE4":5966,"NA":5968},{"trials":5949,"activeCount":102},[],{"trials":5951,"activeCount":102},[],{"trials":5953,"activeCount":102},[5954],{"nctId":5955,"briefTitle":5956,"status":112,"phases":5957,"primaryCompletion":5958,"completion":5958,"start":5959,"enrollment":198,"conditions":5960,"interventions":5962},"NCT04007393","SMART Use of Medication for the Treatment of Adolescent Severe Obesity",[91],"2025-03-11","2019-11-21",[5961],"Adolescent Obesity",[5946,5963],"Topiramate Pill",{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[],{"trials":5969,"activeCount":102},[],{"intervention":5963,"totalTrials":136,"cells":5971},{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5976,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5973,"activeCount":102},[],{"trials":5975,"activeCount":102},[],{"trials":5977,"activeCount":102},[5978],{"nctId":5955,"briefTitle":5956,"status":112,"phases":5979,"primaryCompletion":5958,"completion":5958,"start":5959,"enrollment":198,"conditions":5980,"interventions":5981},[91],[5961],[5946,5963],{"trials":5983,"activeCount":102},[],{"trials":5985,"activeCount":102},[],{"trials":5987,"activeCount":102},[],{"intervention":5989,"totalTrials":136,"cells":5990},"incobotulinum toxin A",{"EARLY_PHASE1":5991,"PHASE1":5993,"PHASE2":5995,"PHASE3":6005,"PHASE4":6007,"NA":6009},{"trials":5992,"activeCount":102},[],{"trials":5994,"activeCount":102},[],{"trials":5996,"activeCount":102},[5997],{"nctId":5998,"briefTitle":5999,"status":112,"phases":6000,"primaryCompletion":6001,"completion":6001,"start":2778,"enrollment":2611,"conditions":6002,"interventions":6004},"NCT05650645","The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial",[91],"2025-12-29",[6003],"Tinnitus",[5989],{"trials":6006,"activeCount":102},[],{"trials":6008,"activeCount":102},[],{"trials":6010,"activeCount":102},[],{"intervention":3679,"totalTrials":136,"cells":6012},{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6017,"PHASE3":6023,"PHASE4":6025,"NA":6027},{"trials":6014,"activeCount":102},[],{"trials":6016,"activeCount":102},[],{"trials":6018,"activeCount":102},[6019],{"nctId":3672,"briefTitle":3673,"status":112,"phases":6020,"start":3675,"enrollment":23,"conditions":6021,"interventions":6022},[90,91],[3677],[3651,3679,3680,3681,3682,3683],{"trials":6024,"activeCount":102},[],{"trials":6026,"activeCount":102},[],{"trials":6028,"activeCount":102},[],{"intervention":3682,"totalTrials":136,"cells":6030},{"EARLY_PHASE1":6031,"PHASE1":6033,"PHASE2":6035,"PHASE3":6041,"PHASE4":6043,"NA":6045},{"trials":6032,"activeCount":102},[],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[6037],{"nctId":3672,"briefTitle":3673,"status":112,"phases":6038,"start":3675,"enrollment":23,"conditions":6039,"interventions":6040},[90,91],[3677],[3651,3679,3680,3681,3682,3683],{"trials":6042,"activeCount":102},[],{"trials":6044,"activeCount":102},[],{"trials":6046,"activeCount":102},[],{"intervention":3683,"totalTrials":136,"cells":6048},{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6059,"PHASE4":6061,"NA":6063},{"trials":6050,"activeCount":102},[],{"trials":6052,"activeCount":102},[],{"trials":6054,"activeCount":102},[6055],{"nctId":3672,"briefTitle":3673,"status":112,"phases":6056,"start":3675,"enrollment":23,"conditions":6057,"interventions":6058},[90,91],[3677],[3651,3679,3680,3681,3682,3683],{"trials":6060,"activeCount":102},[],{"trials":6062,"activeCount":102},[],{"trials":6064,"activeCount":102},[],{"intervention":3693,"totalTrials":136,"cells":6066},{"EARLY_PHASE1":6067,"PHASE1":6069,"PHASE2":6071,"PHASE3":6077,"PHASE4":6079,"NA":6081},{"trials":6068,"activeCount":102},[],{"trials":6070,"activeCount":102},[],{"trials":6072,"activeCount":102},[6073],{"nctId":3685,"briefTitle":3686,"status":112,"phases":6074,"primaryCompletion":3688,"completion":3688,"start":3689,"enrollment":1366,"conditions":6075,"interventions":6076},[90,91],[3666,3667],[3692,3693,3651,3694],{"trials":6078,"activeCount":102},[],{"trials":6080,"activeCount":102},[],{"trials":6082,"activeCount":102},[],{"intervention":6084,"totalTrials":136,"cells":6085},"Cilostazol 100Mg Tab",{"EARLY_PHASE1":6086,"PHASE1":6088,"PHASE2":6090,"PHASE3":6102,"PHASE4":6104,"NA":6106},{"trials":6087,"activeCount":102},[],{"trials":6089,"activeCount":102},[],{"trials":6091,"activeCount":102},[6092],{"nctId":6093,"briefTitle":6094,"status":112,"phases":6095,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":3571,"conditions":6099,"interventions":6101},"NCT05126836","Cilostazol for HFpEF",[91],"2022-06-01","2022-07-01","2021-09-01",[6100],"Heart Failure With Preserved Ejection Fraction",[6084],{"trials":6103,"activeCount":102},[],{"trials":6105,"activeCount":102},[],{"trials":6107,"activeCount":102},[],{"intervention":6109,"totalTrials":136,"cells":6110},"Dynorphin 1 - 13",{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6112,"activeCount":102},[],{"trials":6114,"activeCount":102},[],{"trials":6116,"activeCount":102},[6117],{"nctId":6118,"briefTitle":6119,"status":112,"phases":6120,"primaryCompletion":6121,"completion":6121,"start":6122,"enrollment":102,"conditions":6123,"interventions":6126},"NCT00000244","Effects of Dynorphin 1-13 on Heroin Addiction - 1",[91],"1997-03","1994-08",[6124,6125],"Opioid-Related Disorders","Substance Withdrawal Syndrome",[6109],{"trials":6128,"activeCount":102},[],{"trials":6130,"activeCount":102},[],{"trials":6132,"activeCount":102},[],{"intervention":6134,"totalTrials":136,"cells":6135},"Transarterial chemoembolization",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6151,"PHASE3":6153,"PHASE4":6155,"NA":6157},{"trials":6137,"activeCount":102},[],{"trials":6139,"activeCount":102},[6140],{"nctId":6141,"briefTitle":6142,"status":112,"phases":6143,"primaryCompletion":6144,"completion":6145,"start":6146,"enrollment":4017,"conditions":6147,"interventions":6150},"NCT03259581","Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin",[90],"2021-12-31","2022-02-01","2018-01-02",[6148,6149],"Hepatocellular Carcinoma","Bilirubinemia",[6134],{"trials":6152,"activeCount":102},[],{"trials":6154,"activeCount":102},[],{"trials":6156,"activeCount":102},[],{"trials":6158,"activeCount":102},[],{"intervention":6160,"totalTrials":136,"cells":6161},"Psilocybin",{"EARLY_PHASE1":6162,"PHASE1":6164,"PHASE2":6178,"PHASE3":6180,"PHASE4":6182,"NA":6184},{"trials":6163,"activeCount":102},[],{"trials":6165,"activeCount":102},[6166],{"nctId":6167,"briefTitle":6168,"status":1860,"phases":6169,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":5637,"conditions":6172,"interventions":6176},"NCT04424225","Visual Surround Suppression and Perceptual Expectation Under Psilocybin",[90],"2023-09-01","2021-08-30",[6173,6174,6175],"Perception Disturbance","Visual Suppression","Psychedelic Experiences",[6160,6177],"Niacin",{"trials":6179,"activeCount":102},[],{"trials":6181,"activeCount":102},[],{"trials":6183,"activeCount":102},[],{"trials":6185,"activeCount":102},[],{"intervention":6177,"totalTrials":136,"cells":6187},{"EARLY_PHASE1":6188,"PHASE1":6190,"PHASE2":6196,"PHASE3":6198,"PHASE4":6200,"NA":6202},{"trials":6189,"activeCount":102},[],{"trials":6191,"activeCount":102},[6192],{"nctId":6167,"briefTitle":6168,"status":1860,"phases":6193,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":5637,"conditions":6194,"interventions":6195},[90],[6173,6174,6175],[6160,6177],{"trials":6197,"activeCount":102},[],{"trials":6199,"activeCount":102},[],{"trials":6201,"activeCount":102},[],{"trials":6203,"activeCount":102},[],{"intervention":6205,"totalTrials":136,"cells":6206},"Oral baclofen",{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6219,"PHASE3":6221,"PHASE4":6223,"NA":6225},{"trials":6208,"activeCount":102},[],{"trials":6210,"activeCount":102},[6211],{"nctId":6212,"briefTitle":6213,"status":112,"phases":6214,"primaryCompletion":2665,"completion":2665,"start":4739,"enrollment":3728,"conditions":6215,"interventions":6217},"NCT01749319","Oral and IV Baclofen in Adult Volunteers",[90],[6216],"Baclofen Withdrawal Syndrome",[6205,6218],"Intervenous baclofen",{"trials":6220,"activeCount":102},[],{"trials":6222,"activeCount":102},[],{"trials":6224,"activeCount":102},[],{"trials":6226,"activeCount":102},[],{"intervention":6218,"totalTrials":136,"cells":6228},{"EARLY_PHASE1":6229,"PHASE1":6231,"PHASE2":6237,"PHASE3":6239,"PHASE4":6241,"NA":6243},{"trials":6230,"activeCount":102},[],{"trials":6232,"activeCount":102},[6233],{"nctId":6212,"briefTitle":6213,"status":112,"phases":6234,"primaryCompletion":2665,"completion":2665,"start":4739,"enrollment":3728,"conditions":6235,"interventions":6236},[90],[6216],[6205,6218],{"trials":6238,"activeCount":102},[],{"trials":6240,"activeCount":102},[],{"trials":6242,"activeCount":102},[],{"trials":6244,"activeCount":102},[],{"intervention":6246,"totalTrials":136,"cells":6247},"NK cells and IL-2",{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6260,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":102},[6252],{"nctId":6253,"briefTitle":6254,"status":112,"phases":6255,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":1131,"conditions":6258,"interventions":6259},"NCT03346499","Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2",[90],"2018-11-13","2017-03-09",[1759],[6246],{"trials":6261,"activeCount":102},[],{"trials":6263,"activeCount":102},[],{"trials":6265,"activeCount":102},[],{"trials":6267,"activeCount":102},[],{"intervention":3718,"totalTrials":136,"cells":6269},{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6278,"PHASE3":6280,"PHASE4":6282,"NA":6284},{"trials":6271,"activeCount":102},[],{"trials":6273,"activeCount":102},[6274],{"nctId":3709,"briefTitle":3710,"status":112,"phases":6275,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":3714,"conditions":6276,"interventions":6277},[90],[3716],[3702,3718,3719,3720],{"trials":6279,"activeCount":102},[],{"trials":6281,"activeCount":102},[],{"trials":6283,"activeCount":102},[],{"trials":6285,"activeCount":102},[],{"intervention":3719,"totalTrials":136,"cells":6287},{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6296,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6289,"activeCount":102},[],{"trials":6291,"activeCount":102},[6292],{"nctId":3709,"briefTitle":3710,"status":112,"phases":6293,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":3714,"conditions":6294,"interventions":6295},[90],[3716],[3702,3718,3719,3720],{"trials":6297,"activeCount":102},[],{"trials":6299,"activeCount":102},[],{"trials":6301,"activeCount":102},[],{"trials":6303,"activeCount":102},[],{"intervention":3720,"totalTrials":136,"cells":6305},{"EARLY_PHASE1":6306,"PHASE1":6308,"PHASE2":6314,"PHASE3":6316,"PHASE4":6318,"NA":6320},{"trials":6307,"activeCount":102},[],{"trials":6309,"activeCount":102},[6310],{"nctId":3709,"briefTitle":3710,"status":112,"phases":6311,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":3714,"conditions":6312,"interventions":6313},[90],[3716],[3702,3718,3719,3720],{"trials":6315,"activeCount":102},[],{"trials":6317,"activeCount":102},[],{"trials":6319,"activeCount":102},[],{"trials":6321,"activeCount":102},[],{"intervention":6323,"totalTrials":136,"cells":6324},"Intravenous baclofen",{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6337,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6326,"activeCount":102},[],{"trials":6328,"activeCount":102},[6329],{"nctId":6330,"briefTitle":6331,"status":112,"phases":6332,"primaryCompletion":3579,"completion":3579,"start":2665,"enrollment":6333,"conditions":6334,"interventions":6336},"NCT01931319","Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers",[90],39,[6335],"Safety and Pharmacokinetics of Intravenous Baclofen",[6323],{"trials":6338,"activeCount":102},[],{"trials":6340,"activeCount":102},[],{"trials":6342,"activeCount":102},[],{"trials":6344,"activeCount":102},[],{"intervention":6346,"totalTrials":136,"cells":6347},"fMRI",{"EARLY_PHASE1":6348,"PHASE1":6350,"PHASE2":6360,"PHASE3":6362,"PHASE4":6364,"NA":6366},{"trials":6349,"activeCount":102},[],{"trials":6351,"activeCount":102},[6352],{"nctId":6353,"briefTitle":6354,"status":112,"phases":6355,"primaryCompletion":6356,"completion":6356,"start":5121,"enrollment":3958,"conditions":6357,"interventions":6359},"NCT01111734","Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents",[90],"2015-05",[6358],"Deliberate Self Harm",[6346],{"trials":6361,"activeCount":102},[],{"trials":6363,"activeCount":102},[],{"trials":6365,"activeCount":102},[],{"trials":6367,"activeCount":102},[],{"intervention":6369,"totalTrials":136,"cells":6370},"Subcutaneous hydrocortisone",{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6394,"PHASE3":6396,"PHASE4":6398,"NA":6400},{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[6375],{"nctId":6376,"briefTitle":6377,"status":112,"phases":6378,"primaryCompletion":6379,"completion":6379,"start":6380,"enrollment":3714,"conditions":6381,"interventions":6393},"NCT03718234","Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia",[90],"2023-02-23","2019-01-01",[6382,6383,6384,6385,6386,6387,6388,6389,6390,6391,6392],"Congenital Adrenal Hyperplasia","Hyperplasia","Adrenal Hyperplasia","Congenital Disorders","Adrenocortical Hyperfunction","Disorders of Sex Development","Urogenital Abnormalities","Genetic Diseases, Inborn","Steroid Metabolic Diseases, Inborn","Adrenal Gland Disease","Hydrocortisone",[6369],{"trials":6395,"activeCount":102},[],{"trials":6397,"activeCount":102},[],{"trials":6399,"activeCount":102},[],{"trials":6401,"activeCount":102},[],{"intervention":6403,"totalTrials":136,"cells":6404},"Nicotrol",{"EARLY_PHASE1":6405,"PHASE1":6407,"PHASE2":6416,"PHASE3":6418,"PHASE4":6420,"NA":6422},{"trials":6406,"activeCount":102},[],{"trials":6408,"activeCount":102},[6409],{"nctId":6410,"briefTitle":6411,"status":112,"phases":6412,"primaryCompletion":3989,"completion":3989,"start":6413,"enrollment":136,"conditions":6414,"interventions":6415},"NCT00061074","Tobacco Cessation in Postmenopausal Women (Part II) - 2",[90],"1993-03",[31],[6403],{"trials":6417,"activeCount":102},[],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"trials":6423,"activeCount":102},[],{"intervention":6425,"totalTrials":136,"cells":6426},"Capsule fecal microbiota material",{"EARLY_PHASE1":6427,"PHASE1":6429,"PHASE2":6441,"PHASE3":6443,"PHASE4":6445,"NA":6447},{"trials":6428,"activeCount":102},[],{"trials":6430,"activeCount":102},[6431],{"nctId":6432,"briefTitle":6433,"status":112,"phases":6434,"primaryCompletion":6435,"completion":6436,"start":6437,"enrollment":3664,"conditions":6438,"interventions":6439},"NCT05248191","FMT for Postop Crohn's Disease",[90],"2023-12-25","2024-05-16","2022-04-20",[1103],[6425,6440],"Colonoscopic fecal microbiota material",{"trials":6442,"activeCount":102},[],{"trials":6444,"activeCount":102},[],{"trials":6446,"activeCount":102},[],{"trials":6448,"activeCount":102},[],{"intervention":6440,"totalTrials":136,"cells":6450},{"EARLY_PHASE1":6451,"PHASE1":6453,"PHASE2":6459,"PHASE3":6461,"PHASE4":6463,"NA":6465},{"trials":6452,"activeCount":102},[],{"trials":6454,"activeCount":102},[6455],{"nctId":6432,"briefTitle":6433,"status":112,"phases":6456,"primaryCompletion":6435,"completion":6436,"start":6437,"enrollment":3664,"conditions":6457,"interventions":6458},[90],[1103],[6425,6440],{"trials":6460,"activeCount":102},[],{"trials":6462,"activeCount":102},[],{"trials":6464,"activeCount":102},[],{"trials":6466,"activeCount":102},[],{"intervention":3544,"totalTrials":136,"cells":6468},{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6477,"PHASE3":6479,"PHASE4":6481,"NA":6483},{"trials":6470,"activeCount":102},[],{"trials":6472,"activeCount":102},[6473],{"nctId":3538,"briefTitle":3539,"status":112,"phases":6474,"primaryCompletion":1792,"completion":1792,"start":2283,"enrollment":117,"conditions":6475,"interventions":6476},[90],[3542],[3544,3531],{"trials":6478,"activeCount":102},[],{"trials":6480,"activeCount":102},[],{"trials":6482,"activeCount":102},[],{"trials":6484,"activeCount":102},[],{"intervention":6486,"totalTrials":136,"cells":6487},"Haploidentical Natural Killer (NK) Cells",{"EARLY_PHASE1":6488,"PHASE1":6490,"PHASE2":6501,"PHASE3":6503,"PHASE4":6505,"NA":6507},{"trials":6489,"activeCount":102},[],{"trials":6491,"activeCount":102},[6492],{"nctId":6493,"briefTitle":6494,"status":112,"phases":6495,"primaryCompletion":6496,"completion":6496,"start":6497,"enrollment":1929,"conditions":6498,"interventions":6500},"NCT03899480","Adoptive Transfer of Haploidentical NK Cells and N-803",[90],"2021-04-01","2019-05-01",[496,1760,6499],"Immune Deficiency",[6486],{"trials":6502,"activeCount":102},[],{"trials":6504,"activeCount":102},[],{"trials":6506,"activeCount":102},[],{"trials":6508,"activeCount":102},[],{"intervention":3992,"totalTrials":136,"cells":6510},{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6519,"PHASE3":6521,"PHASE4":6523,"NA":6525},{"trials":6512,"activeCount":102},[],{"trials":6514,"activeCount":102},[6515],{"nctId":3986,"briefTitle":3987,"status":2730,"phases":6516,"start":3989,"enrollment":1366,"conditions":6517,"interventions":6518},[90],[3677],[3681,3992],{"trials":6520,"activeCount":102},[],{"trials":6522,"activeCount":102},[],{"trials":6524,"activeCount":102},[],{"trials":6526,"activeCount":102},[],{"intervention":6528,"totalTrials":136,"cells":6529},"ursodeoxycholic acid",{"EARLY_PHASE1":6530,"PHASE1":6532,"PHASE2":6543,"PHASE3":6545,"PHASE4":6547,"NA":6549},{"trials":6531,"activeCount":102},[],{"trials":6533,"activeCount":102},[6534],{"nctId":6535,"briefTitle":6536,"status":112,"phases":6537,"primaryCompletion":6538,"completion":6538,"start":6539,"enrollment":4017,"conditions":6540,"interventions":6542},"NCT02967250","Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment",[90],"2022-02-28","2020-04-01",[6541],"Parkinson Disease",[6528],{"trials":6544,"activeCount":102},[],{"trials":6546,"activeCount":102},[],{"trials":6548,"activeCount":102},[],{"trials":6550,"activeCount":102},[],{"intervention":6552,"totalTrials":136,"cells":6553},"N-803",{"EARLY_PHASE1":6554,"PHASE1":6556,"PHASE2":6565,"PHASE3":6567,"PHASE4":6569,"NA":6571},{"trials":6555,"activeCount":102},[],{"trials":6557,"activeCount":102},[6558],{"nctId":6559,"briefTitle":6560,"status":112,"phases":6561,"primaryCompletion":6562,"completion":2778,"start":6496,"enrollment":5637,"conditions":6563,"interventions":6564},"NCT04808908","Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease",[90],"2022-07-18",[496,1760,1771],[6552],{"trials":6566,"activeCount":102},[],{"trials":6568,"activeCount":102},[],{"trials":6570,"activeCount":102},[],{"trials":6572,"activeCount":102},[],{"intervention":6574,"totalTrials":136,"cells":6575},"Aspirin",{"EARLY_PHASE1":6576,"PHASE1":6578,"PHASE2":6587,"PHASE3":6589,"PHASE4":6591,"NA":6593},{"trials":6577,"activeCount":102},[],{"trials":6579,"activeCount":102},[6580],{"nctId":6581,"briefTitle":6582,"status":112,"phases":6583,"primaryCompletion":1793,"completion":6584,"start":509,"enrollment":1547,"conditions":6585,"interventions":6586},"NCT02761486","Effect of Aspirin on Gut Microbiome",[90],"2018-08-29",[19],[6574],{"trials":6588,"activeCount":102},[],{"trials":6590,"activeCount":102},[],{"trials":6592,"activeCount":102},[],{"trials":6594,"activeCount":102},[],{"intervention":6596,"totalTrials":136,"cells":6597},"Dose 1",{"EARLY_PHASE1":6598,"PHASE1":6600,"PHASE2":6611,"PHASE3":6613,"PHASE4":6615,"NA":6617},{"trials":6599,"activeCount":102},[],{"trials":6601,"activeCount":102},[6602],{"nctId":6603,"briefTitle":6604,"status":112,"phases":6605,"primaryCompletion":6606,"completion":6606,"start":2650,"enrollment":5637,"conditions":6607,"interventions":6609},"NCT02676674","Vitamin D Levels Following Topical Application of Vitamin D Ointment",[90],"2017-06-15",[6608],"Vitamin D Deficiency",[6596,6610],"Dose 2",{"trials":6612,"activeCount":102},[],{"trials":6614,"activeCount":102},[],{"trials":6616,"activeCount":102},[],{"trials":6618,"activeCount":102},[],{"intervention":6610,"totalTrials":136,"cells":6620},{"EARLY_PHASE1":6621,"PHASE1":6623,"PHASE2":6629,"PHASE3":6631,"PHASE4":6633,"NA":6635},{"trials":6622,"activeCount":102},[],{"trials":6624,"activeCount":102},[6625],{"nctId":6603,"briefTitle":6604,"status":112,"phases":6626,"primaryCompletion":6606,"completion":6606,"start":2650,"enrollment":5637,"conditions":6627,"interventions":6628},[90],[6608],[6596,6610],{"trials":6630,"activeCount":102},[],{"trials":6632,"activeCount":102},[],{"trials":6634,"activeCount":102},[],{"trials":6636,"activeCount":102},[],{"intervention":6638,"totalTrials":136,"cells":6639},"nicardipine",{"EARLY_PHASE1":6640,"PHASE1":6642,"PHASE2":6652,"PHASE3":6654,"PHASE4":6656,"NA":6658},{"trials":6641,"activeCount":102},[],{"trials":6643,"activeCount":102},[6644],{"nctId":6645,"briefTitle":6646,"status":112,"phases":6647,"primaryCompletion":6648,"completion":6649,"start":5123,"enrollment":12,"conditions":6650,"interventions":6651},"NCT00415610","Antihypertensive Treatment in Acute Cerebral Hemorrhage",[90],"2007-09","2008-03",[3302,33,25],[6638],{"trials":6653,"activeCount":102},[],{"trials":6655,"activeCount":102},[],{"trials":6657,"activeCount":102},[],{"trials":6659,"activeCount":102},[],{"intervention":6661,"totalTrials":136,"cells":6662},"injection of botulinum toxin type A.",{"EARLY_PHASE1":6663,"PHASE1":6665,"PHASE2":6674,"PHASE3":6676,"PHASE4":6678,"NA":6680},{"trials":6664,"activeCount":102},[],{"trials":6666,"activeCount":102},[6667],{"nctId":6668,"briefTitle":6669,"status":112,"phases":6670,"primaryCompletion":1876,"completion":3860,"start":845,"enrollment":117,"conditions":6671,"interventions":6673},"NCT00816517","Use of Botulinum Toxin to Treat Psoriasis",[90],[6672],"Psoriasis Vulgaris",[6661],{"trials":6675,"activeCount":102},[],{"trials":6677,"activeCount":102},[],{"trials":6679,"activeCount":102},[],{"trials":6681,"activeCount":102},[],{"intervention":6683,"totalTrials":136,"cells":6684},"intravenous topiramate",{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6696,"PHASE3":6698,"PHASE4":6700,"NA":6702},{"trials":6686,"activeCount":102},[],{"trials":6688,"activeCount":102},[6689],{"nctId":6690,"briefTitle":6691,"status":112,"phases":6692,"primaryCompletion":2284,"completion":2284,"start":2076,"enrollment":37,"conditions":6693,"interventions":6695},"NCT00753493","Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients",[90],[5934,6694],"Migraines",[6683],{"trials":6697,"activeCount":102},[],{"trials":6699,"activeCount":102},[],{"trials":6701,"activeCount":102},[],{"trials":6703,"activeCount":102},[],{"intervention":6705,"totalTrials":136,"cells":6706},"Fecal microbiota",{"EARLY_PHASE1":6707,"PHASE1":6709,"PHASE2":6720,"PHASE3":6722,"PHASE4":6724,"NA":6726},{"trials":6708,"activeCount":102},[],{"trials":6710,"activeCount":102},[6711],{"nctId":6712,"briefTitle":6713,"status":112,"phases":6714,"primaryCompletion":6715,"completion":6716,"start":2445,"enrollment":1647,"conditions":6717,"interventions":6719},"NCT03948919","Fecal Transplant for Ulcerative Colitis",[90],"2023-11-03","2024-01-04",[6718],"Ulcerative Colitis",[6705],{"trials":6721,"activeCount":102},[],{"trials":6723,"activeCount":102},[],{"trials":6725,"activeCount":102},[],{"trials":6727,"activeCount":102},[],{"intervention":6729,"totalTrials":136,"cells":6730},"lisdexamfetamine",{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6741,"PHASE3":6743,"PHASE4":6745,"NA":6747},{"trials":6732,"activeCount":102},[],{"trials":6734,"activeCount":102},[6735],{"nctId":6736,"briefTitle":6737,"status":1860,"phases":6738,"primaryCompletion":4739,"completion":4739,"start":2547,"enrollment":2215,"conditions":6739,"interventions":6740},"NCT01490216","Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence",[90],[5911],[6729],{"trials":6742,"activeCount":102},[],{"trials":6744,"activeCount":102},[],{"trials":6746,"activeCount":102},[],{"trials":6748,"activeCount":102},[],{"intervention":6750,"totalTrials":136,"cells":6751},"Aminoguanidine",{"EARLY_PHASE1":6752,"PHASE1":6754,"PHASE2":6763,"PHASE3":6765,"PHASE4":6767,"NA":6769},{"trials":6753,"activeCount":102},[],{"trials":6755,"activeCount":102},[6756],{"nctId":6757,"briefTitle":6758,"status":112,"phases":6759,"primaryCompletion":3780,"completion":3780,"start":1632,"enrollment":3862,"conditions":6760,"interventions":6762},"NCT02099981","Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients",[90],[6761],"Diabetic Retinopathy",[6750],{"trials":6764,"activeCount":102},[],{"trials":6766,"activeCount":102},[],{"trials":6768,"activeCount":102},[],{"trials":6770,"activeCount":102},[],{"intervention":6772,"totalTrials":136,"cells":6773},"Deuterated phenanthrene",{"EARLY_PHASE1":6774,"PHASE1":6776,"PHASE2":6785,"PHASE3":6787,"PHASE4":6789,"NA":6791},{"trials":6775,"activeCount":102},[],{"trials":6777,"activeCount":102},[6778],{"nctId":6779,"briefTitle":6780,"status":112,"phases":6781,"primaryCompletion":4112,"completion":4112,"start":6648,"enrollment":23,"conditions":6782,"interventions":6784},"NCT01092650","Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine",[90],[6783],"Tobacco Toxicant Exposure",[6772],{"trials":6786,"activeCount":102},[],{"trials":6788,"activeCount":102},[],{"trials":6790,"activeCount":102},[],{"trials":6792,"activeCount":102},[],{"intervention":6794,"totalTrials":136,"cells":6795},"Inhaled Sodium Pyruvate",{"EARLY_PHASE1":6796,"PHASE1":6798,"PHASE2":6807,"PHASE3":6809,"PHASE4":6811,"NA":6813},{"trials":6797,"activeCount":102},[],{"trials":6799,"activeCount":102},[6800],{"nctId":6801,"briefTitle":6802,"status":1860,"phases":6803,"start":6804,"enrollment":2590,"conditions":6805,"interventions":6806},"NCT00332215","A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.",[90],"2006-02",[119],[6794],{"trials":6808,"activeCount":102},[],{"trials":6810,"activeCount":102},[],{"trials":6812,"activeCount":102},[],{"trials":6814,"activeCount":102},[],{"intervention":6816,"totalTrials":136,"cells":6817},"Diazepam",{"EARLY_PHASE1":6818,"PHASE1":6820,"PHASE2":6828,"PHASE3":6830,"PHASE4":6832,"NA":6834},{"trials":6819,"activeCount":102},[],{"trials":6821,"activeCount":102},[6822],{"nctId":6823,"briefTitle":6824,"status":112,"phases":6825,"primaryCompletion":2546,"completion":2546,"start":844,"enrollment":420,"conditions":6826,"interventions":6827},"NCT01364558","A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers",[90],[5934],[6816,6816],{"trials":6829,"activeCount":102},[],{"trials":6831,"activeCount":102},[],{"trials":6833,"activeCount":102},[],{"trials":6835,"activeCount":102},[],{"intervention":6837,"totalTrials":136,"cells":6838},"Deuterated NNN",{"EARLY_PHASE1":6839,"PHASE1":6841,"PHASE2":6851,"PHASE3":6853,"PHASE4":6855,"NA":6857},{"trials":6840,"activeCount":102},[],{"trials":6842,"activeCount":102},[6843],{"nctId":6844,"briefTitle":6845,"status":1860,"phases":6846,"primaryCompletion":6847,"completion":6847,"start":6848,"enrollment":1478,"conditions":6849,"interventions":6850},"NCT02414477","Metabolism of Deuterated NNN in Smokeless Tobacco Users",[90],"2020-02-21","2018-04-15",[6783],[6837],{"trials":6852,"activeCount":102},[],{"trials":6854,"activeCount":102},[],{"trials":6856,"activeCount":102},[],{"trials":6858,"activeCount":102},[],{"intervention":6860,"totalTrials":136,"cells":6861},"Intestinal microbiota transplant",{"EARLY_PHASE1":6862,"PHASE1":6864,"PHASE2":6874,"PHASE3":6876,"PHASE4":6878,"NA":6880},{"trials":6863,"activeCount":102},[],{"trials":6865,"activeCount":102},[6866],{"nctId":6867,"briefTitle":6868,"status":112,"phases":6869,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":3714,"conditions":6872,"interventions":6873},"NCT04884971","Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study",[90],"2023-12-31","2021-11-03",[1233],[6860],{"trials":6875,"activeCount":102},[],{"trials":6877,"activeCount":102},[],{"trials":6879,"activeCount":102},[],{"trials":6881,"activeCount":102},[],{"intervention":6883,"totalTrials":136,"cells":6884},"ALT-803",{"EARLY_PHASE1":6885,"PHASE1":6887,"PHASE2":6897,"PHASE3":6899,"PHASE4":6901,"NA":6903},{"trials":6886,"activeCount":102},[],{"trials":6888,"activeCount":102},[6889],{"nctId":6890,"briefTitle":6891,"status":112,"phases":6892,"primaryCompletion":6893,"completion":6893,"start":1876,"enrollment":5637,"conditions":6894,"interventions":6896},"NCT02191098","Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People",[90],"2019-09-09",[1759,6895],"Stable ART",[6883],{"trials":6898,"activeCount":102},[],{"trials":6900,"activeCount":102},[],{"trials":6902,"activeCount":102},[],{"trials":6904,"activeCount":102},[],{"intervention":6906,"totalTrials":136,"cells":6907},"PhiP",{"EARLY_PHASE1":6908,"PHASE1":6910,"PHASE2":6920,"PHASE3":6922,"PHASE4":6924,"NA":6926},{"trials":6909,"activeCount":102},[],{"trials":6911,"activeCount":102},[6912],{"nctId":6913,"briefTitle":6914,"status":841,"phases":6915,"primaryCompletion":6916,"completion":6916,"start":6916,"enrollment":102,"conditions":6917,"interventions":6919},"NCT01092689","The Role of Meat-borne Carcinogens in Pancreatic Cancer",[90],"2012-01",[6918],"Pancreas Cancer",[6906],{"trials":6921,"activeCount":102},[],{"trials":6923,"activeCount":102},[],{"trials":6925,"activeCount":102},[],{"trials":6927,"activeCount":102},[],{"intervention":6929,"totalTrials":136,"cells":6930},"Topical gabapentin",{"EARLY_PHASE1":6931,"PHASE1":6946,"PHASE2":6948,"PHASE3":6950,"PHASE4":6952,"NA":6954},{"trials":6932,"activeCount":102},[6933],{"nctId":6934,"briefTitle":6935,"status":112,"phases":6936,"primaryCompletion":6937,"completion":6937,"start":6938,"enrollment":4017,"conditions":6939,"interventions":6945},"NCT03346668","Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia",[89],"2021-10-11","2016-01-28",[6940,6941,6942,6943,6944],"Scarring Alopecia","Frontal Fibrosing Alopecia","Lichen Planopilaris","Central Centrifugal Cicatricial Alopecia","Central Centrifugal Scarring Alopecia",[6929],{"trials":6947,"activeCount":102},[],{"trials":6949,"activeCount":102},[],{"trials":6951,"activeCount":102},[],{"trials":6953,"activeCount":102},[],{"trials":6955,"activeCount":102},[],{"intervention":6957,"totalTrials":136,"cells":6958},"Insulin",{"EARLY_PHASE1":6959,"PHASE1":6971,"PHASE2":6973,"PHASE3":6975,"PHASE4":6977,"NA":6979},{"trials":6960,"activeCount":102},[6961],{"nctId":6962,"briefTitle":6963,"status":112,"phases":6964,"primaryCompletion":3957,"completion":6965,"start":6966,"enrollment":2652,"conditions":6967,"interventions":6968},"NCT02866435","Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes",[89],"2019-12-30","2016-11",[3667],[6957,6969,6970],"Glucose","Potassium phosphate",{"trials":6972,"activeCount":102},[],{"trials":6974,"activeCount":102},[],{"trials":6976,"activeCount":102},[],{"trials":6978,"activeCount":102},[],{"trials":6980,"activeCount":102},[],{"intervention":6969,"totalTrials":136,"cells":6982},{"EARLY_PHASE1":6983,"PHASE1":6989,"PHASE2":6991,"PHASE3":6993,"PHASE4":6995,"NA":6997},{"trials":6984,"activeCount":102},[6985],{"nctId":6962,"briefTitle":6963,"status":112,"phases":6986,"primaryCompletion":3957,"completion":6965,"start":6966,"enrollment":2652,"conditions":6987,"interventions":6988},[89],[3667],[6957,6969,6970],{"trials":6990,"activeCount":102},[],{"trials":6992,"activeCount":102},[],{"trials":6994,"activeCount":102},[],{"trials":6996,"activeCount":102},[],{"trials":6998,"activeCount":102},[],{"intervention":6970,"totalTrials":136,"cells":7000},{"EARLY_PHASE1":7001,"PHASE1":7007,"PHASE2":7009,"PHASE3":7011,"PHASE4":7013,"NA":7015},{"trials":7002,"activeCount":102},[7003],{"nctId":6962,"briefTitle":6963,"status":112,"phases":7004,"primaryCompletion":3957,"completion":6965,"start":6966,"enrollment":2652,"conditions":7005,"interventions":7006},[89],[3667],[6957,6969,6970],{"trials":7008,"activeCount":102},[],{"trials":7010,"activeCount":102},[],{"trials":7012,"activeCount":102},[],{"trials":7014,"activeCount":102},[],{"trials":7016,"activeCount":102},[],{"intervention":7018,"totalTrials":136,"cells":7019},"Rituximab",{"EARLY_PHASE1":7020,"PHASE1":7030,"PHASE2":7032,"PHASE3":7034,"PHASE4":7036,"NA":7038},{"trials":7021,"activeCount":102},[7022],{"nctId":7023,"briefTitle":7024,"status":112,"phases":7025,"primaryCompletion":7026,"completion":7026,"start":4028,"enrollment":34,"conditions":7027,"interventions":7029},"NCT03763643","PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant",[89],"2025-02-07",[7028],"Focal Segmental Glomerulosclerosis",[7018],{"trials":7031,"activeCount":102},[],{"trials":7033,"activeCount":102},[],{"trials":7035,"activeCount":102},[],{"trials":7037,"activeCount":102},[],{"trials":7039,"activeCount":102},[],{"intervention":7041,"totalTrials":136,"cells":7042},"SGLT2 inhibitor",{"EARLY_PHASE1":7043,"PHASE1":7053,"PHASE2":7055,"PHASE3":7057,"PHASE4":7059,"NA":7061},{"trials":7044,"activeCount":102},[7045],{"nctId":7046,"briefTitle":7047,"status":1860,"phases":7048,"primaryCompletion":7049,"completion":7049,"start":2869,"enrollment":136,"conditions":7050,"interventions":7052},"NCT06124924","SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot",[89],"2024-08-16",[7051],"Acute Kidney Injury",[7041],{"trials":7054,"activeCount":102},[],{"trials":7056,"activeCount":102},[],{"trials":7058,"activeCount":102},[],{"trials":7060,"activeCount":102},[],{"trials":7062,"activeCount":102},[],{"intervention":7064,"totalTrials":136,"cells":7065},"CBD-dominant",{"EARLY_PHASE1":7066,"PHASE1":7078,"PHASE2":7080,"PHASE3":7082,"PHASE4":7084,"NA":7086},{"trials":7067,"activeCount":102},[7068],{"nctId":7069,"briefTitle":7070,"status":112,"phases":7071,"primaryCompletion":7072,"completion":7072,"start":7073,"enrollment":420,"conditions":7074,"interventions":7076},"NCT05935891","A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)",[89],"2024-04-29","2023-02-09",[7075],"Musculoskeletal Syndrome",[7064,7077],"THC dominant",{"trials":7079,"activeCount":102},[],{"trials":7081,"activeCount":102},[],{"trials":7083,"activeCount":102},[],{"trials":7085,"activeCount":102},[],{"trials":7087,"activeCount":102},[],{"intervention":7077,"totalTrials":136,"cells":7089},{"EARLY_PHASE1":7090,"PHASE1":7096,"PHASE2":7098,"PHASE3":7100,"PHASE4":7102,"NA":7104},{"trials":7091,"activeCount":102},[7092],{"nctId":7069,"briefTitle":7070,"status":112,"phases":7093,"primaryCompletion":7072,"completion":7072,"start":7073,"enrollment":420,"conditions":7094,"interventions":7095},[89],[7075],[7064,7077],{"trials":7097,"activeCount":102},[],{"trials":7099,"activeCount":102},[],{"trials":7101,"activeCount":102},[],{"trials":7103,"activeCount":102},[],{"trials":7105,"activeCount":102},[],{"intervention":7107,"totalTrials":4017,"cells":7108},"Progesterone",{"EARLY_PHASE1":7109,"PHASE1":7111,"PHASE2":7113,"PHASE3":7115,"PHASE4":7117,"NA":7119},{"trials":7110,"activeCount":102},[],{"trials":7112,"activeCount":102},[],{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":102},[],{"trials":7118,"activeCount":102},[],{"trials":7120,"activeCount":102},[7121,7127,7139,7148,7155],{"nctId":7122,"briefTitle":7123,"status":841,"phases":7124,"primaryCompletion":2651,"completion":2651,"start":2651,"enrollment":102,"conditions":7125,"interventions":7126},"NCT01741376","Progesterone and Atomoxetine for Cocaine Cessation",[94],[5911,2742],[7107],{"nctId":7128,"briefTitle":7129,"status":112,"phases":7130,"primaryCompletion":7131,"completion":7132,"start":7133,"enrollment":7134,"conditions":7135,"interventions":7138},"NCT00218257","Progesterone for the Treatment of Cocaine Dependence - 1",[94],"2008-04","2008-06-30","2002-07",96,[7136,7137],"Cocaine Abuse","Cocaine-Related Disorders",[7107],{"nctId":7140,"briefTitle":7141,"status":112,"phases":7142,"primaryCompletion":7143,"completion":7143,"start":2649,"enrollment":7144,"conditions":7145,"interventions":7147},"NCT02579421","Hormones and Reduction in Co-users of Marijuana and Nicotine",[94],"2017-07-27",58,[7146],"Marijuana Dependence",[7107],{"nctId":7149,"briefTitle":7150,"status":112,"phases":7151,"primaryCompletion":1876,"completion":534,"start":3579,"enrollment":535,"conditions":7152,"interventions":7154},"NCT01798394","Progesterone & Postpartum Relapse to Smoking",[94],[7153,31],"Tobacco Use Cessation",[7107],{"nctId":7156,"briefTitle":7157,"status":112,"phases":7158,"primaryCompletion":7143,"completion":7143,"start":5151,"enrollment":7159,"conditions":7160,"interventions":7162},"NCT01744574","Sex Differences, Hormones & Smoking Cessation",[94],216,[7161],"Tobacco Cessation",[7107],{"intervention":7164,"totalTrials":1131,"cells":7165},"N-acetylcysteine",{"EARLY_PHASE1":7166,"PHASE1":7168,"PHASE2":7178,"PHASE3":7196,"PHASE4":7198,"NA":7200},{"trials":7167,"activeCount":102},[],{"trials":7169,"activeCount":102},[7170],{"nctId":7171,"briefTitle":7172,"status":112,"phases":7173,"primaryCompletion":5151,"completion":5151,"start":2547,"enrollment":1929,"conditions":7174,"interventions":7177},"NCT01427517","Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease",[90],[7175,7176],"Parkinson's Disease","Gaucher's Disease",[7164],{"trials":7179,"activeCount":102},[7180,7187],{"nctId":7181,"briefTitle":7182,"status":112,"phases":7183,"primaryCompletion":7184,"completion":7184,"start":543,"enrollment":117,"conditions":7185,"interventions":7186},"NCT02212678","Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease",[91],"2015-09",[6541],[7164],{"nctId":7188,"briefTitle":7189,"status":112,"phases":7190,"primaryCompletion":7191,"completion":7191,"start":7184,"enrollment":7192,"conditions":7193,"interventions":7195},"NCT02583672","Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)",[91],"2025-12-31",33,[7194],"Gaucher Disease Type 1",[7164],{"trials":7197,"activeCount":102},[],{"trials":7199,"activeCount":102},[],{"trials":7201,"activeCount":102},[7202],{"nctId":7203,"briefTitle":7204,"status":1860,"phases":7205,"primaryCompletion":3860,"completion":3860,"start":4739,"enrollment":7206,"conditions":7207,"interventions":7210},"NCT01739790","N-Acetylcysteine for Patients With COPD and Chronic Bronchitis",[94],51,[7208,7209],"COPD","Chronic Bronchitis",[7211],"N-Acetylcysteine",{"intervention":3692,"totalTrials":1131,"cells":7213},{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7235,"PHASE4":7237,"NA":7239},{"trials":7215,"activeCount":102},[],{"trials":7217,"activeCount":102},[],{"trials":7219,"activeCount":102},[7220,7224,7231],{"nctId":4302,"briefTitle":4303,"status":112,"phases":7221,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":1366,"conditions":7222,"interventions":7223},[90,91],[3583,3667],[3692,4293],{"nctId":7225,"briefTitle":7226,"status":112,"phases":7227,"primaryCompletion":4329,"completion":3590,"start":7228,"enrollment":4017,"conditions":7229,"interventions":7230},"NCT00265473","MGA031, Sirolimus and Tacrolimus in Islet Transplantation",[90,91],"2005-11",[3666,3667],[3692],{"nctId":3685,"briefTitle":3686,"status":112,"phases":7232,"primaryCompletion":3688,"completion":3688,"start":3689,"enrollment":1366,"conditions":7233,"interventions":7234},[90,91],[3666,3667],[3692,3693,3651,3694],{"trials":7236,"activeCount":102},[],{"trials":7238,"activeCount":102},[],{"trials":7240,"activeCount":102},[7241],{"nctId":7242,"briefTitle":7243,"status":7244,"phases":7245,"conditions":7246,"interventions":7249},"NCT01606475","Islet Transplant for Type 1 or Surgical Diabetes","NO_LONGER_AVAILABLE",[],[3666,3667,7247,7248],"Labile Diabetes","End-stage Renal Disease",[7250],"Allogeneic islets of Langerhans",{"intervention":2340,"totalTrials":521,"cells":7252},{"EARLY_PHASE1":7253,"PHASE1":7255,"PHASE2":7257,"PHASE3":7263,"PHASE4":7265,"NA":7271},{"trials":7254,"activeCount":102},[],{"trials":7256,"activeCount":102},[],{"trials":7258,"activeCount":102},[7259],{"nctId":3660,"briefTitle":3661,"status":1860,"phases":7260,"primaryCompletion":843,"completion":3663,"start":2360,"enrollment":3664,"conditions":7261,"interventions":7262},[90,91],[3666,3667],[3669,3670,2340,3651],{"trials":7264,"activeCount":102},[],{"trials":7266,"activeCount":102},[7267],{"nctId":2332,"briefTitle":2333,"status":841,"phases":7268,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":102,"conditions":7269,"interventions":7270},[93],[2338],[2319,2340],{"trials":7272,"activeCount":102},[7273],{"nctId":7274,"briefTitle":7275,"status":841,"phases":7276,"primaryCompletion":2309,"completion":2309,"start":1147,"enrollment":102,"conditions":7277,"interventions":7279},"NCT01305395","Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients",[94],[7278],"Cardiac Allograft Vasculopathy",[2340,2340,2340,2340,2340],{"intervention":2745,"totalTrials":521,"cells":7281},{"EARLY_PHASE1":7282,"PHASE1":7284,"PHASE2":7286,"PHASE3":7292,"PHASE4":7298,"NA":7300},{"trials":7283,"activeCount":102},[],{"trials":7285,"activeCount":102},[],{"trials":7287,"activeCount":102},[7288],{"nctId":5748,"briefTitle":5749,"status":112,"phases":7289,"primaryCompletion":3663,"completion":3663,"start":5751,"enrollment":420,"conditions":7290,"interventions":7291},[91],[4125,331],[2745,5739],{"trials":7293,"activeCount":102},[7294],{"nctId":2736,"briefTitle":2737,"status":112,"phases":7295,"primaryCompletion":1755,"completion":1755,"start":2739,"enrollment":2740,"conditions":7296,"interventions":7297},[91,92],[2742,2743],[2717,2745],{"trials":7299,"activeCount":102},[],{"trials":7301,"activeCount":102},[7302],{"nctId":7303,"briefTitle":7304,"status":112,"phases":7305,"primaryCompletion":5751,"completion":5751,"start":7131,"enrollment":1696,"conditions":7306,"interventions":7307},"NCT00709696","Human Laboratory Study Of Varenicline in Smokers",[94],[2742],[2745],{"intervention":7309,"totalTrials":98,"cells":7310},"somatostatin",{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7315,"PHASE3":7324,"PHASE4":7326,"NA":7328},{"trials":7312,"activeCount":102},[],{"trials":7314,"activeCount":102},[],{"trials":7316,"activeCount":102},[7317],{"nctId":7318,"briefTitle":7319,"status":112,"phases":7320,"primaryCompletion":3780,"completion":3780,"start":7321,"enrollment":5637,"conditions":7322,"interventions":7323},"NCT00786825","Measurement of Glucose\u002FGlycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla",[91],"2004-12",[3583],[7309],{"trials":7325,"activeCount":102},[],{"trials":7327,"activeCount":102},[],{"trials":7329,"activeCount":102},[7330],{"nctId":7331,"briefTitle":7332,"status":112,"phases":7333,"primaryCompletion":4219,"completion":4219,"start":7334,"enrollment":7335,"conditions":7336,"interventions":7337},"NCT00793741","Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness",[],"2007-12",19,[3583,3584],[7309],{"intervention":7339,"totalTrials":98,"cells":7340},"olanzapine",{"EARLY_PHASE1":7341,"PHASE1":7343,"PHASE2":7345,"PHASE3":7347,"PHASE4":7349,"NA":7351},{"trials":7342,"activeCount":102},[],{"trials":7344,"activeCount":102},[],{"trials":7346,"activeCount":102},[],{"trials":7348,"activeCount":102},[],{"trials":7350,"activeCount":102},[],{"trials":7352,"activeCount":102},[7353,7360],{"nctId":7354,"briefTitle":7355,"status":112,"phases":7356,"primaryCompletion":7131,"completion":3080,"start":7357,"enrollment":7335,"conditions":7358,"interventions":7359},"NCT00275301","PET Imaging and Olanzapine Treatment in Borderline Personality Disorder",[94],"2005-12",[3016],[7339],{"nctId":7361,"briefTitle":7362,"status":112,"phases":7363,"completion":3688,"start":7364,"enrollment":23,"conditions":7365,"interventions":7368},"NCT00222495","A Comparative Study of New Medications for Psychosis in Adolescents",[94],"2002-08",[4126,4125,7366,7367],"Schizophreniform Disorders","Schizoaffective Disorders",[7369,7339,7370],"quetiapine","risperidone",{"intervention":4132,"totalTrials":98,"cells":7372},{"EARLY_PHASE1":7373,"PHASE1":7375,"PHASE2":7377,"PHASE3":7383,"PHASE4":7385,"NA":7387},{"trials":7374,"activeCount":102},[],{"trials":7376,"activeCount":102},[],{"trials":7378,"activeCount":102},[7379],{"nctId":4118,"briefTitle":4119,"status":112,"phases":7380,"primaryCompletion":4121,"completion":4121,"start":4122,"enrollment":4123,"conditions":7381,"interventions":7382},[91],[331,2312,4125,4126,3961,4127,4128,4129],[4131,4132],{"trials":7384,"activeCount":102},[],{"trials":7386,"activeCount":102},[],{"trials":7388,"activeCount":102},[7389],{"nctId":7390,"briefTitle":7391,"status":112,"phases":7392,"primaryCompletion":2665,"completion":2665,"start":4112,"enrollment":7393,"conditions":7394,"interventions":7395},"NCT01522963","Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms",[94],98,[31],[4132],{"intervention":7369,"totalTrials":98,"cells":7397},{"EARLY_PHASE1":7398,"PHASE1":7400,"PHASE2":7402,"PHASE3":7404,"PHASE4":7406,"NA":7416},{"trials":7399,"activeCount":102},[],{"trials":7401,"activeCount":102},[],{"trials":7403,"activeCount":102},[],{"trials":7405,"activeCount":102},[],{"trials":7407,"activeCount":102},[7408],{"nctId":7409,"briefTitle":7410,"status":112,"phases":7411,"primaryCompletion":6648,"completion":6648,"start":7412,"enrollment":37,"conditions":7413,"interventions":7415},"NCT00407199","The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment",[93],"2006-12",[7414],"Social Phobia",[7369],{"trials":7417,"activeCount":102},[7418],{"nctId":7361,"briefTitle":7362,"status":112,"phases":7419,"completion":3688,"start":7364,"enrollment":23,"conditions":7420,"interventions":7421},[94],[4126,4125,7366,7367],[7369,7339,7370],{"intervention":7423,"totalTrials":136,"cells":7424},"Methylphenidate",{"EARLY_PHASE1":7425,"PHASE1":7427,"PHASE2":7429,"PHASE3":7431,"PHASE4":7433,"NA":7435},{"trials":7426,"activeCount":102},[],{"trials":7428,"activeCount":102},[],{"trials":7430,"activeCount":102},[],{"trials":7432,"activeCount":102},[],{"trials":7434,"activeCount":102},[],{"trials":7436,"activeCount":102},[7437],{"nctId":7438,"briefTitle":7439,"status":1860,"phases":7440,"primaryCompletion":1147,"completion":1147,"start":4329,"enrollment":136,"conditions":7441,"interventions":7465},"NCT01100658","Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors",[94],[7442,7443,7444,7445,7446,7447,7448,7449,7450,7451,7452,7453,7454,7455,7456,7457,7458,7459,7460,7461,7462,7463,7464],"ALL, Childhood","Leukemia, Lymphoblastic","Leukemia, Lymphoblastic, Acute","Leukemia, Lymphoblastic, Acute, L1","Leukemia, Lymphoblastic, Acute, L2","Leukemia, Lymphoblastic, Acute, Philadelphia-Positive","Leukemia, Lymphocytic, Acute","Leukemia, Lymphocytic, Acute, L1","Leukemia, Lymphocytic, Acute, L2","Lymphoblastic Leukemia","Lymphoblastic Leukemia, Acute","Lymphoblastic Leukemia, Acute, Childhood","Lymphoblastic Leukemia, Acute, L1","Lymphoblastic Leukemia, Acute, L2","Lymphoblastic Lymphoma","Lymphocytic Leukemia, Acute","Lymphocytic Leukemia, L1","Lymphocytic Leukemia, L2","Brain Tumors","Cancer of the Brain","Cancer of Brain","Malignant Primary Brain Tumors","Brain Neoplasms, Malignant",[7423],{"intervention":7467,"totalTrials":136,"cells":7468},"Oral placebo",{"EARLY_PHASE1":7469,"PHASE1":7471,"PHASE2":7473,"PHASE3":7475,"PHASE4":7477,"NA":7479},{"trials":7470,"activeCount":102},[],{"trials":7472,"activeCount":102},[],{"trials":7474,"activeCount":102},[],{"trials":7476,"activeCount":102},[],{"trials":7478,"activeCount":102},[],{"trials":7480,"activeCount":102},[7481],{"nctId":7482,"briefTitle":7483,"status":841,"phases":7484,"primaryCompletion":7184,"completion":7184,"start":7485,"enrollment":102,"conditions":7486,"interventions":7488},"NCT01982799","Local Anesthesia and Analgesics in Endodontic Pain",[94],"2014-02",[7487],"Odontalgia",[7467,7489,7490,7491],"Oral ibuprofen","oral naproxen","oral acetaminophen\u002Fhydrocodone + ibuprofen",{"intervention":7489,"totalTrials":136,"cells":7493},{"EARLY_PHASE1":7494,"PHASE1":7496,"PHASE2":7498,"PHASE3":7500,"PHASE4":7502,"NA":7504},{"trials":7495,"activeCount":102},[],{"trials":7497,"activeCount":102},[],{"trials":7499,"activeCount":102},[],{"trials":7501,"activeCount":102},[],{"trials":7503,"activeCount":102},[],{"trials":7505,"activeCount":102},[7506],{"nctId":7482,"briefTitle":7483,"status":841,"phases":7507,"primaryCompletion":7184,"completion":7184,"start":7485,"enrollment":102,"conditions":7508,"interventions":7509},[94],[7487],[7467,7489,7490,7491],{"intervention":7490,"totalTrials":136,"cells":7511},{"EARLY_PHASE1":7512,"PHASE1":7514,"PHASE2":7516,"PHASE3":7518,"PHASE4":7520,"NA":7522},{"trials":7513,"activeCount":102},[],{"trials":7515,"activeCount":102},[],{"trials":7517,"activeCount":102},[],{"trials":7519,"activeCount":102},[],{"trials":7521,"activeCount":102},[],{"trials":7523,"activeCount":102},[7524],{"nctId":7482,"briefTitle":7483,"status":841,"phases":7525,"primaryCompletion":7184,"completion":7184,"start":7485,"enrollment":102,"conditions":7526,"interventions":7527},[94],[7487],[7467,7489,7490,7491],{"intervention":7491,"totalTrials":136,"cells":7529},{"EARLY_PHASE1":7530,"PHASE1":7532,"PHASE2":7534,"PHASE3":7536,"PHASE4":7538,"NA":7540},{"trials":7531,"activeCount":102},[],{"trials":7533,"activeCount":102},[],{"trials":7535,"activeCount":102},[],{"trials":7537,"activeCount":102},[],{"trials":7539,"activeCount":102},[],{"trials":7541,"activeCount":102},[7542],{"nctId":7482,"briefTitle":7483,"status":841,"phases":7543,"primaryCompletion":7184,"completion":7184,"start":7485,"enrollment":102,"conditions":7544,"interventions":7545},[94],[7487],[7467,7489,7490,7491],{"intervention":7547,"totalTrials":136,"cells":7548},"A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs",{"EARLY_PHASE1":7549,"PHASE1":7551,"PHASE2":7553,"PHASE3":7555,"PHASE4":7557,"NA":7559},{"trials":7550,"activeCount":102},[],{"trials":7552,"activeCount":102},[],{"trials":7554,"activeCount":102},[],{"trials":7556,"activeCount":102},[],{"trials":7558,"activeCount":102},[],{"trials":7560,"activeCount":102},[7561],{"nctId":7562,"briefTitle":7563,"status":112,"phases":7564,"primaryCompletion":2546,"completion":5122,"start":7565,"enrollment":7566,"conditions":7567,"interventions":7569},"NCT01600521","A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications",[94],"2004-11",1748,[7568],"Rheumatoid Arthritis",[7547],{"intervention":7571,"totalTrials":136,"cells":7572},"Seromycin",{"EARLY_PHASE1":7573,"PHASE1":7575,"PHASE2":7577,"PHASE3":7579,"PHASE4":7581,"NA":7583},{"trials":7574,"activeCount":102},[],{"trials":7576,"activeCount":102},[],{"trials":7578,"activeCount":102},[],{"trials":7580,"activeCount":102},[],{"trials":7582,"activeCount":102},[],{"trials":7584,"activeCount":102},[7585],{"nctId":7586,"briefTitle":7587,"status":112,"phases":7588,"primaryCompletion":7589,"completion":7589,"start":4739,"enrollment":7590,"conditions":7591,"interventions":7593},"NCT01733030","The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.",[],"2015-10-01",56,[7592],"Post Traumatic Stress Syndrome",[7571,7571],{"intervention":7595,"totalTrials":136,"cells":7596},"Medical Care",{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7598,"activeCount":102},[],{"trials":7600,"activeCount":102},[],{"trials":7602,"activeCount":102},[],{"trials":7604,"activeCount":102},[],{"trials":7606,"activeCount":102},[],{"trials":7608,"activeCount":102},[7609],{"nctId":7610,"briefTitle":7611,"status":112,"phases":7612,"primaryCompletion":7613,"completion":7613,"start":7614,"enrollment":17,"conditions":7615,"interventions":7621},"NCT05022121","Integrated Supported Biopsychosocial Self-Management for Back Related Leg Pain",[94],"2023-02-20","2022-01-26",[7616,7617,7618,7619,7620],"Low Back Pain","Sciatica","Back Related Leg Pain","Pain, Chronic","Intervertebral Disc Displacement",[7595],{"intervention":7623,"totalTrials":136,"cells":7624},"cf-DNA Collection",{"EARLY_PHASE1":7625,"PHASE1":7627,"PHASE2":7629,"PHASE3":7631,"PHASE4":7633,"NA":7635},{"trials":7626,"activeCount":102},[],{"trials":7628,"activeCount":102},[],{"trials":7630,"activeCount":102},[],{"trials":7632,"activeCount":102},[],{"trials":7634,"activeCount":102},[],{"trials":7636,"activeCount":102},[7637],{"nctId":7638,"briefTitle":7639,"status":112,"phases":7640,"primaryCompletion":7641,"completion":7641,"start":7642,"enrollment":892,"conditions":7643,"interventions":7647},"NCT04019353","Cf-DNA Assay During Treatment of Acute Rejection",[],"2023-09-05","2019-06-01",[4375,938,7644,7645,7646],"Kidney Transplant Rejection","Transplant; Complication, Rejection","Transplant Dysfunction",[7623],{"intervention":7649,"totalTrials":136,"cells":7650},"Surfactants, Pulmonary",{"EARLY_PHASE1":7651,"PHASE1":7653,"PHASE2":7655,"PHASE3":7657,"PHASE4":7659,"NA":7661},{"trials":7652,"activeCount":102},[],{"trials":7654,"activeCount":102},[],{"trials":7656,"activeCount":102},[],{"trials":7658,"activeCount":102},[],{"trials":7660,"activeCount":102},[],{"trials":7662,"activeCount":102},[7663],{"nctId":7664,"briefTitle":7665,"status":112,"phases":7666,"primaryCompletion":7667,"completion":7667,"start":844,"enrollment":438,"conditions":7668,"interventions":7670},"NCT01116921","Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates",[94],"2015-04",[7669],"Respiratory Distress Syndrome",[7649],{"intervention":7672,"totalTrials":136,"cells":7673},"0.2% ropivacaine",{"EARLY_PHASE1":7674,"PHASE1":7676,"PHASE2":7678,"PHASE3":7680,"PHASE4":7682,"NA":7684},{"trials":7675,"activeCount":102},[],{"trials":7677,"activeCount":102},[],{"trials":7679,"activeCount":102},[],{"trials":7681,"activeCount":102},[],{"trials":7683,"activeCount":102},[],{"trials":7685,"activeCount":102},[7686],{"nctId":7687,"briefTitle":7688,"status":112,"phases":7689,"primaryCompletion":4764,"completion":4764,"start":7690,"enrollment":7192,"conditions":7691,"interventions":7692},"NCT02380417","Paravertebral Catheter for Lung Transplant",[],"2013-10",[1619],[7672],{"intervention":7694,"totalTrials":136,"cells":7695},"20% lipid",{"EARLY_PHASE1":7696,"PHASE1":7698,"PHASE2":7700,"PHASE3":7702,"PHASE4":7704,"NA":7706},{"trials":7697,"activeCount":102},[],{"trials":7699,"activeCount":102},[],{"trials":7701,"activeCount":102},[],{"trials":7703,"activeCount":102},[],{"trials":7705,"activeCount":102},[],{"trials":7707,"activeCount":102},[7708],{"nctId":7709,"briefTitle":7710,"status":112,"phases":7711,"primaryCompletion":2665,"completion":2665,"start":845,"enrollment":7192,"conditions":7712,"interventions":7713},"NCT00786487","Training Effects on Skeletal Muscle Fatty Acid Metabolism",[94],[797],[7694,7714],"glycerol",{"intervention":7714,"totalTrials":136,"cells":7716},{"EARLY_PHASE1":7717,"PHASE1":7719,"PHASE2":7721,"PHASE3":7723,"PHASE4":7725,"NA":7727},{"trials":7718,"activeCount":102},[],{"trials":7720,"activeCount":102},[],{"trials":7722,"activeCount":102},[],{"trials":7724,"activeCount":102},[],{"trials":7726,"activeCount":102},[],{"trials":7728,"activeCount":102},[7729],{"nctId":7709,"briefTitle":7710,"status":112,"phases":7730,"primaryCompletion":2665,"completion":2665,"start":845,"enrollment":7192,"conditions":7731,"interventions":7732},[94],[797],[7694,7714],{"intervention":7734,"totalTrials":136,"cells":7735},"Bupivacaine liposome",{"EARLY_PHASE1":7736,"PHASE1":7738,"PHASE2":7740,"PHASE3":7742,"PHASE4":7744,"NA":7746},{"trials":7737,"activeCount":102},[],{"trials":7739,"activeCount":102},[],{"trials":7741,"activeCount":102},[],{"trials":7743,"activeCount":102},[],{"trials":7745,"activeCount":102},[],{"trials":7747,"activeCount":102},[7748],{"nctId":7749,"briefTitle":7750,"status":112,"phases":7751,"primaryCompletion":2052,"completion":2052,"start":7752,"enrollment":23,"conditions":7753,"interventions":7755},"NCT03526419","Exparel PK and Breast Milk Excretion",[],"2019-02-01",[7754],"Milk Expression, Breast",[7734],{"intervention":7757,"totalTrials":136,"cells":7758},"Antiretroviral Therapy",{"EARLY_PHASE1":7759,"PHASE1":7761,"PHASE2":7763,"PHASE3":7765,"PHASE4":7767,"NA":7769},{"trials":7760,"activeCount":102},[],{"trials":7762,"activeCount":102},[],{"trials":7764,"activeCount":102},[],{"trials":7766,"activeCount":102},[],{"trials":7768,"activeCount":102},[],{"trials":7770,"activeCount":102},[7771],{"nctId":7772,"briefTitle":7773,"status":112,"phases":7774,"primaryCompletion":3758,"completion":3758,"start":7775,"enrollment":7776,"conditions":7777,"interventions":7778},"NCT00577681","Understanding the Increased Risk of Cardiovascular Disease in People With HIV",[],"2002-01",5472,[1760],[7757],{"intervention":7780,"totalTrials":136,"cells":7781},"Alefacept",{"EARLY_PHASE1":7782,"PHASE1":7784,"PHASE2":7786,"PHASE3":7788,"PHASE4":7790,"NA":7792},{"trials":7783,"activeCount":102},[],{"trials":7785,"activeCount":102},[],{"trials":7787,"activeCount":102},[],{"trials":7789,"activeCount":102},[],{"trials":7791,"activeCount":102},[],{"trials":7793,"activeCount":102},[7794],{"nctId":7795,"briefTitle":7796,"status":112,"phases":7797,"primaryCompletion":7798,"completion":7798,"start":5123,"enrollment":4765,"conditions":7799,"interventions":7800},"NCT00167102","Alefacept in Patients With Severe Scalp Alopecia Areata",[94],"2008-02",[1031],[7780],{"intervention":7802,"totalTrials":136,"cells":7803},"Naltrexone and fMRI",{"EARLY_PHASE1":7804,"PHASE1":7806,"PHASE2":7808,"PHASE3":7810,"PHASE4":7812,"NA":7814},{"trials":7805,"activeCount":102},[],{"trials":7807,"activeCount":102},[],{"trials":7809,"activeCount":102},[],{"trials":7811,"activeCount":102},[],{"trials":7813,"activeCount":102},[],{"trials":7815,"activeCount":102},[7816],{"nctId":7817,"briefTitle":7818,"status":112,"phases":7819,"primaryCompletion":2283,"completion":2283,"start":7820,"enrollment":7821,"conditions":7822,"interventions":7823},"NCT01623440","Food Reward in Native American Women",[],"2009-11",69,[16],[7802],{"intervention":7825,"totalTrials":136,"cells":7826},"Sildenafil",{"EARLY_PHASE1":7827,"PHASE1":7829,"PHASE2":7831,"PHASE3":7833,"PHASE4":7835,"NA":7837},{"trials":7828,"activeCount":102},[],{"trials":7830,"activeCount":102},[],{"trials":7832,"activeCount":102},[],{"trials":7834,"activeCount":102},[],{"trials":7836,"activeCount":102},[],{"trials":7838,"activeCount":102},[7839],{"nctId":7840,"briefTitle":7841,"status":841,"phases":7842,"primaryCompletion":7843,"completion":7843,"start":3737,"enrollment":102,"conditions":7844,"interventions":7845},"NCT01812434","Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients",[94],"2015-03",[7278],[7825],{"intervention":7847,"totalTrials":136,"cells":7848},"Levomilnacipran",{"EARLY_PHASE1":7849,"PHASE1":7851,"PHASE2":7853,"PHASE3":7855,"PHASE4":7857,"NA":7859},{"trials":7850,"activeCount":102},[],{"trials":7852,"activeCount":102},[],{"trials":7854,"activeCount":102},[],{"trials":7856,"activeCount":102},[],{"trials":7858,"activeCount":102},[],{"trials":7860,"activeCount":102},[7861],{"nctId":7862,"briefTitle":7863,"status":112,"phases":7864,"primaryCompletion":1630,"completion":1630,"start":2309,"enrollment":7590,"conditions":7865,"interventions":7866},"NCT02265367","Novel Medication as a Potential Smoking Cessation Aid",[94],[31],[7847],{"intervention":7868,"totalTrials":136,"cells":7869},"Control - Warfarin only",{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7874,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7871,"activeCount":102},[],{"trials":7873,"activeCount":102},[],{"trials":7875,"activeCount":102},[],{"trials":7877,"activeCount":102},[],{"trials":7879,"activeCount":102},[],{"trials":7881,"activeCount":102},[7882],{"nctId":7883,"briefTitle":7884,"status":112,"phases":7885,"primaryCompletion":1658,"completion":1658,"start":3727,"enrollment":6333,"conditions":7886,"interventions":7887},"NCT01447511","Pharmacogenetics of Warfarin Induction and Inhibition",[94],[19],[7868,7888,7889],"Fluconazole - Warfarin","Rifampin - Warfarin",{"intervention":7888,"totalTrials":136,"cells":7891},{"EARLY_PHASE1":7892,"PHASE1":7894,"PHASE2":7896,"PHASE3":7898,"PHASE4":7900,"NA":7902},{"trials":7893,"activeCount":102},[],{"trials":7895,"activeCount":102},[],{"trials":7897,"activeCount":102},[],{"trials":7899,"activeCount":102},[],{"trials":7901,"activeCount":102},[],{"trials":7903,"activeCount":102},[7904],{"nctId":7883,"briefTitle":7884,"status":112,"phases":7905,"primaryCompletion":1658,"completion":1658,"start":3727,"enrollment":6333,"conditions":7906,"interventions":7907},[94],[19],[7868,7888,7889],{"intervention":7889,"totalTrials":136,"cells":7909},{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7916,"PHASE4":7918,"NA":7920},{"trials":7911,"activeCount":102},[],{"trials":7913,"activeCount":102},[],{"trials":7915,"activeCount":102},[],{"trials":7917,"activeCount":102},[],{"trials":7919,"activeCount":102},[],{"trials":7921,"activeCount":102},[7922],{"nctId":7883,"briefTitle":7884,"status":112,"phases":7923,"primaryCompletion":1658,"completion":1658,"start":3727,"enrollment":6333,"conditions":7924,"interventions":7925},[94],[19],[7868,7888,7889],{"intervention":7927,"totalTrials":136,"cells":7928},"fenofibrate",{"EARLY_PHASE1":7929,"PHASE1":7931,"PHASE2":7933,"PHASE3":7935,"PHASE4":7937,"NA":7939},{"trials":7930,"activeCount":102},[],{"trials":7932,"activeCount":102},[],{"trials":7934,"activeCount":102},[],{"trials":7936,"activeCount":102},[],{"trials":7938,"activeCount":102},[],{"trials":7940,"activeCount":102},[7941],{"nctId":7942,"briefTitle":7943,"status":112,"phases":7944,"primaryCompletion":7690,"completion":7945,"start":2336,"enrollment":7590,"conditions":7946,"interventions":7948},"NCT00613613","Fenofibrate and Pharmacogenetic Impact in Dyslipidemia",[],"2013-12",[7947],"Dyslipidemia",[7927,7927],{"intervention":7950,"totalTrials":136,"cells":7951},"Intravenous Immunoglobulin",{"EARLY_PHASE1":7952,"PHASE1":7954,"PHASE2":7956,"PHASE3":7958,"PHASE4":7960,"NA":7962},{"trials":7953,"activeCount":102},[],{"trials":7955,"activeCount":102},[],{"trials":7957,"activeCount":102},[],{"trials":7959,"activeCount":102},[],{"trials":7961,"activeCount":102},[],{"trials":7963,"activeCount":102},[7964],{"nctId":7965,"briefTitle":7966,"status":112,"phases":7967,"primaryCompletion":7968,"completion":7969,"start":7843,"enrollment":23,"conditions":7970,"interventions":7972},"NCT02414490","IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements",[],"2019-05","2020-05",[7971],"Chronic Inflammatory Demyelinating Polyneuropathy",[7950],{"intervention":7974,"totalTrials":136,"cells":7975},"Initiation of anti-retroviral therapy",{"EARLY_PHASE1":7976,"PHASE1":7978,"PHASE2":7980,"PHASE3":7982,"PHASE4":7984,"NA":7986},{"trials":7977,"activeCount":102},[],{"trials":7979,"activeCount":102},[],{"trials":7981,"activeCount":102},[],{"trials":7983,"activeCount":102},[],{"trials":7985,"activeCount":102},[],{"trials":7987,"activeCount":102},[7988],{"nctId":7989,"briefTitle":7990,"status":112,"phases":7991,"primaryCompletion":543,"completion":543,"start":7992,"enrollment":29,"conditions":7993,"interventions":7995},"NCT01490346","Tissue Drug Levels of HIV Medications",[],"2008-09",[7994],"Human Immunodeficiency Virus",[7974],{"intervention":7997,"totalTrials":136,"cells":7998},"Fluzone High-Dose - 2 doses",{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8003,"PHASE3":8005,"PHASE4":8007,"NA":8009},{"trials":8000,"activeCount":102},[],{"trials":8002,"activeCount":102},[],{"trials":8004,"activeCount":102},[],{"trials":8006,"activeCount":102},[],{"trials":8008,"activeCount":102},[],{"trials":8010,"activeCount":102},[8011],{"nctId":8012,"briefTitle":8013,"status":112,"phases":8014,"primaryCompletion":8015,"completion":8015,"start":8016,"enrollment":8017,"conditions":8018,"interventions":8020},"NCT05663463","Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients",[94],"2025-06-16","2023-09-11",74,[8019],"Solid Organ Transplant",[7997,8021],"Fluzone High-Dose - 1 dose of HD",{"intervention":8021,"totalTrials":136,"cells":8023},{"EARLY_PHASE1":8024,"PHASE1":8026,"PHASE2":8028,"PHASE3":8030,"PHASE4":8032,"NA":8034},{"trials":8025,"activeCount":102},[],{"trials":8027,"activeCount":102},[],{"trials":8029,"activeCount":102},[],{"trials":8031,"activeCount":102},[],{"trials":8033,"activeCount":102},[],{"trials":8035,"activeCount":102},[8036],{"nctId":8012,"briefTitle":8013,"status":112,"phases":8037,"primaryCompletion":8015,"completion":8015,"start":8016,"enrollment":8017,"conditions":8038,"interventions":8039},[94],[8019],[7997,8021],{"intervention":8041,"totalTrials":136,"cells":8042},"Nicotine lozenge 4 mg",{"EARLY_PHASE1":8043,"PHASE1":8045,"PHASE2":8047,"PHASE3":8049,"PHASE4":8051,"NA":8053},{"trials":8044,"activeCount":102},[],{"trials":8046,"activeCount":102},[],{"trials":8048,"activeCount":102},[],{"trials":8050,"activeCount":102},[],{"trials":8052,"activeCount":102},[],{"trials":8054,"activeCount":102},[8055],{"nctId":8056,"briefTitle":8057,"status":112,"phases":8058,"primaryCompletion":2309,"completion":2309,"start":8059,"enrollment":7590,"conditions":8060,"interventions":8061},"NCT02347605","Medicinal Nicotine for Preventing Cue Induced Craving",[94],"2013-09",[31],[8041],{"intervention":8063,"totalTrials":136,"cells":8064},"Macrolide Antibiotic",{"EARLY_PHASE1":8065,"PHASE1":8067,"PHASE2":8069,"PHASE3":8071,"PHASE4":8073,"NA":8075},{"trials":8066,"activeCount":102},[],{"trials":8068,"activeCount":102},[],{"trials":8070,"activeCount":102},[],{"trials":8072,"activeCount":102},[],{"trials":8074,"activeCount":102},[],{"trials":8076,"activeCount":102},[8077],{"nctId":8078,"briefTitle":8079,"status":112,"phases":8080,"primaryCompletion":3590,"completion":544,"start":2077,"enrollment":8081,"conditions":8082,"interventions":8083},"NCT00325897","Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease",[94],1142,[3084],[8063],{"intervention":8085,"totalTrials":136,"cells":8086},"Drug-Eluting Beads (DEB) with Doxorubicin",{"EARLY_PHASE1":8087,"PHASE1":8089,"PHASE2":8091,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8088,"activeCount":102},[],{"trials":8090,"activeCount":102},[],{"trials":8092,"activeCount":102},[],{"trials":8094,"activeCount":102},[],{"trials":8096,"activeCount":102},[],{"trials":8098,"activeCount":102},[8099],{"nctId":8100,"briefTitle":8101,"status":841,"phases":8102,"primaryCompletion":5705,"completion":5705,"start":1767,"enrollment":102,"conditions":8103,"interventions":8104},"NCT01489410","Comparing Lipiodol\u002FEthanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma",[94],[6148],[8085,8105],"Lipiodol Ethanol Mixture",{"intervention":8105,"totalTrials":136,"cells":8107},{"EARLY_PHASE1":8108,"PHASE1":8110,"PHASE2":8112,"PHASE3":8114,"PHASE4":8116,"NA":8118},{"trials":8109,"activeCount":102},[],{"trials":8111,"activeCount":102},[],{"trials":8113,"activeCount":102},[],{"trials":8115,"activeCount":102},[],{"trials":8117,"activeCount":102},[],{"trials":8119,"activeCount":102},[8120],{"nctId":8100,"briefTitle":8101,"status":841,"phases":8121,"primaryCompletion":5705,"completion":5705,"start":1767,"enrollment":102,"conditions":8122,"interventions":8123},[94],[6148],[8085,8105],{"intervention":8125,"totalTrials":136,"cells":8126},"Paroxetine",{"EARLY_PHASE1":8127,"PHASE1":8129,"PHASE2":8131,"PHASE3":8133,"PHASE4":8135,"NA":8137},{"trials":8128,"activeCount":102},[],{"trials":8130,"activeCount":102},[],{"trials":8132,"activeCount":102},[],{"trials":8134,"activeCount":102},[],{"trials":8136,"activeCount":102},[],{"trials":8138,"activeCount":102},[8139],{"nctId":8140,"briefTitle":8141,"status":112,"phases":8142,"primaryCompletion":2284,"completion":2284,"start":8143,"enrollment":8144,"conditions":8145,"interventions":8146},"NCT00218439","Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1",[94],"2005-10",105,[31],[8125],{"intervention":8148,"totalTrials":136,"cells":8149},"Flurbiprofen Control - Flurbiprofen Only",{"EARLY_PHASE1":8150,"PHASE1":8152,"PHASE2":8154,"PHASE3":8156,"PHASE4":8158,"NA":8160},{"trials":8151,"activeCount":102},[],{"trials":8153,"activeCount":102},[],{"trials":8155,"activeCount":102},[],{"trials":8157,"activeCount":102},[],{"trials":8159,"activeCount":102},[],{"trials":8161,"activeCount":102},[8162],{"nctId":8163,"briefTitle":8164,"status":112,"phases":8165,"primaryCompletion":3579,"completion":3579,"start":5751,"enrollment":3664,"conditions":8166,"interventions":8167},"NCT01061112","Effects of Genotype on CYP2C9 Drug Interactions",[],[19],[8148,8168,8169,8170,8171,8172],"Flurbiprofen Inhibition - Flurbiprofen & Fluconazole","Ketoprofen Control - Ketoprofen Only","Ketoprofen Inhibition - Ketoprofen & Fluconazole","Tolbutamide Control - Tolbutamide Only","Tolbutamide Inhibition - Tolbutamide & Fluconazole",{"intervention":8168,"totalTrials":136,"cells":8174},{"EARLY_PHASE1":8175,"PHASE1":8177,"PHASE2":8179,"PHASE3":8181,"PHASE4":8183,"NA":8185},{"trials":8176,"activeCount":102},[],{"trials":8178,"activeCount":102},[],{"trials":8180,"activeCount":102},[],{"trials":8182,"activeCount":102},[],{"trials":8184,"activeCount":102},[],{"trials":8186,"activeCount":102},[8187],{"nctId":8163,"briefTitle":8164,"status":112,"phases":8188,"primaryCompletion":3579,"completion":3579,"start":5751,"enrollment":3664,"conditions":8189,"interventions":8190},[],[19],[8148,8168,8169,8170,8171,8172],{"intervention":8169,"totalTrials":136,"cells":8192},{"EARLY_PHASE1":8193,"PHASE1":8195,"PHASE2":8197,"PHASE3":8199,"PHASE4":8201,"NA":8203},{"trials":8194,"activeCount":102},[],{"trials":8196,"activeCount":102},[],{"trials":8198,"activeCount":102},[],{"trials":8200,"activeCount":102},[],{"trials":8202,"activeCount":102},[],{"trials":8204,"activeCount":102},[8205],{"nctId":8163,"briefTitle":8164,"status":112,"phases":8206,"primaryCompletion":3579,"completion":3579,"start":5751,"enrollment":3664,"conditions":8207,"interventions":8208},[],[19],[8148,8168,8169,8170,8171,8172],{"intervention":8170,"totalTrials":136,"cells":8210},{"EARLY_PHASE1":8211,"PHASE1":8213,"PHASE2":8215,"PHASE3":8217,"PHASE4":8219,"NA":8221},{"trials":8212,"activeCount":102},[],{"trials":8214,"activeCount":102},[],{"trials":8216,"activeCount":102},[],{"trials":8218,"activeCount":102},[],{"trials":8220,"activeCount":102},[],{"trials":8222,"activeCount":102},[8223],{"nctId":8163,"briefTitle":8164,"status":112,"phases":8224,"primaryCompletion":3579,"completion":3579,"start":5751,"enrollment":3664,"conditions":8225,"interventions":8226},[],[19],[8148,8168,8169,8170,8171,8172],{"intervention":8171,"totalTrials":136,"cells":8228},{"EARLY_PHASE1":8229,"PHASE1":8231,"PHASE2":8233,"PHASE3":8235,"PHASE4":8237,"NA":8239},{"trials":8230,"activeCount":102},[],{"trials":8232,"activeCount":102},[],{"trials":8234,"activeCount":102},[],{"trials":8236,"activeCount":102},[],{"trials":8238,"activeCount":102},[],{"trials":8240,"activeCount":102},[8241],{"nctId":8163,"briefTitle":8164,"status":112,"phases":8242,"primaryCompletion":3579,"completion":3579,"start":5751,"enrollment":3664,"conditions":8243,"interventions":8244},[],[19],[8148,8168,8169,8170,8171,8172],{"intervention":8172,"totalTrials":136,"cells":8246},{"EARLY_PHASE1":8247,"PHASE1":8249,"PHASE2":8251,"PHASE3":8253,"PHASE4":8255,"NA":8257},{"trials":8248,"activeCount":102},[],{"trials":8250,"activeCount":102},[],{"trials":8252,"activeCount":102},[],{"trials":8254,"activeCount":102},[],{"trials":8256,"activeCount":102},[],{"trials":8258,"activeCount":102},[8259],{"nctId":8163,"briefTitle":8164,"status":112,"phases":8260,"primaryCompletion":3579,"completion":3579,"start":5751,"enrollment":3664,"conditions":8261,"interventions":8262},[],[19],[8148,8168,8169,8170,8171,8172],{"intervention":8264,"totalTrials":136,"cells":8265},"Adiponectin and TNFa",{"EARLY_PHASE1":8266,"PHASE1":8268,"PHASE2":8270,"PHASE3":8272,"PHASE4":8274,"NA":8276},{"trials":8267,"activeCount":102},[],{"trials":8269,"activeCount":102},[],{"trials":8271,"activeCount":102},[],{"trials":8273,"activeCount":102},[],{"trials":8275,"activeCount":102},[],{"trials":8277,"activeCount":102},[8278],{"nctId":8279,"briefTitle":8280,"status":112,"phases":8281,"primaryCompletion":8282,"completion":4028,"start":1646,"enrollment":12,"conditions":8283,"interventions":8286},"NCT03505541","Adipokines Effect in Myometrial Contractility",[],"2019-06-30",[8284,8285,16],"Myometrium; Contractility","GDM",[8264],{"intervention":8288,"totalTrials":136,"cells":8289},"Steroid-Free Maintenance Immunosuppression",{"EARLY_PHASE1":8290,"PHASE1":8292,"PHASE2":8294,"PHASE3":8296,"PHASE4":8298,"NA":8300},{"trials":8291,"activeCount":102},[],{"trials":8293,"activeCount":102},[],{"trials":8295,"activeCount":102},[],{"trials":8297,"activeCount":102},[],{"trials":8299,"activeCount":102},[],{"trials":8301,"activeCount":102},[8302],{"nctId":8303,"briefTitle":8304,"status":112,"phases":8305,"primaryCompletion":8306,"completion":8306,"start":3727,"enrollment":8307,"conditions":8308,"interventions":8312},"NCT01277770","Studies of Kidney Transplant Outcome",[],"2019-05-06",7500,[8309,8288,8310,8311],"Transplant Recipient (Kidney)","Post-Transplant Infections","Thymoglobulin",[8288,8313],"Evaluation of the DGF nomogram in Thymoglobulin",{"intervention":8313,"totalTrials":136,"cells":8315},{"EARLY_PHASE1":8316,"PHASE1":8318,"PHASE2":8320,"PHASE3":8322,"PHASE4":8324,"NA":8326},{"trials":8317,"activeCount":102},[],{"trials":8319,"activeCount":102},[],{"trials":8321,"activeCount":102},[],{"trials":8323,"activeCount":102},[],{"trials":8325,"activeCount":102},[],{"trials":8327,"activeCount":102},[8328],{"nctId":8303,"briefTitle":8304,"status":112,"phases":8329,"primaryCompletion":8306,"completion":8306,"start":3727,"enrollment":8307,"conditions":8330,"interventions":8331},[],[8309,8288,8310,8311],[8288,8313],{"intervention":8333,"totalTrials":136,"cells":8334},"Efavirenz + Tenofovir DF\u002FEmtricitabine",{"EARLY_PHASE1":8335,"PHASE1":8337,"PHASE2":8339,"PHASE3":8341,"PHASE4":8343,"NA":8345},{"trials":8336,"activeCount":102},[],{"trials":8338,"activeCount":102},[],{"trials":8340,"activeCount":102},[],{"trials":8342,"activeCount":102},[],{"trials":8344,"activeCount":102},[],{"trials":8346,"activeCount":102},[8347],{"nctId":8348,"briefTitle":8349,"status":841,"phases":8350,"primaryCompletion":3495,"completion":5121,"start":4675,"enrollment":102,"conditions":8351,"interventions":8352},"NCT00863668","Raltegravir Activity In Lymphoid Tissues",[94],[2406,1760],[8333,8353],"Raltegravir + Tenofovir DF\u002FEmtricitabine",{"intervention":8353,"totalTrials":136,"cells":8355},{"EARLY_PHASE1":8356,"PHASE1":8358,"PHASE2":8360,"PHASE3":8362,"PHASE4":8364,"NA":8366},{"trials":8357,"activeCount":102},[],{"trials":8359,"activeCount":102},[],{"trials":8361,"activeCount":102},[],{"trials":8363,"activeCount":102},[],{"trials":8365,"activeCount":102},[],{"trials":8367,"activeCount":102},[8368],{"nctId":8348,"briefTitle":8349,"status":841,"phases":8369,"primaryCompletion":3495,"completion":5121,"start":4675,"enrollment":102,"conditions":8370,"interventions":8371},[94],[2406,1760],[8333,8353],{"intervention":8373,"totalTrials":136,"cells":8374},"Pinaverium",{"EARLY_PHASE1":8375,"PHASE1":8377,"PHASE2":8379,"PHASE3":8381,"PHASE4":8383,"NA":8385},{"trials":8376,"activeCount":102},[],{"trials":8378,"activeCount":102},[],{"trials":8380,"activeCount":102},[],{"trials":8382,"activeCount":102},[],{"trials":8384,"activeCount":102},[],{"trials":8386,"activeCount":102},[8387],{"nctId":8388,"briefTitle":8389,"status":2730,"phases":8390,"primaryCompletion":1681,"completion":4016,"start":3736,"enrollment":8391,"conditions":8392,"interventions":8394},"NCT01641224","A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome",[94],800,[8393],"Irritable Bowel Syndrome",[8373,8395,8396,8397,8398,8399],"Ledebouriella Root","Radix codonopsitis","Radix curcumae","Fingered citron","Tuckahoe",{"intervention":8395,"totalTrials":136,"cells":8401},{"EARLY_PHASE1":8402,"PHASE1":8404,"PHASE2":8406,"PHASE3":8408,"PHASE4":8410,"NA":8412},{"trials":8403,"activeCount":102},[],{"trials":8405,"activeCount":102},[],{"trials":8407,"activeCount":102},[],{"trials":8409,"activeCount":102},[],{"trials":8411,"activeCount":102},[],{"trials":8413,"activeCount":102},[8414],{"nctId":8388,"briefTitle":8389,"status":2730,"phases":8415,"primaryCompletion":1681,"completion":4016,"start":3736,"enrollment":8391,"conditions":8416,"interventions":8417},[94],[8393],[8373,8395,8396,8397,8398,8399],{"intervention":8396,"totalTrials":136,"cells":8419},{"EARLY_PHASE1":8420,"PHASE1":8422,"PHASE2":8424,"PHASE3":8426,"PHASE4":8428,"NA":8430},{"trials":8421,"activeCount":102},[],{"trials":8423,"activeCount":102},[],{"trials":8425,"activeCount":102},[],{"trials":8427,"activeCount":102},[],{"trials":8429,"activeCount":102},[],{"trials":8431,"activeCount":102},[8432],{"nctId":8388,"briefTitle":8389,"status":2730,"phases":8433,"primaryCompletion":1681,"completion":4016,"start":3736,"enrollment":8391,"conditions":8434,"interventions":8435},[94],[8393],[8373,8395,8396,8397,8398,8399],{"intervention":8397,"totalTrials":136,"cells":8437},{"EARLY_PHASE1":8438,"PHASE1":8440,"PHASE2":8442,"PHASE3":8444,"PHASE4":8446,"NA":8448},{"trials":8439,"activeCount":102},[],{"trials":8441,"activeCount":102},[],{"trials":8443,"activeCount":102},[],{"trials":8445,"activeCount":102},[],{"trials":8447,"activeCount":102},[],{"trials":8449,"activeCount":102},[8450],{"nctId":8388,"briefTitle":8389,"status":2730,"phases":8451,"primaryCompletion":1681,"completion":4016,"start":3736,"enrollment":8391,"conditions":8452,"interventions":8453},[94],[8393],[8373,8395,8396,8397,8398,8399],{"intervention":8398,"totalTrials":136,"cells":8455},{"EARLY_PHASE1":8456,"PHASE1":8458,"PHASE2":8460,"PHASE3":8462,"PHASE4":8464,"NA":8466},{"trials":8457,"activeCount":102},[],{"trials":8459,"activeCount":102},[],{"trials":8461,"activeCount":102},[],{"trials":8463,"activeCount":102},[],{"trials":8465,"activeCount":102},[],{"trials":8467,"activeCount":102},[8468],{"nctId":8388,"briefTitle":8389,"status":2730,"phases":8469,"primaryCompletion":1681,"completion":4016,"start":3736,"enrollment":8391,"conditions":8470,"interventions":8471},[94],[8393],[8373,8395,8396,8397,8398,8399],{"intervention":8399,"totalTrials":136,"cells":8473},{"EARLY_PHASE1":8474,"PHASE1":8476,"PHASE2":8478,"PHASE3":8480,"PHASE4":8482,"NA":8484},{"trials":8475,"activeCount":102},[],{"trials":8477,"activeCount":102},[],{"trials":8479,"activeCount":102},[],{"trials":8481,"activeCount":102},[],{"trials":8483,"activeCount":102},[],{"trials":8485,"activeCount":102},[8486],{"nctId":8388,"briefTitle":8389,"status":2730,"phases":8487,"primaryCompletion":1681,"completion":4016,"start":3736,"enrollment":8391,"conditions":8488,"interventions":8489},[94],[8393],[8373,8395,8396,8397,8398,8399],{"intervention":8491,"totalTrials":136,"cells":8492},"Long-Acting Growth Hormone",{"EARLY_PHASE1":8493,"PHASE1":8495,"PHASE2":8497,"PHASE3":8499,"PHASE4":8501,"NA":8503},{"trials":8494,"activeCount":102},[],{"trials":8496,"activeCount":102},[],{"trials":8498,"activeCount":102},[],{"trials":8500,"activeCount":102},[],{"trials":8502,"activeCount":102},[],{"trials":8504,"activeCount":102},[8505],{"nctId":8506,"briefTitle":8507,"status":112,"phases":8508,"primaryCompletion":8509,"completion":8509,"start":8510,"enrollment":7335,"conditions":8511,"interventions":8514},"NCT04938466","Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy",[],"2024-10-30","2021-08-05",[8512,8513],"Growth Hormone Deficiency","Growth Hormone Treatment",[8491],{"intervention":8516,"totalTrials":136,"cells":8517},"Allopurinol",{"EARLY_PHASE1":8518,"PHASE1":8520,"PHASE2":8522,"PHASE3":8524,"PHASE4":8526,"NA":8528},{"trials":8519,"activeCount":102},[],{"trials":8521,"activeCount":102},[],{"trials":8523,"activeCount":102},[],{"trials":8525,"activeCount":102},[],{"trials":8527,"activeCount":102},[],{"trials":8529,"activeCount":102},[8530],{"nctId":8531,"briefTitle":8532,"status":112,"phases":8533,"primaryCompletion":3860,"completion":2214,"start":3579,"enrollment":457,"conditions":8534,"interventions":8536},"NCT02371421","Genetics of Hyperuricemia Therapy in Hmong",[],[8535],"Hyperuricemia, Gout",[8516],{"intervention":8538,"totalTrials":136,"cells":8539},"Lorenzo's Oil",{"EARLY_PHASE1":8540,"PHASE1":8542,"PHASE2":8544,"PHASE3":8546,"PHASE4":8548,"NA":8550},{"trials":8541,"activeCount":102},[],{"trials":8543,"activeCount":102},[],{"trials":8545,"activeCount":102},[],{"trials":8547,"activeCount":102},[],{"trials":8549,"activeCount":102},[],{"trials":8551,"activeCount":102},[8552],{"nctId":8553,"briefTitle":8554,"status":7244,"phases":8555,"conditions":8556,"interventions":8558},"NCT02233257","Expanded Access for Lorenzo's Oil (GTO\u002FGTE) in Adrenoleukodystrophy",[],[8557],"X-linked Adrenoleukodystrophy",[8538],{"intervention":8560,"totalTrials":136,"cells":8561},"deuterated phenanthrene tetraol",{"EARLY_PHASE1":8562,"PHASE1":8564,"PHASE2":8566,"PHASE3":8568,"PHASE4":8570,"NA":8572},{"trials":8563,"activeCount":102},[],{"trials":8565,"activeCount":102},[],{"trials":8567,"activeCount":102},[],{"trials":8569,"activeCount":102},[],{"trials":8571,"activeCount":102},[],{"trials":8573,"activeCount":102},[8574],{"nctId":8575,"briefTitle":8576,"status":112,"phases":8577,"primaryCompletion":8578,"completion":3957,"start":1893,"enrollment":8579,"conditions":8580,"interventions":8582},"NCT01673711","Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer",[],"2019-03-31",350,[4743,8581,31],"Squamous Lung Dysplasia",[8560,8583,8584],"pharmacological study","laboratory biomarker analysis",{"intervention":8583,"totalTrials":136,"cells":8586},{"EARLY_PHASE1":8587,"PHASE1":8589,"PHASE2":8591,"PHASE3":8593,"PHASE4":8595,"NA":8597},{"trials":8588,"activeCount":102},[],{"trials":8590,"activeCount":102},[],{"trials":8592,"activeCount":102},[],{"trials":8594,"activeCount":102},[],{"trials":8596,"activeCount":102},[],{"trials":8598,"activeCount":102},[8599],{"nctId":8575,"briefTitle":8576,"status":112,"phases":8600,"primaryCompletion":8578,"completion":3957,"start":1893,"enrollment":8579,"conditions":8601,"interventions":8602},[],[4743,8581,31],[8560,8583,8584],{"intervention":8584,"totalTrials":136,"cells":8604},{"EARLY_PHASE1":8605,"PHASE1":8607,"PHASE2":8609,"PHASE3":8611,"PHASE4":8613,"NA":8615},{"trials":8606,"activeCount":102},[],{"trials":8608,"activeCount":102},[],{"trials":8610,"activeCount":102},[],{"trials":8612,"activeCount":102},[],{"trials":8614,"activeCount":102},[],{"trials":8616,"activeCount":102},[8617],{"nctId":8575,"briefTitle":8576,"status":112,"phases":8618,"primaryCompletion":8578,"completion":3957,"start":1893,"enrollment":8579,"conditions":8619,"interventions":8620},[],[4743,8581,31],[8560,8583,8584],{"intervention":8622,"totalTrials":136,"cells":8623},"Tenofovir",{"EARLY_PHASE1":8624,"PHASE1":8626,"PHASE2":8628,"PHASE3":8630,"PHASE4":8632,"NA":8634},{"trials":8625,"activeCount":102},[],{"trials":8627,"activeCount":102},[],{"trials":8629,"activeCount":102},[],{"trials":8631,"activeCount":102},[],{"trials":8633,"activeCount":102},[],{"trials":8635,"activeCount":102},[8636],{"nctId":8637,"briefTitle":8638,"status":112,"phases":8639,"primaryCompletion":8640,"completion":8640,"start":8641,"enrollment":26,"conditions":8642,"interventions":8645},"NCT03218085","Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract",[],"2024-02-15","2017-07-14",[4857,8643,8644],"Menopause","Inflammation Vagina",[8622,8646],"Emtricitabine",{"intervention":8646,"totalTrials":136,"cells":8648},{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8650,"activeCount":102},[],{"trials":8652,"activeCount":102},[],{"trials":8654,"activeCount":102},[],{"trials":8656,"activeCount":102},[],{"trials":8658,"activeCount":102},[],{"trials":8660,"activeCount":102},[8661],{"nctId":8637,"briefTitle":8638,"status":112,"phases":8662,"primaryCompletion":8640,"completion":8640,"start":8641,"enrollment":26,"conditions":8663,"interventions":8664},[],[4857,8643,8644],[8622,8646],{"intervention":8666,"totalTrials":136,"cells":8667},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":8668,"PHASE1":8670,"PHASE2":8672,"PHASE3":8674,"PHASE4":8676,"NA":8678},{"trials":8669,"activeCount":102},[],{"trials":8671,"activeCount":102},[],{"trials":8673,"activeCount":102},[],{"trials":8675,"activeCount":102},[],{"trials":8677,"activeCount":102},[],{"trials":8679,"activeCount":102},[8680],{"nctId":8681,"briefTitle":8682,"status":112,"phases":8683,"primaryCompletion":8684,"completion":8685,"start":8686,"enrollment":1547,"conditions":8687,"interventions":8688},"NCT03377608","Modifiers of Tenofovir in the Female Genital Tract",[],"2018-03-29","2018-04-02","2017-11-17",[4857,5153],[8666,8689],"Depo-Provera",{"intervention":8689,"totalTrials":136,"cells":8691},{"EARLY_PHASE1":8692,"PHASE1":8694,"PHASE2":8696,"PHASE3":8698,"PHASE4":8700,"NA":8702},{"trials":8693,"activeCount":102},[],{"trials":8695,"activeCount":102},[],{"trials":8697,"activeCount":102},[],{"trials":8699,"activeCount":102},[],{"trials":8701,"activeCount":102},[],{"trials":8703,"activeCount":102},[8704],{"nctId":8681,"briefTitle":8682,"status":112,"phases":8705,"primaryCompletion":8684,"completion":8685,"start":8686,"enrollment":1547,"conditions":8706,"interventions":8707},[],[4857,5153],[8666,8689],{"intervention":8709,"totalTrials":136,"cells":8710},"MRI Contrast",{"EARLY_PHASE1":8711,"PHASE1":8713,"PHASE2":8715,"PHASE3":8717,"PHASE4":8719,"NA":8721},{"trials":8712,"activeCount":102},[],{"trials":8714,"activeCount":102},[],{"trials":8716,"activeCount":102},[],{"trials":8718,"activeCount":102},[],{"trials":8720,"activeCount":102},[],{"trials":8722,"activeCount":102},[8723],{"nctId":8724,"briefTitle":8725,"status":1860,"phases":8726,"primaryCompletion":8727,"completion":8727,"start":8728,"enrollment":1527,"conditions":8729,"interventions":8730},"NCT02550366","Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI",[],"2024-01-19","2016-01-01",[2501],[8709],{"intervention":8732,"totalTrials":136,"cells":8733},"Depakote ER",{"EARLY_PHASE1":8734,"PHASE1":8736,"PHASE2":8738,"PHASE3":8740,"PHASE4":8742,"NA":8744},{"trials":8735,"activeCount":102},[],{"trials":8737,"activeCount":102},[],{"trials":8739,"activeCount":102},[],{"trials":8741,"activeCount":102},[],{"trials":8743,"activeCount":102},[],{"trials":8745,"activeCount":102},[8746],{"nctId":8747,"briefTitle":8748,"status":112,"phases":8749,"completion":3919,"start":3689,"enrollment":892,"conditions":8750,"interventions":8751},"NCT00222482","Depakote ER in Borderline Personality Disorder",[94],[3016],[8732],{"intervention":7370,"totalTrials":136,"cells":8753},{"EARLY_PHASE1":8754,"PHASE1":8756,"PHASE2":8758,"PHASE3":8760,"PHASE4":8762,"NA":8764},{"trials":8755,"activeCount":102},[],{"trials":8757,"activeCount":102},[],{"trials":8759,"activeCount":102},[],{"trials":8761,"activeCount":102},[],{"trials":8763,"activeCount":102},[],{"trials":8765,"activeCount":102},[8766],{"nctId":7361,"briefTitle":7362,"status":112,"phases":8767,"completion":3688,"start":7364,"enrollment":23,"conditions":8768,"interventions":8769},[94],[4126,4125,7366,7367],[7369,7339,7370]]